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Abstract 
 
Abstract 
The overall aim of the thesis was to introduce new analytical techniques to characterize solid 
dispersion formulations. Solid dispersion formulations are employed to enhance the dissolution 
behavior and apparent solubility of poorly soluble compounds. This formulation strategy uses 
typically an amorphous physical form of a poorly soluble drug and combines it with a carrier 
for stabilization. The amorphous form presents higher free energy compared to a crystalline 
drug form thereby yielding a higher dissolution rate and possibly more complete oral absorption 
as well as bioavailability. The selection of appropriate excipients is crucial to guarantee the 
formulation performance and stability during the shelf life of the final product. To investigate 
drug formulation characteristics and predict their performance, different analytical techniques 
are needed. Along with the classical characterization techniques, novel approaches such as 
fluorescence spectroscopy and diffusing wave spectroscopy are introduced in the present thesis. 
The chapters 1 and 2 of this thesis cover fundamental aspects of poorly soluble drugs: an 
overview is given on amorphous solid dispersion (ASD) manufacturing technologies and 
characteristics of polymers and surfactants used in ASD. Moreover, analytical tools to 
characterize solid dispersions are presented. Among them, special emphasis is given to novel 
approaches such as Diffusing Wave Spectroscopy (DWS) and Fluorescence Spectroscopy. 
As for the selection of excipients, drug polymer miscibility is a crucial requisite for the 
performance of an ASD formulation. One of the methods to predict drug-polymer miscibility 
is to employ solubility parameter approach; its application in solid dispersion formulations is 
outlined in the Chapter 3. 
 
The first study introduces a novel fluorescence quenching approach together with size exclusion 
chromatography to study drug-polymer interactions that emerge from ASDs drug release in an 
aqueous medium. Celecoxib was combined with different pharmaceutical polymers and the 
resulted solid dispersion was evaluated by the (modified) Stern-Volmer model. Drug 
accessibility by the quencher and its affinity to the drug were compared in physical mixtures as 
well as within the ASDs using different polymer types. It was possible to gain knowledge about 
specific drug-polymer interactions and the amount of drug embedded in the evolving drug-
polymer aggregates upon formulation dispersion and drug dissolution. More research in the 
future will show how such in vitro findings translate into performance of an ASD in vivo. 
Abstract 
The second study of this thesis has also a biopharmaceutical focus and investigates formulation 
differences from a microrheological perspective by considering further an in vitro absorption 
sink using a biphasic dissolution equipment. Indeed, biphasic dissolution testing can simulate 
an intestinal absorption from dispersed formulation by using an organic layer. This study 
employed ketoconazole, a poorly soluble drug, together with different grades of HPMCAS and 
formulations were produced by hot melt extrusion (HME). Diffusing wave spectroscopy 
highlighted microrheological differences among the different polymer grades and plasticizers 
in the aqueous phase. These differences were found to influence drug release and finally the 
uptake in the organic layer that was intended to mirror the absorption process. There is surely 
more research needed before final conclusions can be drawn but the obtained findings point 
already to an important contribution of microrheological differences that evolved upon 
formulation dispersion. 
 
The third study also emphasized microrheology but with a focus on non-dispersed solid 
dispersions. It was aimed to investigate microstructuring during phase transitions in drug-
polymer solid dispersions. This formulation microstructuring is critical for the physicochemical 
properties such as stability of the final dosage form. In this study, eutectic mixtures of 
polyethylene glycol (PEG) were investigated using two drugs: fenofibrate and flurbiprofen. 
Unlike fenofibrate, the drug flurbiprofen was strongly interacting with the polymer and this was 
also confirmed by the rheological characterization. Therefore, broadband DWS provided 
valuable mechanistic information on the drug-polymer interactions and macromolecular 
structuring during the cooling of the eutectic melts. 
 
.
Acknowledgments 
 
 
 
 
Acknowledgments 
I would like to thank Prof. Dr. Imanidis for the opportunity to carry out this PhD thesis, for 
fruitful discussions and all his advice. I am also grateful to Prof. Dr. Kuentz for all the scientific 
discussions and his enthusiasm.  
I would like to thank the IPT group in Muttenz, especially to Ursula and Michael for their 
friendship and support. I would like to thank also Dr. Aleandri for his support in using 
instruments and learning about fluorescence spectroscopy. I am also thankful to ls instruments 
for technical support as well as scientific discussions about DWS. 
 
I am grateful to all of my friends, Federica for her support, advises and motivation during all 
these years, Teresa, and Antoin, who always make me laugh, Isabelle for her patience and help 
in learning German and exploring the Swiss culture, Anne for discussions about the value of 
science, Chiara, and Valentina for their support and introducing me to “italianistics”. Thanks 
also go to all my shared apartment friends for listening, teaching me different recipes, and for 
making me always laugh.  
 
Also, I would like to thank my parents and my sister who were always there to support me.  
 
 
  
 
 
Contents 
Abstract .....................................................................................................................................................  
Acknowledgments .....................................................................................................................................  
1.Introduction .......................................................................................................................................... 1 
1.1 Background ............................................................................................................................. 1 
1.2 Objective ................................................................................................................................. 4 
2. Theoretical section .............................................................................................................................. 6 
2.1 Dissolution and solubility ....................................................................................................... 6 
2.2 Solid dispersion ...................................................................................................................... 8 
2.2.1 Excipients for solid dispersions ..................................................................................... 12 
2.2.2 Solid dispersion manufacturing technologies ................................................................ 16 
2.3 Selected aspects of ASDs formulation ................................................................................. 20 
2.3.1 Drug-polymer miscibility .............................................................................................. 20 
2.3.2 Drug supersaturation ..................................................................................................... 23 
2.4 Physical characterization of solid dispersions ...................................................................... 26 
2.4.1 Emerging analytical tools .............................................................................................. 28 
3. Application of the solubility parameter concept to assist with oral delivery of poorly water-soluble 
drugs - a PEARRL review ..................................................................................................................... 35 
3.1 Introduction .......................................................................................................................... 36 
3.2 Theory and experimental aspects of the solubility parameter concept ................................. 37 
3.2.1 Introduction to the solubility parameter concept ........................................................... 37 
3.3 Experimental and in silico determination of solubility parameters ...................................... 39 
3.3.1 Introduction to solubility parameter determination ....................................................... 39 
3.3.2 Classical determination of solubility parameter ............................................................ 40 
3.3.3 Determination of partial solubility parameters using solvent solubility data ................ 44 
3.3.4 Determination of partial solubility parameters using intrinsic viscosity measurements 46 
3.3.5 Determination of partial solubility parameters of liquids using inverse gas 
chromatography ..................................................................................................................................... 48 
3.3.6 Other experimental methods to determine solubility parameter.................................... 51 
3.3.7 Group contribution methods to calculate partial solubility parameters ......................... 53 
3.4 Applications of solubility parameters in pharmaceutics ....................................................... 56 
3.4.1 Organic solvent selection .............................................................................................. 56 
3.4.2 Co-crystal and salt screening ......................................................................................... 57 
3.4.3 Solubility parameter concept in lipid-based formulations ............................................. 60 
3.4.4 Solid dispersions ............................................................................................................ 63 
3.4.5 Mesoporous silica .......................................................................................................... 67 
3.4.6 Application of solubility parameters in the formulation of nano- and microparticulate 
systems  ....................................................................................................................................... 68 
3.5 Conclusions .......................................................................................................................... 70 
4.Towards a better understanding of solid dispersions in aqueous environment by a fluorescence 
quenching approach ............................................................................................................................... 71 
4.1 Introduction .......................................................................................................................... 72 
4.2 Materials and methods .......................................................................................................... 74 
4.2.1 Materials ........................................................................................................................ 74 
4.2.2 Methods ......................................................................................................................... 74 
4.3 Results .................................................................................................................................. 81 
4.3.1 Bulk characterization of physical mixtures and solid dispersions ................................. 81 
4.3.2 Characterization of drug-polymer interactions .............................................................. 82 
4.4 Discussion ............................................................................................................................. 87 
4.5 Conclusions .......................................................................................................................... 92 
5.Biphasic drug release testing coupled with diffusing wave spectroscopy for mechanistic 
  
 
understanding of solid dispersion performance ..................................................................................... 94 
5.1 Introduction .......................................................................................................................... 95 
5.2 Materials and methods .......................................................................................................... 97 
5.2.1 Materials ........................................................................................................................ 97 
5.2.2 Preparation of solid dispersions and physical mixtures ................................................. 97 
5.2.3 Powder X-ray diffraction (PXRD) ................................................................................ 98 
5.2.4 Differential scanning calorimetry (DSC) ...................................................................... 98 
5.2.5 Biphasic dissolution test ................................................................................................ 98 
5.2.6 USP II dissolution test ................................................................................................... 99 
5.2.7 Diffusing wave spectroscopy (DWS) .......................................................................... 100 
5.2.8 Statistical analysis ....................................................................................................... 100 
5.3 Results ................................................................................................................................ 102 
5.3.1 In vitro characterization of crystalline KCZ ................................................................ 102 
5.3.2 Bulk characterization of crystalline material and solid dispersions ............................ 103 
5.3.3 Biphasic dissolution experiment of ASDs ................................................................... 105 
5.3.4 Microrheological characterization ............................................................................... 106 
5.3.5 Statistical analysis ....................................................................................................... 109 
5.4 Discussion ........................................................................................................................... 110 
5.5 Concluding remarks ............................................................................................................ 114 
6.Broadband Diffusing Wave Spectroscopy reveals microstructuring of polymer-drug system ........ 115 
6.1 Introduction ........................................................................................................................ 116 
6.2 Materials and methods ........................................................................................................ 117 
6.2.1 Materials ...................................................................................................................... 117 
6.2.2 Methods ....................................................................................................................... 117 
6.3 Results ................................................................................................................................ 122 
6.3.1 Solid state characterizations ........................................................................................ 122 
6.3.2 DWS ............................................................................................................................ 125 
6.4 Discussion ........................................................................................................................... 132 
6.5 Conclusions ........................................................................................................................ 135 
Final remarks and outlook ................................................................................................................... 136 
7. Bibliography: ................................................................................................................................... 138 
1 
 
 
 
 
 
 
Chapter 1 
 
1 Introduction 
1.1 Background 
Drugs which exhibit poor water solubility are a major challenge to formulation scientist because 
they might show low oral absorption and bioavailability. For an orally administered drug to 
have a therapeutic effect, the drug molecule must first dissolve in the gastrointestinal (GI) 
fluids, pass through GI mucosa to reach the systemic circulation to finally exhibit a 
pharmacological interaction with the target site. When the drug is poorly soluble, drug 
molecules may not dissolve completely in the GI fluids so that already the absorption step 
becomes erratic. 
 
Based on solubility and permeability characteristics, drugs are classified in four different 
classes and this schematic approach is called biopharmaceutical classification system (BCS).1 
BCS Class I is assigned to drugs with high solubility and high permeability, BCS II compounds 
have low solubility and high permeability, BCS III drugs exhibit high solubility and low 
permeability and finally, BCS IV drugs show low solubility and low permeability. (Figure 
2.1).The BCS approach has not been tailored for formulation development so that the approach 
was modified to the developability classification system (DCS), which differentiates within the 
Class II between dissolution rate-limited and solubility-limited class II compounds.2 This aspect 
is crucial for the determination of an appropriate formulation strategy to enhance oral 
bioavailability. 
 
Numerous formulation strategies focus on the enhancement of the dissolution rate to increase 
oral bioavailability of BCS class II compounds.3–5 Some formulations can generate drug 
supersaturation so they temporarily lead a higher apparent solubility and solid dispersions (SDs) 
are here a key formulation approach.3–5 This technology combines an active pharmaceutical 
ingredient (API) in usually its amorphous form together with a polymer as excipient. 
Amorphous materials lack the long-range ordering in the solid-state that is otherwise typical for 
crystalline molecules. This lack of crystallinity is especially advantageous in terms of 
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generating apparent solubility and a high dissolution rate.6 However, not every drug is 
susceptible to be transformed into its amorphous form. To assess if a drug is suitable of being 
developed in its amorphous solid form, the glass-forming ability (GFA) of the drug should be 
estimated. The GFA is commonly understood as the ease of vitrification of a liquid upon 
cooling.7 This tendency to form a glass is not only relevant to form an ASD but also for the 
tendency of the drug to reconvert to its crystalline form. The crystallization might be fast or 
long depending on the storage conditions and on the physicochemical drug properties.1 Indeed, 
the amorphous form presents a high free energy form with increased molecular mobility 
compared to their crystalline solid form.1 The latter mobility can be differentiated based on 
different kinds of relaxation and these are critical for physical stability.8 To increase the physical 
stability of an amorphous form in the solid-state, the drug is commonly formulated with a 
polymer. The presence of a polymer is generally required to obtain an appropriate level of 
stability of the amorphous form because it inhibits the solid-state crystallization and there is 
also a common biopharmaceutical functionality. Thus, polymers can maintain a certain level of 
drug supersaturation within the dissolution medium, which drives permeation to a higher extent 
of drug absorption.9–15 
 
To provide stability and inhibit recrystallization of the amorphous form, a molecular mixing 
between the API and the carrier is required. Generally, phase separation or crystallization can 
be avoided by restricting the molecular mobility of an amorphous drug and polymer during the 
preparation and storage. A relatively high glass transition temperature (Tg) of the polymer 
increases the Tg of the amorphous mixture to lower the mobility of the drug molecules thereby 
acting as crystallization inhibitor. In addition, drug-polymer interactions enhance the 
stabilization of the amorphous form.1 Drug and polymer should be homogeneously mixed at a 
molecular level during processing, and the miscibility between the formulation components 
should be maintained during storage conditions.1 Apart from crystallization, there could be also 
amorphous de-mixing of drug and polymer, which in turn accelerates the crystallization step of 
no longer stabilized drug. Therefore, the knowledge of phase behavior of the drug and carrier 
system is required to understand such a phase separation. Various methods are used for the 
prediction of drug-polymer miscibility. Among them, Flory-Huggins interaction parameter and 
solubility parameter can be used for this purpose. This topic of drug-polymer miscibility is 
treated in more detail in the following chapter. 
 
As mentioned, the goal of solid dispersion formulations is to increase the apparent solubility 
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and dissolution rate following oral administration. This intended advantage in the dissolution 
behavior of amorphous over crystalline form is typically a rapid dissolution and then minimized 
or retarded precipitation until the concentration reaches the solubility limit of the crystalline 
form.16. The proposed mechanistic view of drug dissolution from ASD includes the carrier-
controlled and drug-controlled dissolution depending on the solubility of the drug in the 
concentrated solution of the carrier.17 In the carrier-controlled dissolution, the drug dissolves 
into the polymer-rich diffusion layer at a high rate that there is an insufficient time for the 
particles to be released intact into the medium.17 As a consequence, the drug is molecularly 
dispersed within the polymer-rich diffusion layer.17 When the dissolution of the drug into the 
polymer-rich diffusion layer is rather slow, the drug is released as solid particles. Consequently, 
the dissolution is mainly influenced by the properties of the drug itself such as particle size or 
the physical form and this mechanism is described as drug-controlled dissolution.17 Many of 
the carriers used might increase the apparent or thermodynamic solubility of the drug, through 
the formation of a soluble complex, as described for the case of cyclodextrins.17 Indeed, it has 
been reported that solid dispersions might form different aggregates also with bile salts and 
other lipids present in the GI tract, which might help to maintain a high level of drug 
supersaturation in vivo.18 The drug and polymer nanostructure formation occurs rapidly in 
aqueous media and due to their stability, they create an aqueous suspension that can enhance 
oral drug absorption. These drug and polymer nanoaggregates were usually observed with 
hydroxypropyl methylcellulose acetate succinate (HPMCAS) that is an enteric coating polymer, 
presenting various advantages such as an amphiphilic nature.18,19  
 
Depending on the physicochemical characteristics of the API and polymer, ASDs are primarily 
manufactured by either the fusion method or a solvent method.20 Hot melt extrusion (HME) is 
one of the commonly employed fusion methods, where the API and the polymer are heated to 
form a molten mixture that is subsequently cooled and solidified. The crystalline API should 
be melted, and the polymer should have a Tg that is as low as possible to promote softening at 
these temperatures. Another commonly applied method for solid dispersion manufacturing is 
spray drying, where the carrier and the drug are mixed in a volatile solvent following 
atomization of the solution or suspension and fast drying of the liquid with a stream of heated 
air.21 Since both API and the carrier are dissolved in a common volatile solvent, this method 
favorites molecular mixing.22 Independent of the manufacturing process, drug and polymer 
miscibility is a key aspect to consider when formulating solid dispersions.  
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1.2 Objectives 
The general aim of this thesis is to introduce novel analytical approaches to assist in developing 
solid dispersion formulations. Considering the high number of low water-soluble APIs, solid 
dispersions represent a key technology to increase dissolution rate and therefore apparent drug 
solubility. In a solid dispersion, the API is mixed with an excipient either on a molecular, 
colloidal or particulate level. There are standard techniques to analyze the physical state of the 
solid form but there is an increasing interest to have further analytical options to gain a deeper 
understanding of drug-excipient interactions both in the undispersed formulation as well as 
following aqueous dispersion. Therefore, the objective of this thesis is to explore the potential 
of Fluorescence Spectroscopy and Diffusing Wave Spectroscopy (DWS) in analytics of oral 
solid dispersions. 
 
Following an introduction to the important aspects of solid dispersion technology, there is 
chapter 3 dedicated to the solubility parameter approach and how it is used for drug-excipient 
miscibility in solid dispersions and other oral formulations. This is followed by the main 
objectives to introduce an approach of Fluorescence Spectroscopy as well as DWS to 
characterize solid dispersions. The former approach is intended to analyze celecoxib, a native 
fluorescent drug by quenching to achieve mechanistic drug-excipient interactions upon aqueous 
dispersions of the formulations (Chapter 4). A particular aim of this work is to better understand 
how accessible or “free” the drug is to a fluorescence quencher since the topic of free drug in 
supersaturating formulations is of great interest in this field of pharmaceutical technology. 
Apart from this approach of fluorescence analysis, the present thesis aims to explore the 
potential of DWS to characterize solid dispersions.  
One aim is to use DWS to study aqueous dispersions of amorphous systems to achieve a better 
mechanistic understanding of drug release from solid dispersions. This study is complemented 
with release analysis by considering an absorption sink using an organic phase and fiber optical 
UV probes for kinetic concentration determination, which provides a biopharmaceutical 
framework to the DWS analysis. (Chapter 5).  
 
This thesis further intends to evaluate DWS for the analysis of solid dispersion microstructuring 
during a phase transition. Eutectic mixtures are studied as solidification occurs to simulate a 
melt method such as hot melt extrusion (Chapter 6). This study explores the advantages of DWS 
in a broad frequency band to study solidification of formulations in a non-contact way and 
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therefore without any mechanical disturbance as it would otherwise result from, for example, 
any mechanical approach of rheology. Finally, the present research should contribute to an 
improved understanding of solid dispersions and it should provide some guidance on how 
excipients can be selected for practical usage.
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2 Theoretical section 
2.1 Dissolution and solubility  
Before a drug can be absorbed, it must first dissolve in the GI fluids, which makes this step 
critical from a biopharmaceutical perspective. The dissolution of a drug can be described by the 
Brunner Nernst/Noyes Whitney equation:23 
𝑑𝑀
𝑑𝑡
=
𝐷𝐴 
h
(𝐶𝑠 − 𝐶𝑡)    eq. 1 
Where the dM/dt is the dissolution rate, while D is the diffusion rate coefficient, A is the total 
surface area of the drug particles, h is the diffusion layer thickness, Cs is the aqueous solubility 
of the drug, and Ct is the concentration dissolved at time t. From eq. 1, it is evident that drugs 
presenting a low solubility (Cs) will have also a small concentration gradient (Cs-Ct) resulting 
in a low dissolution rate. This concentration gradient could be only increased by concentrations 
higher than the equilibrium solubility, which requires drug supersaturation as it can be achieved 
from solid dispersions. While dissolution from pure drug can be described by a simple model 
like eq. 1, a mathematic description of release from solid dispersion formulations is 
substantially more complex. Drug dissolution from solid dispersions has been described by two 
main mechanisms: carrier controlled and drug-controlled mechanism.17 In the carrier-controlled 
dissolution mechanism, the particles dissolve into the polymer-rich diffusion layer at a 
sufficiently high rate so that there is no time for particles to be release intact into the dissolution 
medium.17 Therefore, the drug is in this scenario dispersed molecularly into the polymer rich 
layer. If it is not precipitating at the given concentration, the drug would diffuse through the 
layer slowly as predicted by the Stokes-Einstein equation (eq.2): 17 
 
𝐷 =
𝑘𝑏𝑇
6π𝑟𝜂
     eq. 2 
Where kb is Boltzmann’s constant, η is the viscosity and r is the hydrodynamic radius of the 
diffusing molecule at the temperature T. Alternative to this mechanism of carrier-controlled 
dissolution, the overall release of poorly water-soluble drugs in hydrophilic carriers can have 
the drug release as rate-limiting step. This is for example a likely mechanism in case of eutectic 
melts due to the crystalline nature of the poorly water-soluble drug.17 
 
Solubility and permeability are characteristic for each compound and they can be divided into 
the four classes of the biopharmaceutical classification system (BCS) as mentioned before. 
Theoretical section 
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24(Figure 2.1). This thesis will deal with BCS Class II drugs that are of primary interest to 
formulators as they generally have to be formulated by special formulation technology such as 
solid dispersions.2 There are other classification schemes and the Developability Classification 
(DSC) system is particularly suited for a formulation development purpose. This scheme has 
been recently refined to even more adapt to the needs of formulation scientists.2,25,26 More of a 
drug disposition viewpoint takes the Biopharmaceutical Drug Disposition Classification 
System (BDDCS) in which drugs are classified based on their metabolism and solubility.27 This 
complements the BCS systems since the oral bioavailability depends not just on drug solubility 
and permeability but also on active influx and efflux transport as well as intestinal and hepatic 
metabolism. 
 
Figure 2.1: Biopharmaceutical classification system (BCS). (Adapted from Lubrizol Life 
Science) 
 
Various technological approaches have been reported to increase the apparent solubility and 
dissolution rate of BCS class II drugs and these include particle engineering, salt formation, use 
of surface-active agents, lipids and/or co-solvents, and generation of solid dispersions. 3–5,28–30 
As mentioned before, enhancement of apparent solubility can be obtained by changing the 
physical state of the API, from crystalline to an amorphous solid since the latter has as higher 
free energy.31,32 The three-dimensional long-range order that exists in a crystalline material does 
not exist in an amorphous form, and the position of molecules is more random compared to the 
liquid state.33 An amorphous material usually has different physical properties compared to the 
crystalline compound; it presents enhanced thermodynamic properties relative to the crystalline 
state and higher molecular mobility.33 The advantage of enhanced apparent solubility comes 
with the disadvantage of the possibility that the amorphous form may spontaneously transform 
Theoretical section 
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into the crystalline state.33 Therefore to stabilize an amorphous pure drug, a polymeric carrier 
or other excipients should be employed. This solid dispersion technique has gone through 
different generations of formulation types and this is dealt in more detail in the following 
section.34 
 
2.2 Solid dispersion  
As mentioned before, solid dispersions represent one of the main approaches to improve 
apparent drug solubility and dissolution rate.1 The term solid dispersion was introduced already 
in 1971 by Chiou and Regelman and it was defined as the “dispersion of one or more active 
ingredients in a carrier at the solid-state, prepared by either the melting, the solvent or melting 
solvent method”.1 Chiou and Regelman were also the first to introduce a solid dispersion 
classification based on the physical state of the API present in the carrier. In table 2.1 the 
classification of different solid dispersions is presented, which considers systems with two 
components, drug and an excipient that is commonly a polymer. 
 
Table 2.1 Solid dispersion classification. (Adapted from 1) 
 
 
This classification system involves the physical state of the API and the carrier. The first solid 
dispersions developed were eutectic mixtures. In such eutectic mixtures, API and carrier are 
both in a crystalline physical state.1 The eutectic mixture consists of two components, which 
are completely miscible in the molten state, while they present limited miscibility in the solid 
form. When drug and polymer are mixed at a certain composition called the eutectic point, these 
two crystallize simultaneously yielding two a phase of separate crystalline components. 35–37 If 
the mixture is not at the eutectic point, then one component will start to crystallize and separate 
Theoretical section 
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until the specific mixing ratio of the eutectic point is reached. 1 
Solid solutions are comparable to the liquid solutions and consist of just one phase.38 Solid 
solutions can be classified based on their miscibility, for example, continuous versus 
discontinuous solid solutions or according to the way the solvated molecules are distributed.38 
In the continuous solid solution, the components are miscible in all the ratios. However, this 
type of solid solutions has not been reported for pharmaceutical compounds.38 Discontinuous 
solid solutions present a limited solubility of each component in each other, so the drug loading 
is a common issue for this type of solid dispersion.1,38 
 
When API is in an amorphous form, solid dispersions can be divided into glass solutions and 
glass suspensions. A glass solution names a molecular dispersion of a drug within an amorphous 
carrier, yielding a homogenous single-phase system. Since the glass solution has higher 
viscosity compared to the liquid solution, the dispersion of an API might not be homogenous, 
and this needs to be improved during mixing. As amorphous carriers, there were initially low 
molecular excipients employed, but these days, polymers such as poly(vinylpyrrolidone) PVP 
and cellulose derivates are commonly used. 34,39,40 
Depending on the amount of drug in a carrier, solid solutions can be thermodynamically stable 
but amorphous dispersions have higher drug loading and are supersaturated within the polymer 
matrix. Amorphous material can exist in glassy or supercooled liquid states, separated by 
different glass transitions. These differing temperatures can come with two to three orders of 
magnitude changes in the mean relaxation time and viscosity. 1 
 
The mobility linked to the glass transition might be directly related to the issue of 
physicochemical instability.41 However, the Tg alone may not directly predict the stability of 
several amorphous materials. In these cases, the instability was rather connected to local 
mobility.41 The molecular mobility responsible for the glass transition is also called “global 
mobility”.41 Such global molecular motions are commonly known as α-relaxation. Glassy 
systems have also the mentioned local motions in which no translational degrees of freedom 
are given so these are typically rotational or intramolecular movements and are named β-
relaxation.41 These relaxations are also called Johari-Goldstein relaxations and they play a 
significant role in the physical stability of amorphous material especially below the Tg.1 It has 
been suggested that this relaxation might be a precursor to glass transition and can influence 
global mobility.41 The storage temperature of such formulations should be well below the Tg, 
to decrease such molecular mobility. Recent work particularly emphasized a Tg(beta) below 
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which all Johari-Goldstein relaxations come to a halt so that good kinetic stability can be 
targeted.23,42  
The type of solid dispersion that is obtained is partly determined by global molecular mobility 
on the one hand and miscibility of drug and polymer on the other hand. Especially, the more 
concentrated systems can lead to separation of the components into a glass suspension that often 
has a high probability of recrystallizing.23 Thus, increasing the drug load at a certain 
temperature can lead to different types of solid dispersions. 
If the drug is not miscible in the polymer matrix at a given mixing ratio, rapid crystallization 
can occur and result in phase separation, creating drug rich and polymer-rich phases. The 
presence of polymer decreases the diffusion rate of the drug in the media and impedes drug 
crystallization from the supersaturated solution as mentioned before.43 Interesting is the 
addition of a surfactant as it is often done for biopharmaceutical reasons and leads to the third 
generation type of solid dispersion.34 Thus, several improvements may be achieved by such a 
surfactant addition such as improved drug wettability, solubility, and drug-polymer 
miscibility.34 However, even if the inclusion of these excipients might increase the solubility 
and bioavailability, there is always a great risk for phase separation and immiscibility in the 
given polymer blends.12 
 
 
Figure 2.2 Phase diagram of the API and polymer phase behavior. (Adapted from 43,44) 
 
While the addition of surfactant would complicate phase behavior in general, it is helpful to 
visualize a simplified view of phases obtained along with an increasing drug load. Such a 
simplified phase behavior of the API/polymer system and the temperature-dependent solubility 
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of the API in the polymer is presented in Figure 2.2. Four regions can be identified: a region of 
the thermodynamically stable melt, glass solution, kinetically stable glass and 
thermodynamically and kinetically unstable melt.42 At a given temperature, an ASD is 
thermodynamically stable and will not crystallize when the API content is low (represented in 
the area of glass solution and thermodynamically stable melt).44 For a determinate API content, 
the solubility line provides the temperature at which API content can be completely dissolved 
in the polymer, which may be determined by DSC measurements. When the amount of API is 
higher than its solubility in the polymer at the given temperature, the ASD is supersaturated and 
API recrystallization may occur (kinetically stable glass and thermodynamically and kinetically 
unstable melt areas in the graph). However, if the storage temperature is low enough then the 
glass transition temperature, the molecular mobility of the drug might be so low that the 
crystallization is inhibited or slowed for the pharmaceutically relevant time period.44 These 
kinds of formulations are called kinetically stabilized ASDs.44 
 
It is therefore important to understand drug and polymer interactions based on the features of 
the components to achieve adequate miscibility with the drug of interest.45 Herein, a traditional 
approach to evaluate drug and polymer miscibility is to compare their solubility parameters 
based on the assumption that they will give a regular solution.45–47 Also, drug and polymer 
interactions can stabilize the solid dispersion even in the presence of a small amount of polymer. 
However, drug and polymer should be mixed at a molecular level already during the processing. 
Assessment of the phase behavior of solid dispersions can be done by employing two 
complementary techniques such as powder x-ray diffraction (PXRD) and the modulated 
differential scanning calorimetry (mDSC), as outlined in a recent research article.43 A detailed 
discussion about miscibility within the ASDs is presented in the following section. 
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2.2.1 Excipients for solid dispersions 
Historically, excipients employed for solid dispersions might be classified in the following 
groups: 20,23 
1. Polyglycols: polyethylene glycoles (PEG) and polyethylene polypropylene glycol 
copolymers 
2. Polyvinylpyrrolidone polymers: PVP, polyvinylalcohols (PVA), crospovidones (PVP-
CL), polyvinylpovidone/polyvinyl acetate (PVP-VA) copolymers, polyvinyl acetate phthalate 
(PVAP) 
3. Cellulosic derivates: hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose 
(HPMC), carboxymethylethylcellulose (CMEC), cellulose acetate phthalate (CAP), 
hydroxypropylmethylcellulose phthalate (HPMCP) and hydroxypropylmethylcellulose acetate 
succinate (HPMC-AS) 
4. Acrylates and methacrylate copolymers  
 
Based on the type of excipients, ASDs can be classified into different generations: low 
molecular weight, highly water-soluble carriers, such as urea, short-chain carboxylic acids 
(citric/succinic acid) and sugars (sucrose, mannitol, and trehalose), polymeric carriers such as 
PVP, PEG, cellulose derivates and surfactant-polymer based systems.23 A schematic 
representation of the different generations of solid dispersions is illustrated in Figure 2.3. 
 
 
 
Figure 2.3. Solid dispersion classification based on complexity. (Adapted from31) 
 
The first generation of solid dispersion employs mostly crystalline carriers of low-molecular 
weight or semicrystalline carriers such as PEG or poloxamer. In PEG-based solid dispersions, 
the crystalline drug is usually dispersed as micronized crystalline particles or present in its 
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amorphous form.48 Improvement of drug absorption is in these cases mostly due to improved 
wettability of drug and faster dissolution rate compared to a conventional solid dosage form.48. 
Once other polymers than PEGs are used as vehicle, a second generation of solid dispersions is 
obtained. This solid dispersion generation uses mostly amorphous vehicles with good 
solubilization properties so that drug can be incorporated in a non-crystalline form. Such 
polymeric carriers have been the most successful in solid dispersion formulations because they 
can provide amorphous drug dispersions. Polymeric carriers can be classified in synthetic and 
natural product-based polymers. Within the first category, polyvinylpyrrolidone (PVP), 
polyethylenglycole (PEG), and polymethacrylates are, for example, included; whereas natural 
product-based carriers are mainly starches and celluloses with further semi-synthetic 
derivatives than constitute again a separate category of polymeric excipients. 
The selection of polymer for any amorphous solid dispersion requires first well-established oral 
acceptability and hence a suitable regulatory status. The polymer is further chosen for its ability 
to stabilize drug in the polymeric matrix as well as to promote and sustain supersaturation upon 
aqueous dispersion. The physical-chemical characteristics and the role of the amorphous carrier 
in the formulation of ASDs have been outlined in the review article by Van Duong et al. 49 and 
presented in Table 2.2. The selection of an amorphous carrier will impact on the 
physicochemical characteristics and the dissolution performance of the final ASDs. As an 
example, it has been widely reported that molecular weight has a strong effect on the dissolution 
rate. Thus, the dissolution rate generally decreases as the molecular weight of the carrier 
increases and there is typically a lower drug solubility of the carrier as well as a longer process 
of swelling with higher viscosity in the diffusion boundary layer. All of these factors contribute 
to a comparatively slower release with polymer selection of higher molecular weight.49 Also, 
the carrier content contributes to the dissolution rate; indeed, decreasing carrier content is 
associated with the decrease in the dissolution rate because the drug is more concentrated and 
hence less stabilized in the amorphous aggregates.49 Chemical aspects of the polymer are 
relevant for molecular interactions so each carrier might exert a specific influence on the 
dissolution rate and may exhibit particular capability to maintain supersaturation of the drug.49 
A good example of chemical modifications can be found in the group of cellulose polymers. 
Among them, hydroxypropyl methylcellulose acetate succinate (HPMCAS) is a particular 
derivate of cellulose, which is known as enteric coating polymer and presents interesting 
moieties of acetyl and succinoyl groups.50 The key feature of this polymer is its capacity to 
dissolve at different pH due to the amount of the given acetyl and succinoyl groups. Enteric 
polymers employed for a pH-controlled drug release from ASDs may present especially for 
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drug bases an advantage. A high release of protonated base can lead to excessive supersaturation 
of drug upon transfer into the duodenum that exhibits a higher pH thereby leading to high risk 
of drug precipitation.50 The correlation between the drug release and the substituents in 
HPMCAS has been investigated. Thus, the proportion of the acetyl to succinoyl substitution is 
highest in AS-LF which is soluble at lower pH (5.5), where the HF grade has a lowest proportion 
of the acetyl to succinoyl substitution and it dissolves at higher pH (6.5).50 The ratio of succinoyl 
to acetyl groups was shown to play an important role in the inhibition of drug recrystallization.51 
During the dissolution process, it has been reported that numerous polymer-drug aggregates 
can form, which function as a drug reservoir. They provide a free drug concentration, which is 
sustained by replacing the amount of drug absorbed.16,32–35   
 
Recently, it has been demonstrated that if the carrier has surface activity or even self-
emulsifying properties, the drug release may be further improved, which led to the development 
of the third generation of solid dispersions.20,56 In these systems, the polymeric carrier is either 
itself surface-active or a surfactant is added.31 The presence of a surfactant in the solid 
dispersion formulation increases wettability, dispersion, and solubilization of the drug in 
aqueous media 53,57 Polyethoxylated surfactants such as Gelucire, Tween and Labrasol have 
shown improved dissolution and enhanced oral availability when included in the ASDs. 58,59 
 
Lipid-based excipients are used as well, which are ingredients derived from vegetable oils, fatty 
acids or waxes. Vegetable oils include triacylglycerols (fatty acid esters of glycerol), 
phospholipids and lipophilic vitamins.60 They are used to produce a wide variety of ingredients 
by various processes and the physical properties of these lipids depend on the unsaturation in 
fatty acids, the fatty acid chain length, and free hydroxyl groups or fatty acid content. Therefore, 
these ingredients can be either liquid or solid, and they often present different polymorphic 
forms. These excipients may further differ in their hydrophilic lipophilic balance (HLB) value 
and different colloids can form in aqueous dispersion such as micelles with the more 
hydrophilic lipid-based surfactants.61 Sodium lauryl sulfate and block copolymers of ethylene 
oxide and propylene oxide have been also employed to increase the dissolution rate and the 
solubility of different active ingredients.23 
 
Among the lipid-based surfactants, Gelucires have been often employed for their solubilizing 
properties.62,63 The Gelucire family are polyethylene glycol (PEG) glycerides composed of 
mono-, di- and triglycerides and mono- and diesters of PEG that have started to be employed 
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in ASDs formulations.62,64–66 The presence of the PEG provides some water miscibility to the 
lipid bases thereby removing the necessity of incorporating surfactants or related molecules to 
allow drug release to occur over a relevant time scale. The lipid chain length plays here a role 
for sustained drug release. On this basis, there has been a growing interest in the use of Gelucire 
50/13 as a vehicle for controlled release dosage forms. The mechanism of the controlled release 
might be because Gelucire 50/13 swells in water and forms a diffusion barrier to drug release.67 
The functionality of lipids in the formulation of poorly soluble drugs is linked to their excipient 
tendency to self-assemble in an aqueous environment. When lipids are included in ASDs, the 
mechanism of the dissolution process is more complex.53,57 Surfactants provide better powder 
wetting, enhance the formation of nanoaggregates and improve drug solubility due to inclusion 
into micelles.57 Formulations at high surfactant concentrations spontaneously form a fine 
dispersion or emulsion upon contact with water, therefore favoring higher drug dissolution. 
Especially the formation of colloidal dispersions can facilitate increased solubilization and 
absorption of poorly soluble drugs.53 While these are biopharmaceutical advantages of using 
lipids in ASDs, any excipient has particular physicochemical properties that can be important 
for the performance of the given solid dispersion and Table 2.2. provides here an overview. 
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Table 2.2 Important parameters of the carrier in ASDs formulation (adapted from 49) 
 
 
2.2.2 Solid dispersion manufacturing technologies  
The processing technologies are classified into two main classes, which are the following: 
solvent-based or fusion-based methods. A schematic classification with subgroups of the 
different technologies for solid dispersion manufacturing is the following:1 
 
a) Solvent-based technologies where drug and excipients are first solubilized in a solvent 
prior to a solidification 
-Spray drying (rapid removal of the solvent in a controlled temperature and pressure 
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environment) 
-Fluid bed granulation/layering/film coating: removal of the solvent using various conventional 
pharmaceutical equipment 
-Coprecipitation: solvent-controlled precipitation technologies such as microprecipitated bulk 
powder (MBP) 
-Supercritical fluid-based technologies  
-Cryogenic processing 
-Electrospinning 
-Rotating jet spinning 
b) Fusion-based technologies where the drug and the excipient are mixed and heated 
-Melt granulation 
-Hot melt extrusion 
-KinetiSol 
-Deposition of molten material on a carrier by fluid bed process  
 
There is also the possibility to prepare amorphous systems by mechanical energy, i.e. co-milling 
with excipients. This has in the past barely have relevance to manufacturing of solid dispersions 
but there is growing interest in this approach because of co-amorphous systems that are 
preferably prepared by this manufacturing method.68 Therefore, mechanical energy appears to 
become a third class of amorphization methods apart from solvent-based and heat-based 
methods. 
 
The selection of the preparation method depends on the physical properties of the API such as 
thermal stability, melting point, and solubility in organic solvents.23 The solvent method 
involves the preparation of a solution of drug and polymer in a common solvent, followed by 
evaporation of the volatile solvent to yield a solid dispersion. This technique favors a molecular 
level mixing between the components, which increases the chance of yielding a stable ASD. 
Volatile solvents are usually evaporated at a low temperature, preventing thermal 
decomposition of the drug and/or polymer. Solvent evaporation might present challenges with 
respect to potential phase separation. An aspect can be therefore how fast the solvent is 
removed. While on a small scale there is often rotary evaporation employed, a later scale-up 
method is usually spray drying for which the drying conditions may become critical for the 
homogeneity and hence the quality of the solid dispersion. 
Selecting the right solvent in which both drug and polymer are soluble might be challenging. 
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In this regard, solubility parameters can be helpful to screen solvent candidates regarding drug 
and excipient affinity to a common solvent, but it is still possible that there is finally no 
sufficient solubilization identified in a common pharmaceutical solvent. 
 
 
 
Figure 2.4. Schematic illustration of spray drying technology. (Adapted from 69) 
 
Spray drying is the most commonly employed solvent method, which consists of four stages: 
the atomization of the liquid, mixing of the liquid with the drying gas, evaporation of the liquid 
and separation of the particles from the gas.70 A schematic representation of spray drying 
technology is in Figure 2.4. The solution of API and carrier is introduced in a heated chamber 
via a pump system with controlled droplet size, and spray rate, followed by fast evaporation of 
the solvent and collection and separation of the remaining solid particles, which form an ASD. 
API and the carrier must be dissolved or suspended in a common solvent, which in most cases 
is organic. Numerous solvents and solvents mixtures with varying polarity can be employed; 
also, this technique has the advantage of being easily scaled up for manufacturing and control 
of the final particle size.23 With spray drying, it is possible to obtain ASDs with superior 
physical stability using established manufacturing equipment. It allows rapid removal of the 
solvent, fast solidification, equipment available from lab to full-scale commercial products, 
low-temperature processing suitable for highly volatile solvents and continuous processing.23 
However, the final physical state of the API depends on the chemical nature of the substance 
and it might be amorphous, crystalline mixtures, crystals with induced imperfections or 
metastable crystal forms. The solid form depends mainly on a drug’s inherent glass-forming 
ability and less on the preparation method.71 In this context, the glass-forming ability of sixteen 
poorly soluble drugs with varying molecular structures and physicochemical properties have 
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been investigated.72 The results confirmed that only half of the APIs could be amorphized 
completely by spray drying.72,73 
 
Figure 2.5. Hot melt extrusion technology. (Adapted from www.thermofisher.com) 
 
In the class of the heat-based manufacturing method, HME has become increasingly important 
in recent years. As presented in Figure 2.5, a physical mixture of drug and polymer is introduced 
into the extruder at high temperatures, which melts or softens the mass to facilitate mixing. The 
material is then continuously extruded, cooled and chopped into small pieces for further down-
stream processing to, for example, a powder or pellets. The main advantages compared to other 
methods is that it is solvent-free, it can run continuously, scale-up is straight forward and the 
footprint of HME in a manufacturing facility is rather low.74 At process temperatures, the 
crystalline API should be melted and stable at these high temperatures, and the polymer should 
have a sufficiently low Tg to obtain softening at these temperatures. Besides, processing 
parameters such as feed rate, shear force, temperature, die geometry, barrel design, and screw 
speed are key aspects in the process design of the final product.75  
 
The selection of a suitable polymer for HME is important for stabilizing ASDs, as well as for 
the processing characteristics. Therefore, the selected polymer enhances formulation 
characteristics but also enables the process itself. Small molecules can be further added as 
excipients to the physical mixture to lower the viscosity of the molten material or to decrease 
the processing temperature.1 In some cases, the drug itself might provide better processing 
characteristics and may act, for example, a plasticizer for the polymer.76,77 
 
An important factor in the solid dispersion formulation is the mixing process, which is relevant 
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for different manufacturing processes as well as for the final drug product stability. As outlined 
in the next paragraphs, miscibility is studied using in silico as well as experimental tools. 
However, the manufacturing process likely influences the practical mixing capacity and phase 
behavior kinetics of solid dispersions. Previous research outlines that heat is an important 
energy input for drug and excipient mixing. Heat pre-treatment of the solution before spray 
drying can result in higher kinetic miscibility. Amorphization of the copolymer by spray drying 
before using it as an excipient for hot melt extrusion can represent a benefit. It was reported 
that spray drying might produce more stable solid dispersions due to the molecular mixing of 
the drug and the polymer in a common solvent.78,79 On the other hand, a recent research article 
outlined that HME allows higher drug loading. These considerations show that based on the 
given drug and polymer matrix, there is not a completely free choice of the manufacturing 
technique, but the given physicochemical mixture properties are likely to favor one over the 
other technique. If there is a strategic preference for one manufacturing technique, then these 
processes should be already considered in the selection of the formulation apart from aspects 
of stability and biopharmaceutical performance.79  
 
2.3 Selected aspects of ASDs formulation  
2.3.1  Drug-polymer miscibility  
Drug and polymer miscibility is one of the key aspects to consider for adequate excipient 
selection in ASDs. Not just during the manufacturing, but also during the shelf life of the 
product, drug and polymer miscibility should be maintained in a single phase to present the 
advantages associate with the amorphous physical form of the drug. Phase changes might occur 
due to water absorption during storage and they are likely to occur during dissolution.14 Water 
increases the molecular mobility of the system and decreases the Tg, which might lead to phase 
separation if only kinetic miscibility of the components was given. It is important to assess if 
miscibility between the polymer and the drug will be achieved during processing, for example, 
hot-melt extrusion, spray drying, or freeze-drying. Experimentally, this is commonly done with 
Differential Scanning Calorimetry (DSC). A single Tg will be detected in the case of a miscible 
homogenous solid dispersion. This temperature will be observed between the values of the 
individual Tg values of the single components. However, one limitation of this approach is that 
the phase separation should be larger than on a level of 30 nm domains when using DSC for 
detecting the Tg. Indeed, when the phase separation is on such a microscopic scale, the 
conventional analytical techniques such as DSC powder X-ray diffraction (PXRD) are typically 
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not able to detect it. 
 
For this purpose, further analytical tools such as atomic force microscopy are attractive to study 
early signs of phase separation.80 Moreover, confocal Raman imaging shows promising results 
when analyzing the excipient distribution within solid dispersions.81 It was shown that a 
distinctive single Tg by DSC is not always an indication of a homogenous ASD and therefore 
cannot provide all the necessary information for physical stability.81 As a result, the physical 
stability of ASD and processing conditions demonstrated a better correlation when using Raman 
microscopy as an additional tool.81  
 
Besides the experimental approaches, numerous other methods can predict polymer and drug 
miscibility. The two main theoretical approaches for drug and polymer miscibility are based on 
the Flory-Huggins (F-H) theory and that of the solubility parameter.1 Flory-Huggins theory is 
based on lattice approach and addresses particularly the situation of polymers to estimation of 
free energy of mixing of polymer-solvent or polymeric mixtures. The obtained parameter, d-p 
is known as the F-H interaction parameter. This can be estimated from different experimental 
as well as theoretical approaches, including the solubility parameter prediction and the melting 
point depression approach.82 The determination of drug solubility within the polymer matrix is 
commonly done employing the melting point depression method. Polymer-induced melting 
point depression can be used to experimentally determine the drug-polymer miscibility, just by 
DSC: various physical mixtures of a drug and polymer are heated at a different rate and the end 
of the melting point endotherm is determined as the intersection between the dissolution 
endotherm and the baseline after dissolution.1,82 The F-H theory is a classical theory for 
polymer-solvent system to provide the Gibbs free energy of mixing. A small molecule such as 
a drug can be considered equivalent to the solvent in the polymeric mixtures, and therefore can 
be described by the F-H theory.83 Apart from the F-H theory approach to drug-polymer 
miscibility, the use of solubility parameters is extensively reported in the literature to aid in the 
development of solid dispersions. A recent review article highlights the application of solubility 
parameters to assist with bio-enabling formulations such as lipid-based formulation, 
mesoporous silica, and solid dispersions.84 The solubility parameter approach is based on the 
concept of ‘like dissolves like’, meaning that compounds with similar properties will more 
likely be miscible.85 Historically various approaches have been developed in this field, but the 
main are the Hildebrand total solubility parameter or consideration of partial solubility 
parameters as Hansen Solubility Parameters (HSP). When considering the total solubility 
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parameter, cohesive energy density is the central aspect. It represents the sum of different 
energies per volume arising from drug and polymer interactions, including Van der Waals and 
polar interactions as well as hydrogen bonding. The final value for the solubility parameter is 
obtained from the square root of the cohesive energy density CED (eq. 3). 1  
𝛿𝑡 = (𝐶𝐸𝐷)
1
2 =  (
Δ𝐸𝑣
𝑉𝑚
)
1/2
    eq.3 
 
where the ΔEv is the energy of vaporization and Vm the molar volume. CED is defined as the 
cohesive energy per unit volume. The Hansen solubility parameter can be calculated from 
partial contributions to cohesive energy density (eq. 4) 1:   
𝛿2 = 𝛿𝑑
2 +  𝛿𝑝
2 +  𝛿ℎ
2               eq. 4 
 
Where δd, δp, δh are the dispersive, polar and hydrogen bonding respectively. HSP considers the 
dispersion, polar interaction, and hydrogen bond contribution for a given molecule. The main 
application is still in the solubility assessment in different solvents.86,87 However, it has also 
been applied to predict drug and excipient miscibility for ASDs. A recent research article 
compares the Hildebrand and Hansen solubility parameter prediction to the experimental set up 
of data for polymers.88 Using 75 different polymers, it has been reported that both Hansen and 
Hildebrand solubility parameter have similar predictive accuracy (circa 70%).88 
 
Miscibility prediction based on the Hildebrand approach was employed for ASDs by 
Greenhalgh et al.89 This approach considers the difference in solubility parameters between the 
drug and the polymer. It was observed that for a difference between 1.6 to 7.0 MPa, the system 
was completely miscible; on the contrary, when this difference was between 10.8 and 18.0 MPa, 
the systems were immiscible. Partially immiscible systems in the liquid state were found to 
have a value between 7.4 and 15.9 MPa.89 
 
Similar results have been reported also with HSP. Solubility parameter differences below 7 
predict a miscible system as in the case of, for example, Soluplus or arabic gum with 
lacidipine.90 Based on the HSP, these two carriers have been selected as the most effective 
nucleation and crystal growth inhibitors.91 HSP is also reliable in the prediction of a co-crystal 
formation.92 The established cut off was 8.5 MPa, but this, however, did not bring real 
advantages.92 The solubility parameter prediction was not reliable in the case of some drug-
polymer interactions, for example when pronounced acid and basic interactions were present.28 
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Thus, the main drawbacks of the solubility parameter prediction have been evaluated by 
Thurpin et al.93 This article highlighted the theoretical limitations in employing the solubility 
parameter approach; in particular when a neglected entropic contribution was highly relevant 
for the experimental system. The same authors propose new in silico methods that consider all 
parts of the free energy of mixing and predicted then more accurately drug-polymer 
miscibility.93 New prediction methods are employed for the calculation of solubility parameters 
based on pure chemical structure. Among them, screening charge densities of molecular 
surfaces ( the so-called σ-profiles) have also been used by the conductor like screening model 
for real solvents (COSMO-RS) and can be employed in a quantitative structure-property 
relationship (QSPR) to predict solubility parameters.94 Another study suggested using partial 
solvation parameters instead of the Hansen solubility parameter since the novel concepts have 
several advantages, in particular, the distinction between hydrogen bond acceptors and 
donors.82 The different methods to predict drug-excipient miscibility may show in the future 
even further advancements. Interesting is here, for example, the use of machine learning 
algorithms if sufficient data are available to train algorithms. In a recent research article, a 
machine learning approach was used for the prediction of the physical stability of solid 
dispersions. The prediction success is 82% for ASD stability. Also, modeling and experimental 
data were compared and they confirmed the results.95 
 
2.3.2  Drug supersaturation 
As mentioned before, ASDs benefit from a higher apparent solubility and therefore higher 
dissolution rate due to the relatively higher energy of the amorphous form. Higher concentration 
in solution compared to the intrinsic solubility of a compound is called supersaturation. The 
ability to achieve supersaturation is key to generate a high concentration gradient in the GI 
lumen to drive absorption and an ideal ASD formulation should maintain such supersaturation 
during the dissolution process. 
The theory of the behavior of supersaturating formulations has called this ability to 
supersaturate a “spring” effect, while the capacity to sustain such high concentrations was 
named a “parachute”.16 Upon water dispersion, the high-energy amorphous compound quickly 
dissolves and thereby reaches supersaturated concentrations and the extent of this spring effect 
is depending on the compound properties. Also depending on the compound are the kinetics of 
crystallization that may bring the compound to a less soluble but more stable crystalline form. 
Some excipients, such as polymeric carriers used in ASD, might retard or inhibit the rate and 
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the extent of precipitation of dissolved compound, leading to a further increase in absorption 
due to this “parachute” effect.16 (Figure 2.6) 
 
 
Figure 2.6. Representation of the “spring” and “parachute” effect. (Adapted from 16) 
 
Of all the formulation factors considered, selection of the carrier and the drug loading are the 
most important. The presence of the carrier inhibits the crystallization of the API already in the 
solid form and prevents that crystallization occurs that would diminish generation of initial drug 
supersaturation and hence the “spring effect”. Polymers maintain supersaturation of the API 
during the dissolution by different mechanisms. Molecular interactions of drug and polymer 
can interfere with nuclei formation and the formation of drug-polymer aggregates has been 
reported.50,96 Polymers can also retard crystallization by growth inhibition and hereby the 
adsorption on surfaces and local generation of high viscosity are mechanisms that can account 
for this.97 Recent studies have outlined that increasing hydrophobicity of the polymer, for 
example adding hydrophobic moieties improves the stability and the supersaturation of the API 
in the solid dispersion.98 Such introduced hydrophobicity facilitates direct dispersive 
interactions of drug and polymer that can form a basis of the “parachute effect” of a formulation.  
It is helpful to recall that dissolution of an ASD can be kinetically mediated primarily by either 
the drug or polymer.17 Upon contact with an aqueous environment, solid dispersions yield a 
polymer-rich and a drug rich diffusion layer.17 In the case of carrier-mediated dissolution, the 
drug diffuses fast into the diffusion layer while in the case of a drug-driven dissolution 
mechanism, drug particles migrate from the ASD to the dissolution medium. No formation of 
a polymer-rich diffusion layer is then observed in this scenario.17 
The interactions of drug and excipients can be complex especially in the intestinal environment 
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that further includes endogenous compounds such as bile salts and phospholipids. Therefore, 
interactions are more difficult to understand and predict due to the complex phase separation 
that is often involved. Previous studies have reported that upon contact with an aqueous solution 
simulating the gastrointestinal media, ASDs rapidly disperse and provide numerous drug-
polymer aggregates.18,19,99–102  
 
Therefore, a more complex system evolves when an amorphous formulation dissolves and 
disperses into a wide range of species ranging from the free or solvated drug, bile salt micelles, 
free or solvated polymer, polymer colloids, amorphous drug and polymer aggregates and large 
amorphous and drug particles.18,103 Formation of nanoaggregates provides a more complex view 
to explain the sustained supersaturation of solid dispersions because the drug may form 
nanoaggregates that act as a reservoir that continuously replace the supersaturated free drug in 
solution.18,19  
 
The free drug concentration that is the true supersaturation driving the absorption is due to the 
release from these particles and colloids in an aqueous environment. The aqueous dispersion of 
a lipophilic drug alone can exhibit complex phase behavior, leading to a drug rich and water-
rich phase. This phenomenon is called liquid-liquid phase separation (LLPS).104,105 Such 
generation of a LLPS is expected to occur regularly when ASDs disperse in GI fluids. This 
phenomenon is observed when the drug concentration exceeds the amorphous drug solubility 
in the aqueous environment, provoking the formation of mentioned two different phases, a drug 
rich and a water-rich phase. In the water-rich phase, the amorphous solubility of the compound 
is present, while the drug rich phase includes a water-saturated amorphous compound but as 
nanodroplets. The presence of these represents the drug reservoir, which provides drug to the 
water-rich phase until the amount of the drug in the drug rich phase have been depleted. To gain 
a deeper understanding of the drug distribution in the drug rich or water-rich phase, fluorescence 
spectroscopy was employed. One peak was present when the drug was distributed in the drug 
rich phase, while two peaks were observed when the drug was partitioning in the drug rich 
phase.106 Such work suggests that fluorescence spectroscopy can provide valuable insights into 
the mechanism of drug dissolution.107 Indeed, it appeared that drug loading represented the 
main reason for the limiting dissolution mechanism; at low drug loading, dissolution is mainly 
polymer-controlled, while at higher drug loading it becomes mainly drug-controlled.107 This 
example highlights the importance of novel analytical approaches not just to guide the selection 
of excipients and drug loads but also to achieve an improved mechanistic understanding of 
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ASDs.  
 
2.4 Physical characterization of solid dispersions 
Many challenges might arise during the formulation of ASDs. New emerging characterization 
techniques can yield valuable insights into the characteristics of ASDs, both quantitatively and 
quantitatively. These techniques might be employed to investigate the physicochemical 
properties at different stages of formulation development. Recent review articles outlined the 
most important techniques used for the ASD characterization.6,108,109 Among the available 
techniques, thermal analysis techniques and spectroscopic techniques are the most abundantly 
employed techniques for solid-state characterization.  
Among the thermal characterization methods, differential scanning calorimetry (DSC) or 
modulated- temperature differential scanning calorimetry (mDSC) are most often employed to 
determine the solid-state of the drug and drug-polymer interactions within the formulation. In 
the solid dispersion, if the drug is in its amorphous form, no endothermic peak will be present. 
Also, a shift of the Tg in case of drug-polymer interactions might be observed.110 Moreover, 
melting point depression is one of the most common experimental methods to assess drug-
polymer miscibility as mentioned before. 
 
Apart from thermal methods, drug-polymer miscibility can be assessed also by spectroscopic 
techniques. Fourier Transform Infrared (FT-IR) Spectroscopy is employed to study specific 
interactions between the polymer and the drug functional groups.110 FT-IR and Raman 
microscopy can even provide direct visualization of the distribution of the different excipients 
as well as the physical form of the components.43,111,112 These two vibrational spectroscopic 
imaging techniques differ in spatial resolution: indeed this resolution is reported to be around 
10 µm for FT-IR microscopy and 1 µm for Raman microscopy.111 Moreover, Terahertz Raman 
Imaging has been used to detect different polymorphic forms and to monitor API crystallization 
during the dissolution process and also to characterize the physical form of excipient including 
their spatial distribution.111 Solid-State Nuclear Magnetic Resonance (ssNMR) is another 
method to determine the physical form of the components and to assess drug-polymer 
interactions and miscibility. The main advantage of this technique is the detection of phase 
separated domains with a size below the detection limit of DSC. The miscibility and the drug-
polymer interaction are estimated from the spin-lattice relaxation times (1H T1).
113,114 When 
phase separation is present, protons in each phase will have their relaxation times. When a 
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single-phase system is present, spin diffusion averages individual relaxations resulting in a 
uniform average relaxation time, different from the relaxation time of pure components.113,114 
Interesting is further solid-state fluorescence spectroscopy that has been applied to study 
properties of the API within dry powder inhaler (DPI) formulations.111 This is one of several 
versions to apply fluorescence spectroscopy and there is much potential to make use of it in the 
pharmaceutical analysis of amorphous systems. Thus, fluorescence spectroscopy was, for 
example, employed to demonstrate a phase separation with the formation of drug-rich 
domains.115 The immiscibility was detected at a length scale of less than 10 nm, and this 
technique offered early detection of such lack of homogeneity even though the DSC results 
showed miscibility based on a single Tg.115,116 Fluorescence spectroscopy was employed further 
to study phase separation which occurred in the aqueous phase during the ASD dissolution 
under non-sink conditions.116 This LLPS phenomenon occurs when the amorphous solubility is 
exceeded and water-saturated colloidal amorphous drug aggregates form in solution. For this 
fluorescence analytics, an environmentally sensitive probe, i.e. Nile red, was used to detect the 
amount of amorphous aggregates that evolved from the various ASDs.117 
 
Another promising analytical field for solid dispersion analysis is rheology. Rheological 
properties of amorphous solid dispersion determine the processability, the mixing and may have 
on a microscopic level also a biopharmaceutical relevance. Thus, polymer elasticity, viscosity, 
and viscoelasticity properties are considered for the development of ASDs. Recently, 
rheological techniques have been employed to study the ASD microstructure as a function of 
processing methods, drug distribution, and its physical form.114 Indeed, crystalline particles or 
aggregates of API present an increased elastic response compared to the amorphous physical 
form.114 Rheological measurements also outlined that the incorporation of API resulted in a 
plasticizing effect in the system.114 Among the analytical techniques used for characterizing 
rheological properties of solid dispersions, dynamic mechanical analysis (DMA) and 
thermomechanical analysis (TMA) are the most employed. DMA measures the strain in the 
oscillator rheology versus the frequency or the temperature.43 Recently, a new light scattering 
tool called Diffusing Wave Spectroscopy (DWS) started to be employed for microrheological 
characterizations of pharmaceutical systems.118  
Finally, there are certainly further techniques to be named in the framework of solid dispersion 
analysis. Other techniques to assess drug-polymer miscibility are not limited but include 
dielectric relaxation spectroscopy (DRS), atomic force microscopy (AFM),119 positron 
annihilation lifetime spectroscopy (PALS),120 fluorescence resonance energy transfer 
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(FRET).43 The following section provides more details on the emerging analytical methods that 
were relevant in the framework of the current thesis. 
 
2.4.1 Emerging analytical tools 
2.4.1.1  Fluorescence Spectroscopy 
The last two decades have seen a growing trend towards fluorescence spectroscopy applications 
in biological sciences. Fluorescence occurs when an orbital electron of an atom or molecule 
relaxes to its ground state by emitting a photon from an excited singlet state.121 In the excited 
singlet state, the electron in the orbital is paired to the second electron in the ground state 
orbital.121 Therefore, the return to the ground state is possible and occurs rapidly with the 
emission of a photon. The emission rates of fluorescence are typically 10-8 s so that the typical 
fluorescence lifetime is circa 10 ns. Typically, aromatic molecules exhibit fluorescence and 
they are called fluorophores.121 A schematic absorption and emission spectra for a fluorescent 
molecule is presented in Figure 2.7. It points to the aspect that the emission spectra occur at 
lower energies and therefore longer wavelengths. The energy of emission is usually less than 
the energy of absorption. 
 
Figure 2.7. Absorption and fluorescence emission spectra. (Adapted from121) 
 
The fluorescence spectroscopy measurements can provide information on a broad range of 
molecular processes, such as the interaction of fluorescent molecules with the solvent medium, 
rotation diffusion of molecules, conformational changes and binding interactions.121 Organic 
molecules such as drugs exhibit autofluorescence and are defined as an intrinsic fluorophore.121 
Extrinsic fluorophores such as dyes (for example Prodan) are added to the sample which does 
not exhibit natural fluorescence.121 
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An interesting way to get information about fluorescence lifetime and excited state deactivation 
is by introducing quenchers (e.g. acceptor molecules) and by observing the fluorescence 
intensity as a function of their concentration. From the consideration of the excited state 
population, it is possible to obtain the so-called Stern Volmer equation that describes 
fluorescence quenching. The fluorescence intensity in absence and presence of quencher F0/F 
are here plotted versus the quencher concentration.121 The plot of F0/F versus [KI] should be 
linearly dependent upon the concentration of quencher and it yields an intercept of one on the 
y-axis and a slope equal to the Stern-Volmer quenching constant KD (1/M × s) when the 
quenching process is dynamic. Analysis of the linearity or deviation from linearity in the Stern 
Volmer approach is of interest to learn about a given system and in particular about the 
accessibility of the fluorescent molecule by the quencher.121 
 
Applications of fluorescence spectroscopy in pharmaceutical sciences have been limited up to 
now and interestingly, the Stern Volmer approach has to the best of our knowledge not yet been 
used to study ASDs. Other fluorescence spectroscopy methods have been applied to study the 
local environment of the ASD, concerning the miscibility, phase separation and ASD 
dissolution performance.122–125. Indomethacin and itraconazole two native fluorescence 
molecules, have an excitation band within the typical confocal microscope lasers and therefore 
allow to study drug distribution within the matrix.124 A good correlation between the phase 
separation and reduced physical stability was found, suggesting once again that miscibility is 
an important factor for ASDs.124 Fluorescence optical and fluorescence confocal microscopy 
allows discerning between the drug and the polymer regions in the ASD when adding 
fluorophores to the formulation. Hydrophobic dyes such as Prodan can partition into drug rich 
domains within the formulation, while hydrophilic molecules partition into polymer-rich 
domains.116,126,127 Indeed, changes in the fluorescence spectrum of the drug or the fluorescent 
probe such as pyrene have been correlated to changes in the local environment and therefore an 
indication of the phase separation.122 Distribution of different excipient within the ASD has 
been analyzed also using fluorescent probes such as pyrene.115,123 Fluorescence-based 
techniques have been also employed to compare two different manufacturing techniques such 
as spin-coated ASDs and film casting; within the spatial resolution of 300 nm, smaller domains 
in the first techniques were observed and resolved.126  
Various studies have assessed the efficacy of fluorescence spectroscopy in studying the 
mechanism of drug release from ASDs.115,122 With this purpose, pyrene was employed as a 
model compound to study the mechanism of dissolution from ASDs. The ratio of emission 
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between the third peak and the first peak has been considered as a parameter to assess changes 
in the local environment of the probe. The association of the pyrene with the carrier yields a 
different emission spectrum compared to the spectrum of free solute in solution.115,122 The use 
of fluorescence spectroscopy in drug release analysis supports the previously outlined different 
mechanisms of amorphous drug dissolution.107 Indeed, drug loading represents the main reason 
for alternative dissolution mechanisms; at low drug loading, dissolution is mainly polymer-
controlled, while at higher drug loading, it is mainly drug-controlled.107 Drug dissolution is 
faster than the phase separation in an aqueous environment at low drug loading, whereas carrier 
phase separation due to the water absorption is leading to a decreased drug dissolution rate.107 
Fluorescence spectroscopy was also applied to study excipient interaction upon water 
dispersion.123 When the dissolution behavior of itraconazole in presence of surfactant was 
assessed different spectra were obtained when pyrene was associated with micellar or non-
micellar solutions, which provided valuable mechanistic insights.123 The same model 
compound was used to study the entrapment between the polymer and surfactant.128 Finally, 
fluorescence spectroscopy techniques were used to gain a deeper understanding of the drug 
distribution in the drug-rich or water-rich phase in liquid-liquid phase separation (LLPS).91,96,97. 
One peak was present when the drug was primarily in the drug-rich phase, while two peaks 
were observed when the drug was partitioning in between drug-rich phase and water-rich 
phase.106  
 
This brief overview of fluorescence application in pharmaceutical analysis of ASDs suggests 
that there have been many recent advancements but there are also further analytical 
opportunities that remain to be explored; one of these is the use of fluorescence quenching 
analysis according to the Stern Volmer approach. 
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2.4.1.2  Diffusing Wave Spectroscopy (DWS) 
Diffusing Wave Spectroscopy (DWS) is a relatively new analytical technique that explores the 
diffusive behavior of light in a strongly scattering media and characterizes the temporal 
fluctuation of multiply scattered light to the motion of scattering particles.129 Therefore, this 
technique can be employed to study particle motion in concentrated fluids such as colloids, 
microemulsion and other systems that present strong scattering.130–132 Compared to other light 
scattering techniques such as particle sizing, the main advantage is that DWS extends the 
application from dilute samples to more concentrated and even milky systems that are strongly 
scattering light.130–132  
 
 
 
Figure 2.8. Schematic illustration of the DWS. (Adapted from www.lsinstruments.com) 
 
Multiple scattering can be thought of as a succession of several single scattering events, which 
randomizes the photon path over a photon mean free path length l*.129 The principle of DWS 
illustrated in a simplified scheme Figure 2.8 as follows: coherent light waves (e.g. an incident 
coherent laser beam such as from an Ar+-ion laser operating in the single frequency mode at a 
wavelength of 514 nm) travel through a sample along the various random scattering paths 
described by a photon random walk, and set up a highly irregular intensity pattern that is called 
“speckle”.133,134 The speckle is a result of the interference of many waves from many paths of 
various lengths at the detector. The time of photons passing through the scattering path is much 
shorter than the time t0 which takes a colloidal particle to move a distance of the order of the 
optical wavelength λ0 = 2π/k0 (t0 = 1/Dk0).133,134 An illustration of the principle of DWS is 
outlined in Figure 2.8. The time-dependent phase shift φ(t) of the scattered optical field due to 
the motion of scattering particles accumulate along the paths and give rise to the speckle. The 
time scale does not depend on the angle of observation, but it depends on the geometry of the 
scattering cell which controls the typical path length and distribution.133 
 
DWS is well suited to study interparticle correlation in colloidal suspensions at very high 
volume fractions and with extraordinary sensitivity to a small displacement of scatters.129 
The photon mean free path l* is the length over which photon transport is randomized in a 
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multiple scattering medium. Knowing l* is important because it is an indication of the turbidity 
of the system and affects the length and time scales probed by DWS.129 The average intensity 
in the fluctuated light is characterized by the normalized intensity autocorrelation function 
(eq.5)129:  
 
g(2)(t)=<I(t0)I(t0+t)>/<I>
2             eq. 5 
 
where the quantity <I> is the average intensity, while t represents the lag time. Using the Siegert 
relation (eq.6), the intensity correlation function and the field autocorrelation are related:  
 g(2)(t)=1+׀g(1)(t)׀2 eq. 6 
where  is an instrumental factor given by the collection optics. Once the field correlation 
function and l* have been measured, the mean square displacement (MSD, <r2(t)>) of a 
sample can be calculated employing (eq.7):135,136 
 g(2)(t)-1 ∝ |∫ 𝑃(𝑠)𝑒𝑥𝑝 [−
1
3
𝑘2 < 𝛥𝑟2(𝑡) >
𝑠
𝑙∗
]  𝑑𝑠
∞
0
|
2
     eq. 7 
where k = 2πn/λ is the optical wavenumber including n as the refractive index of the medium 
and λ is the laser wavelength. P(s) represents the distribution of the photon trajectories of length 
s in the sample of thickness L, while l* is the transport mean free path which characterizes the 
typical step length of the photon random walk.  
DWS has extended the use of light scattering to numerous fields, especially in the physics and 
chemistry of colloids and other complex fluids.133 The reason is that DWS presents unique 
rheological measurement capabilities: it employs small sample volume, short acquisition time, 
non-contact analytics, and good sensitivity. The local rheology is analyzed and the probe can 
be used to map its spatial heterogeneity and extended range of frequencies over numerous 
decades of time scales.129 DWS experiments have been, for example, employed to study 
gelation phenomena, including physically and chemically cross-linked polymers.137 Narita et 
al. studied the sol-gel transition of a solution of poly(vinyl alcohol) cross-linked by borax in 
water.137 These polymer networks exhibit gel-like characteristics elasticity at time scales shorter 
than the lifetime of the network bridge, but show sol-like fluidity at longer time scales.137 
Microrheological characterizations have been performed not only on polymers but also on 
various other biological samples. For example, a study of the hydrogel network formation of a 
peptide and the resulted kinetics have been investigated by DWS.138 The resulted gelation 
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kinetics was slow, allowing to study the assembly and the network formation including the 
critical gel point.138 A similar approach was pursued by Schultz et al., who investigated the 
kinetics of the gelation, including the gelation point and the relaxation time for PEG-Heparin 
Hydrogels.139  
 
To date, several studies demonstrated the utility of DWS in the characterization of cell 
rheology.140,141 Indeed, due to the high sensitivity, DWS can detect micro displacement of the 
tracer particles, generating the measurement of the viscoelastic moduli that are more precise 
and undisturbed compared to the mechanical rheology. 140,141 In this context, Palmer et al. 
employed DWS to study rheological properties of a biopolymer network formed by filamentous 
actin (F-actin).142 F-actin is considered one of the key constituents in the mechanical integrity 
of eukaryotic cells because it contributes to the cell rigidity. Palmer et al. found that at small 
frequencies, the actin filament network is characterized as viscoelastic gels because it presents 
rheological characteristics of a gel, such as a much larger elastic modulus than the loss modulus. 
142 On the other hand at high frequencies, F actin networks are liquid-like: the loss modulus 
dominates the elastic modulus and the network loses its solid-like properties.142 In the same 
context, high-frequency rheological measurements were employed to study the cytoskeleton 
dynamic of living cells.143 The complex network of the cytoskeleton in cells displays the 
viscoelastic behavior, where the elastic and viscous responses are frequency dependent. When 
comparing the cytoskeleton response under drug treatment, the viscoelastic properties differed 
in the presence of a benign or malign tumor.143  
 
The application of microrheology in the field of food science has increased over the last 
decades. For example, particle- tracking microrheology was used to study the structural 
dynamics of caseinate-stabilized emulsions containing xanthan and the gelation of casein 
proteins, as well as glucan polysaccharides.144,145 Various authors have employed DWS to study 
short and long-range interactions of β-globulin-stabilized emulsion or the flocculation stability 
of dextran in the presence of sucrose, the impact of chitosan on microrheological properties of 
soybean isolate protein-stabilized curcumin, or the caseinate-stabilized emulsions containing 
xanthan.146–149 Also, the temperature effect on caseinate emulsion has been studied by DWS. 
150 Interactions between high-methoxyl pectin (HMP) and soybean-soluble polysaccharide 
(SSPS) with sodium caseinate-stabilized emulsions were studied by DWS.151 It showed the 
stabilization effect of SSPS in acidified sodium caseinate emulsions; indeed the acid-induced 
aggregation of the oil droplet was completely inhibited by the 0.2% of SSPS.151 
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Few studies have investigated the use of DWS in the pharmaceutical field.118,152,153 Among 
these, DWS has been employed as a process analytical tool for pharmaceutical emulsion 
manufacturing; indeed, rheological behavior using the intensity correlation function provided 
qualitative information on emulsion analytics.118 These data together with a static measurement 
of the transport mean free path (l*) correlated very well the evolution of droplet size distribution 
occurring during manufacturing.118  
 
The use of DWS has not yet been investigated upon water dispersion or during the 
manufacturing of ASD. The importance of rheological properties in the pharmaceutical field 
has been already outlined in previous studies; for example, high molecular weight polymers 
influence the viscosity of the diffusion boundary layer around the ASD aggregates, controlling 
the diffusion of the drug released. Low molecular polymer employed for ASD formulation, will 
dissolve rapidly, resulting in the release of the drug as a single entity.154 Viscosity of the 
dissolution media increases with the food intake, influencing the drug dissolution kinetics.154,155 
Current in vitro models for food effect prediction often makes use of pharmacopeias 
compendial media, considering parameters such as pH, bile salts and lipolytic enzymes as well 
as phospholipid amount. The viscosity of the media might change during dissolution and 
permeation processes. There is a study that revealed the applicability of the in vitro model to 
predict the food viscosity effect.156 Novel in vitro predictive dissolution testing considers the 
influence of the viscosity on the kinetics of drug dissolution. The viscosity influences the 
hydrodynamic environment and therefore the dissolution rate.157 
 
Not just the viscosity of the media but also more generally the rheological properties of 
pharmaceutical materials such as polymer are central to the field of formulation development. 
This is particularly important for melt processing, such as hot-melt extrusion and melt 
granulation. Molecular weight and melt viscosity of the polymer during the processing are key 
parameters for HME process. Recent studies investigated the influence of a drug’s solid-state 
on the melt viscosity and the influence of the drug concentration, temperature and shear rate on 
polymer crystallization using rheological tests.158,159 Given the importance of microrheology in 
dosage form manufacture and biopharmaceutical considerations, there is much potential to 
employ DWS in pharmaceutics and a particular analytical opportunity is a use in the 
characterization of ASDs. 
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3 Application of the solubility parameter concept to 
assist with oral delivery of poorly water-soluble 
drugs - a PEARRL review 
 
Summary 
Objectives: Solubility parameters have been used for decades in various scientific fields 
including pharmaceutics. It is, however, still a field of active research both on a conceptual and 
experimental level. This work addresses the need to review solubility parameter applications in 
pharmaceutics of poorly water-soluble drugs. 
Summary: An overview of the different experimental and calculation methods to determine 
solubility parameters is provided, which covers from classical to modern approaches. In the 
pharmaceutical field, solubility parameters are primarily used to guide organic solvent 
selection, co-crystals and salt screening, lipid-based delivery, solid dispersions, and nano- or 
microparticulate drug delivery systems. Solubility parameters have been applied for a 
quantitative assessment of mixtures or they are simply used to rank excipients for a given drug. 
Conclusions: Especially partial solubility parameters hold great promise for aiding the 
development of poorly soluble drug delivery systems. This is particularly true in early stage 
development, where compound availability and resources are limited. The experimental 
determination of solubility parameters has its merits despite being rather labour-intensive 
because further data can be used to continuously improve in silico predictions. Such 
improvements will ensure that solubility parameters will also in the future guide scientists in 
finding suitable drug formulations. 
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3.1 Introduction 
Solubility parameters have received much attention and numerous applications have been 
reported in diverse scientific fields.160 Pharmaceutics has been a prime discipline for applying 
solubility parameters to formulation design. Previous studies have, for example, reported the 
use of solubility parameters to predict suitable solvents for solutes; select polymer blends, and 
to describe surface and adhesion phenomena.160 It would be interesting to have an overview of 
such pharmaceutical applications with a particular emphasis on the development of poorly 
soluble drug formulations. 
Development of new formulations requires the use of different tools to predict and analyse the 
physiochemical properties and interactions of dosage form components.161,162 For prediction of 
material properties and their interactions, for example, solubility parameters are routinely used 
with high levels of success.161 Historically, this strategy has been employed in drug 
development for the selection of solvents for coating. Since then, further applications, as well 
as more robust thermodynamic methods for solubility parameter calculations have also been 
reported. Specifically, such thermodynamic methods can be used for study and prediction of 
the physical and chemical properties of compounds together with their effects on mixtures and 
dosage forms.161  
 
The definition of solubility parameter was first coined by Hildebrand and Scott in 1950.160 An 
important theoretical development was then proposed later in 1967 with introduction of the so-
called Hansen Solubility Parameter (HSP).160 This concept divides the total solubility parameter 
(δt) in to three different contributions: polar, non-polar and hydrogen bonding and it is therefore 
more versatile than the original one-dimensional solubility parameter defined by Hildebrand 
which does not account these specific contributions.161  
Solubility parameters can be derived experimentally from heat of vaporisation, internal 
pressures, surface tensions and other material characteristics as outlined by Hildebrand and 
Scott.163 Since then, a number of researchers have reported new methods to predict more 
accurately solubility parameter values, considering for example purely acidic or basis 
compounds164 for a specific process technique.165 More recent predictions of solubility 
parameters rely on molecular dynamics simulations or on the Conductor-like Screening model 
(COSMO) and these computational methods have been compared by Diaz et al.166 Important in 
this context is the research of Panayiotou and co-workers who contributed to the theoretical 
concept of solubility parameter and proposed a modern quantitative structure-property 
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relationship.167 Noteworthy is further the recent article by Louwerse et al. that broadly 
summarized limitations of the solubility parameter concept and proposed theoretical 
improvments.168 
Previously, different authors161,169,170 have shown the practical importance of solubility 
parameters, but a general overview of their applications in the pharmaceutical field is missing. 
This article addresses the particular need to review the use of solubility parameters in 
pharmaceutics with respect to formulation of poorly soluble drugs. The latter oral delivery 
systems are central to the PEARRL research consortium that is about both, the design of such 
formulations as well as new tools for their biopharmaceutical assessment. 
 
3.2 Theory and experimental aspects of the solubility parameter 
concept 
3.2.1  Introduction to the solubility parameter concept 
The principle of "like dissolves like" is a well-known term within chemical and pharmaceutical 
sciences, which can be more generally described as "like seeks like". The usefulness of such 
approaches depends of course on the ability to assign a numerical value to molecular similarity 
or dissimilarity. Such a quantitative number is provided by the solubility parameter, which is a 
rather simple but very powerful approach. 
 
For a better understanding of the solubility parameter concept, it is helpful to discuss its 
historical origins that are linked to the theory of non-ideal solutions. For such solutions, the 
activity of a solute, 2 is the product of the concentration X2 (mole fraction) and the activity 
coefficient, 2 (Equation 1): 
𝛼2 =  𝑋2𝛾2 (1) 
It is a central task of thermodynamic theories to predict 2 and a classical approach is that by 
Scatchard,171 and by Hildebrand and Wood:172 
 ln(𝛾2 ) = (𝑤22 + 𝑤11 − 2𝑤12)
𝑉2𝜑1
2
𝑅𝑇
 (2) 
where V2 is the volume of the solute and φ1 is the volume fraction of the solvent and R, T are 
the gas constant and temperature, respectively (Equation 2). The term w11 denotes the energy 
needed to remove solute molecules from the bulk, while w22 equals to the idealised removal of 
solvent molecules to generate a cavity in the solvent for the molecule to dissolve. Such an 
idealised transfer of the molecule would lead to gained insertion energy in the solvent or release 
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of solvation energy of -2w12. It was an important idea to approximate the interaction term w12 
by the square root of the product of w11 and w22 so that the following equation is obtained: 
ln(𝛾2 ) = [(𝑤11)
0.5 − (𝑤22)
0.5]2
𝑉2𝜑1
2
𝑅𝑇
 (3) 
The advantage of having only pure component properties of the solvent and solute in Equation 
3 is that they can be listed for the different chemicals without the need to additionally determine 
a specific interaction parameter like w12. Hildebrand and Scott
163 coined the notion of the 
solubility parameter, x that is here given for the solute as follows (Equation 4): 
𝛿2 = (𝑤22)
0.5 (4) 
The solubility parameter is the square root of energy per volume and it is often named as square 
root of cohesive energy density. Units can also be expressed in MPa0.5 and hence can also be 
viewed as an internal pressure.  
 
Equation 3 and 4 show that in the absence of difference in the solubility parameters, the activity 
coefficient 2 becomes unity so that ideal solubility is reached and activity and concentration 
are equal. Regular solution theory does not consider more complex non-ideal solutions that may 
lead to an activity coefficient of smaller than unity. Even though regular solution theory is 
limited in scope, it marked the birth of the solubility parameter concept that is more broadly 
applicable. 
 
The solubility parameter, for example, can be applied to any mixing process. According to 
Hildebrand and Scott, the enthalpy of a mixing process is proportional to the square difference 
in solubility parameters for the mixture components, 1 and 2 (Equation 5):163  
𝛥𝐻𝑀 =  𝜑1𝜑2𝑉𝑀(𝛿1− 𝛿2)
2          (5) 
where 1 and 2 are the volume fractions of the mixing components that can be for example a 
drug and polymer.  
 
Apart from mixing enthalpy, a solubility parameter can be linked to any thermal property or to 
any other molecular interaction parameter. A latter example is the well-known Flory chi 
parameter 12 that can be expressed in terms of Equation 6 for mixtures that involve a 
polymer:160,173 
𝜒12=
𝑉(𝛿1− 𝛿2)
2
𝑅𝑇
   +  𝛽     (6) 
where β is an entropy correction term and V is the molar volume of, a solvent or drug in mixture 
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with a polymer. It seems that β may not be required for essentially non-polar systems but in 
other cases, such an empirical correction of β may be needed to avoid under prediction of 
12.160,173 These examples show that particular care is needed when the solubility parameter is 
used for quantitative conversion to other physicochemical properties or parameters. 
 
The solubility parameter approach is comparatively simple but the art lies in correct application 
for each given system. The total solubility parameter is for example primarily useful to describe 
apolar components, whereas Hansen introduced the more versatile concept of partial solubility 
parameters.85,160 As previously mentioned, the basic idea in this approach is to split the total 
cohesion energy (Etot) into different parts that originate from separate molecular interactions. 
The dispersive energy (Ed) stems from atomic non-polar forces i.e. dispersive Van der Waals 
interactions, whereas forces between molecules of permanent dipoles constitute a polar energy 
contribution (Ep). Due to the specific nature of hydrogen bonding, this energy contribution is 
considered separately (Eh). These partial cohesion energies Ed, Ep, and Eh are divided by molar 
volume to result in the corresponding total and partial solubility parameters according to 
Equation 7 and 8:160 
𝐸𝑡𝑜𝑡 
𝑉
=  
𝐸𝑑 
𝑉
+
𝐸𝑝 
𝑉
+
𝐸ℎ 
𝑉
  (7) 
𝛿2 = 𝛿𝑑
2 +  𝛿𝑝
2 +  𝛿ℎ
2 (8)  
Equation 8 shows that a three dimensional (3-D) version of the solubility parameter is obtained 
by consideration of the different partial contributions to cohesive energy density. Figure 1 
depicts a series of solvents in this space of dispersive, polar, and hydrogen bonding contribution 
to the HSP. The invention of partial solubility parameters has certainly advanced the original 
cohesive energy density approach and opened the field to diverse potential applications 
wherever molecular interactions of the type "like seeks like" play a critical role. We will in the 
following part first describe the different ways to obtain total or partial solubility parameters 
and will then discuss the different applications in the pharmaceutical field. Finally, gaps and 
current trends will be discussed. 
 
3.3 Experimental and in silico determination of solubility 
parameters 
3.3.1  Introduction to solubility parameter determination  
Solubility parameters can be evaluated directly by vaporisation of solvents (or sublimation of 
Application of the solubility parameter concept to assist with oral delivery of poorly water-soluble drugs 
- a PEARRL review 
 
 
40 
 
solids) as described in the original definition. This, however, is only feasible for materials that 
can be either vaporised or sublimated (in case of solids), which is often not possible. Many 
pharmaceutically relevant materials such as coating polymers, polymers for amorphous solid 
dispersions, drug compounds, or surfactants, require other methods. Therefore, indirect 
methods have been widely used in the literature for determination of solubility parameters, 
which are based upon relationships between diverse physicochemical properties and cohesion 
energy. Solubility parameters can be deduced from measurements of other substance properties 
than vaporisation. Some of the different methods to obtain a solubility parameter are 
schematically depicted in Figure 2 and for further reference see the comprehensive review on 
this topic by Barton.174 Values for solubility parameters determined using these various 
methods may vary based upon method setup and/or material. This section describes the methods 
that have or could be used to characterise pharmaceutical compounds. 
 
3.3.2  Classical determination of solubility parameter 
3.3.2.1 Classical approach via latent heat of evaporation 
As mentioned earlier, the (total) solubility parameter, was introduced by Hildebrand and Scott, 
and was defined as the root of the cohesive energy density (CED). The cohesive energy density 
was in turn defined as the energy needed to break all attractive interactions in one mole of a 
solvent divided by the molar volume according to Equation 9:  
𝛿𝑡 = (𝐶𝐸𝐷)
1
2 =  (
Δ𝐸𝑣
𝑉𝑚
)
1/2
 (9) 
where Ev is the latent energy of evaporation and Vm is the molar volume of the solvent. This 
molar cohesive energy can be further expressed as: 
Δ𝐸𝑣 =  Δ𝐻𝑣 − 𝑅𝑇 (10) 
Equation 10 can be expressed in terms of latent heat of vaporisation Hv (in case of solvents) 
the universal gas constant R and the absolute temperature T. Hv can be obtained from 
calorimetric or vapour-pressure data to finally determine δt. 
 
Hansen expanded the total solubility parameter into three components, δd, δp, δh as discussed 
for Equation 8. This means for nonpolar molecules that δp and δh are zero and hence δt equals 
δd. For polar molecules, the situation is more difficult and calculation methods were developed 
to assess the partial solubility parameters based on accessible physical properties. 
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Figure 1. Common solvents are displayed according to their Hansen solubility parameter (HSP) 
with dispersive (dd), polar (dp) and hydrogenbonding (dh) contribution. Other excipients or 
also drugs can be represented in this Hansen space and a close proximity of substances 
suggeststheir miscibility (for colour codes please refer to the online version of the article) 
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Figure 2. Different methods to obtain one or three dimensional solubility parameter (δx). 
 
3.3.2.2  Calculation of the non-polar dispersion solubility parameter 
The energy of evaporation can be divided into a polar and nonpolar part by using the 
homomorph approach.175–177 The homomorph of a polar molecule is a nonpolar molecule with 
nearly the same size and shape as that of the polar molecule of interest. The dispersion energy 
part of evaporation of a polar molecule is therefore approached by the energy of evaporation of 
the homomorph at the same reduced temperature, Tr. The reduced temperature Tr is defined as: 
𝑇𝑟 =  
𝑇
𝑇𝑐
 (11) 
Equation 11 includes the absolute temperature T and the critical temperature Tc, which can be 
estimated based upon the Lydersen group contributions.160 Corrections to this approach are 
required for molecules containing atoms which are significantly greater than carbon, e.g. 
chlorine, bromine, sulphur, but not for oxygen and nitrogen.160 For instance, when the 
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evaporation energy of the nonpolar carbon tetrachloride is compared with the nonpolar 
homomorph 2,2 dimethyl propane, a difference of 1580 cal/mol (6610 Joule/mol) is found. This 
difference is divided by four to obtain a correction factor for a chlorine atom in a molecule.178 
Dividing by the molar volume and then taking the square root (see Equation 9) gives the 
dispersion solubility parameter.160 
 
3.3.2.3  Calculation of the polar solubility parameter 
The polar parameter of a polar molecule was originally calculated by Hansen and Skaarup178 
using the Böttcher equation and expressed in cal/cm³ (Equation 12): 
𝛿𝑝
2 =
12108
𝑉𝑚
2
𝜖−1
2𝜖+𝑛𝐷
2 (𝑛𝐷
2 + 2)𝜇² (12) 
where μ is the dipole moment, in Debye, Vm the molar volume in cm³/mole, nD the refractive 
index using the sodium D line and  the dielectric constant. Later a more simplified equation 
was used by Hansen and Beerbower179 according to Equation 13 in (MPa)1/2: 
𝛿𝑝 =
37.4𝜇
𝑉𝑚
1/2
 (13) 
 
3.3.2.4  Calculation of the hydrogen bond solubility parameter 
Hansen and Skaarup178 used data from infrared spectroscopy to assign an energy of evaporation 
of 5000 cal/mol for the OH…O hydrogen bond, hence for a solvent containing hydroxyl groups, 
the hydrogen solubility parameter can be calculated utilizing Equation 14: 
𝛿ℎ = √
5000𝑁
𝑉𝑚
 (14) 
where N is the number of alcohol groups in the solvent molecule. More often, δh is calculated 
by subtracting the dispersion and polar contributions from the total solubility parameter 
according to Equation 15:160,180 
(𝛿ℎ)² = (𝛿𝑡)² − (𝛿𝑝)
2
− (𝛿𝑑)
2 (15) 
Since hydrogen bonding has a profound effect on solubility, attempts have been undertaken to 
further expand the hydrogen bond solubility parameter. A hydrogen bond comprises a hydrogen 
bond donor and a hydrogen bond acceptor and molecules can therefore be classified as174 i) 
proton donor e.g. trichloromethane, ii) proton acceptor, e.g. ketones, aldehydes, esters, ethers, 
tertiary amines, aromatic hydrocarbons, alkenes iii) proton donor/acceptor, e.g. alcohols, 
carboxylic acids, water, primary and secondary amines, and iv) proton non-donor/non-acceptor, 
e.g. alkanes, carbon disulphide and tetrachloromethane. From a qualitative point of view, 
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miscibility can be predicted if hydrogen bonds are formed upon mixing, while demixing occurs 
when hydrogen bonds are destroyed (e.g. water mixed with alkanes).  
An extension of the hydrogen bond solubility parameter to account for hydrogen bond donor 
and acceptor properties has been suggested by Small181 and others (Sorenson et al.182), using 
Equation 16: 
𝛿ℎ
2 = 2𝛿𝑎𝛿𝑏   (16) 
where δa is the acidic solubility parameter (the donor proton of the hydrogen bond, which is the 
electron acceptor in the Lewis acid framework) and δb is the basic solubility parameter (Lewis 
base, electron donor). Beerbower and Martin179 developed the concept to estimate the solubility 
of naphthalene, benzoic acid, p-hydroxybenzoic acid and methyl p-hydroxybenzoate in 
different solvents.183 However, improvement in accurate miscibility prediction was limited (e.g. 
benzoic acid: 63% acceptable –i.e. less than 30% error versus observed - predictions using four 
parameters versus 60% acceptable predictions with the three Hansen solubility parameters). 
 
3.3.3 Determination of partial solubility parameters using solvent solubility 
data  
Determination of solubility parameters for drug substances and polymers typically cannot be 
accomplished through the measurement of the energy of evaporation (because of their non-
volatility and due to the fact that evaporation frequently is accompanied by degradation) and 
therefore only indirect methods can be used. Solubility determination of a solid in a series of 
selected solvents, which cover the solubility design space in terms of δd, δp and δh, is a 
frequently used technique to achieve this goal.160,184–190  
 
Typically, 10-40 solvents are used for the solubility measurements, which can be conducted as 
e.g. a classical shake-flask approach where the thermodynamic solubility is determined or only 
kinetic solubility values are estimated by continuously adding small drug amounts to solvents 
with optical detection of residual drug. Generally, the solvents are selected such that the 
compound of interest has good solubility in at least half of the solvents screened. The solubility 
parameters can then be calculated with multiple regression analysis based on mole fractions 
solubilised in the various solvents185,186 or with more modern computer software that uses an 
iterative method for improving drug solubility parameter estimates in a Cartesian coordinate 
system (Figure 1) of δd, δp, δh.. The distances between the sample reference point to point 
representations are calculated for solvents. Then the iterative method adjusts the partial 
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solubility parameters such that the distance between compatible and incompatible solvents are 
minimized and maximized, respectively. This iterative minimization/maximization process can 
then determine a more reliable solubility parameter as recently done by Howell and co-
workers.191  
 
Table 1. Overview of experimentally determined HSP for pharmaceutical polymers 
Polymer δd 
(MPa)1/2 
δp 
(MPa)1/2 
δh (MPa)1/2 Reference Remarks 
HPMC 2906, F4M 18.2 16.5 15.5 192 34 solvents 
HPMC 2208, K4M 18.0 15.3 19.4 192 34 solvents 
HPMC 2910 E4M 17.4 14.9 19.3 192 34 solvents 
HPMC 2910 E15 18.8 9.4 11.8 193 29 solvents, 
calculation 
using HSPiP 
software194 
HPMC 2910 E5 18.7 9.8 11.6 193 29 solvents, 
calculation 
using HSPiP 
software194 
Methylcellulose A4M 18.0 15.3 19.4 192 17 solvents 
HPC, Klucel H – Dow 
data 
17.2 9.8 13.5 192  
HPC, Klucel H, 
Solubility data from 
Exxon – Dow 
calculation 
17.6 10.2 15.4 192  
HPMCAS 716 (L 
grade) 
17.7 11.87 10.19 Dow 
technical 
information 
Dow 
technical 
information 
 
Not 
mentioned 
HPMCAS 912 (M-
grade) 
16.73 12.37 10.33 Not 
mentioned 
HPMCAS 126 (H 
grade) 
18.09 12.76 9.67 Not 
mentioned 
HPMCAS MG / Aqoat 
MG 
16.2 10.9 9.0 195 Jansen 
analysis using 
HSPiP 
software of 
the solubility 
data of 110 
solvents 194 
HPMCAS L grade 18.9 12.4 9.0 193 29 solvents, 
calculation 
using HSPiP 
software 194 
HPMC phthalate HP 
50 
20.4 10.2 11.7 193 
PVP K30 18.3 12.9 11.4 193 
 
Drug substances as well as polymers can be used as samples. For example, HPMC and 
HPMCAS are frequently used polymers in stabilised amorphous solid dispersions and with the 
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“like dissolves like“ approach the solubility parameter seems as a feasible way to provide a first 
guess on the active pharmaceutical ingredient (API) miscibility in these systems. An overview 
of experimentally determined HSP using the solvent method is provided in Table 1. For 
HPMCAS, the values were consistent between three independent determinations (see 
references given in Table 1). For HPMC, a difference was noted for the polarity and hydrogen 
bonding parameters between Janssen and Archer.192 This may be attributed both to i) substantial 
difference in molecular weight ii) the usage of a limited number of solvents, e.g. 10 and iii) the 
usage of water as solvent by Archer,192 which is generally not recommended due to the 
complexity of the solvent.160 
 
Solubility parameters obtained via the solvent approach have also been reported for 
characterization of drug molecules and solid excipients such as, preservatives.183–185,190,196,197 
These studies use about 10-25 different solvents in order to obtain an accurate determination of 
the partial solubility parameters, which seems to be reasonable given the number of unknowns 
in the regression analysis. Verheven and co-workers185 investigated five chemically related 
molecules and reported that the method was sufficient enough to capture the differences 
between molecules. Barra et al.184 reported a similar finding by investigating a number of free 
acids and their associated sodium salts and finally, as well as those results published by Kitak 
and co-workers190 could find differences between two ibuprofen salts and the free acid. The 
method is therefore generally perceived as sufficiently precise to determine accurate partial 
solubility parameters by solubility screening in a number of organic solvents or mixtures of 
these. 
 
3.3.4 Determination of partial solubility parameters using intrinsic 
viscosity measurements 
The use of viscosity measurements is a frequently used technique to determine the solubility 
parameter for polymers.160,195,206,198–205 In this approach, the intrinsic viscosity of the polymer 
of interest is determined in a number of solvents.160,198,199 Intrinsic viscosity, [η], is given by: 
[𝜂] = lim
𝑐→0
(
𝜂𝑠−𝜂0
𝜂0 𝑐
)  (17) 
Equation 17 can be expressed in terms of the solution viscosity (ηs) or, the solvent viscosity (η0) 
where c is the solution concentration. The conformation of a polymer in solution is dependent 
on its interactions with the solvent. In so-called "good solvents" with many interactions, the 
polymers can swell to some extent, which increases of solutions viscosity. By contrast, in 
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solvents with limited interactions (i.e. a "poor solvent") the polymer will reduce the contact area 
to the solvent by shrinking. An interesting approach is to normalize intrinsic viscosities for a 
polymer in a solvent that provides the highest viscosity value. These normalised data can be 
used to determine the HSP according to the equations below 18-20:199 
𝛿𝐷2 = ∑(𝛿𝐷𝑖 × [𝜂]𝑖)/Σ[𝜂]𝑖  (18) 
𝛿𝑃2 = ∑(𝛿𝑃𝑖 × [𝜂]𝑖)/Σ[𝜂]𝑖 (19) 
𝛿𝐻2 = ∑(𝛿𝐻𝑖 × [𝜂]𝑖)/Σ[𝜂]𝑖 (20) 
where the subscript 2 indicates the polymer and ‘i’ the solvents. The intrinsic viscosity of the i-
th solvent is described by the parameter [η]i. The solvents that are most compatible have the 
highest intrinsic viscosities and are closest to the geometric centre of a sphere in the Hansen 
space that encloses good solvents.160 The separating distance from the centre of the sphere to a 
last still compatible solvent provides the interaction sphere radius R0 and is defined according 
to Equation 21:  
𝑅0
2 = 4(𝛿𝑑𝑖 − 𝛿𝑑𝑝)
2
+ (𝛿𝑝𝑖 − 𝛿𝑝𝑝)
2
+ (𝛿ℎ𝑖 − 𝛿ℎ𝑝)
2
 (21) 
where δdi, δpi, δhi are partial solubility parameters of the last still compatible solvent, whereas 
δdp, δpp, δhp denote the partial solubility parameters of the sample polymer. Analogues to 
Equation 21, is possible to calculate the distance between the sample polymer and any solvent, 
which is called “solubility parameter distance”, Ra. This distance parameter is of more general 
use and is not restricted to viscosimetry to determine solubility parameters.  
 
An alternative method to determine the partial solubility parameters via intrinsic viscosity was 
developed by Mieczkowski.207,208 In this method, the values of the volume fraction of a solvent 
(φs) were determined for three mixtures of solvents at which the maximum intrinsic viscosity 
was found. These fractions were then inserted into to Equation 22: 
∑ 𝑝𝑖(𝑎𝑖 − 𝑏𝑖) − [𝜑𝑠 ∑ (𝑎𝑖 − 𝑏𝑖)
2 + ∑ 𝑏𝑖(𝑎𝑖 − 𝑏𝑖)
3
𝑖=1
3
𝑖=1 ] = 0
3
𝑖=1                                           (22) 
where pi is the component of the solubility parameter of the polymer, ai is the component of the 
first solvent and bi is the component of the second solvent. Using this method, the HSPs for 
PEO (polyethylene oxide) 2000 were determined as δd: 17.3 ± 2 MPa1/2, δp: 3.0 ± 1 MPa1/2 and 
δh: 9.4 ± 0.5 MPa1/2. 
 
Furthermore, Bustamante et al.202 also employed viscosity to determine the partial solubility 
parameter of HPMC with 28-30% methoxy and 7-12% hydroxypropyl content and an 
approximate molecular weight of 86 kDa (equivalent to Dow E4M). The experimental results 
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were fitted according to following regression model (Equation 23): 
𝑙𝑛[𝜂] =  𝐶0  + 𝐶1𝛿1𝑑 + 𝐶2𝛿1𝑑
2 + 𝐶3𝛿1𝑝 + 𝐶4𝛿1𝑝
2 + 𝐶5𝛿1ℎ + 𝐶6𝛿1ℎ
2                                    (23) 
Whereas the subscripts 1 refers to solvent and the subscript 2 in the following Equations 24-26 
to the polymer: 
𝛿2𝑑 = − (
𝐶1
2𝐶2
)                                                                                                                      (24) 
𝛿2𝑝 = − (
𝐶3
2𝐶4
)                                                                                                                      (25) 
𝛿2𝑑 = − (
𝐶5
2𝐶6
)                                                                                                                      (26) 
An extended regression model was used to allow the determination of the Lewis acid (δa) and 
base (δb) solubility parameters according to Equation 27:  
𝑙𝑛[𝜂] =  𝐶0  + 𝐶1𝛿1𝑑 + 𝐶2𝛿1𝑑
2 + 𝐶3𝛿1𝑝 + 𝐶4𝛿1𝑝
2 + 𝐶5𝛿1𝑎 + 𝐶6𝛿1𝑏 + 𝐶7𝛿1𝑎𝛿1𝑏                (27) 
Solubility parameters of HPMC for dispersion, polarity and hydrogen bonding were reported 
to be 14 MPa1/2, 16.8 MPa1/2and, 31 MPa1/2, respectively. As can be seen in Table 1, the data 
obtained by Bustamante202 for δd and δp were in line with the values obtain by Archer192 while 
there was a substantial difference for the δh solubility parameter. This difference may be 
attributed to the use of different Hansen solubility parameters for water. Bustamante used 15.5 
MPa1/2, 15.95 MPa1/2 and 42.34 MPa1/2, while Archer used 19.5 MPa1/2, 17.8 MPa1/2 and 17.6 
MPa1/2 for dispersion, polar and hydrogen bonding respectively. Additionally, Madsen and co-
workers203 employed viscosity to determine the solubility parameter for the pharmaceutical 
polymers, PLGA and polycaprolactone (PCL). The authors demonstrated that the solubility 
parameter could be correlated with protein release from the two polymer systems. This example 
underpins again, how broadly the solubility parameter approach can be applied. 
 
3.3.5  Determination of partial solubility parameters of liquids using 
inverse gas chromatography 
The HSP for pharmaceutical liquids are difficult to determine experimentally using “solubility” 
methods. Additionally, many pharmaceutical substances including, for example, polymers, 
polysorbates, ethoxylated oils and vitamin E TPGS are complex mixtures without defined 
chemical structure and hence are difficult to approach theoretically. In such cases, the 
determination of the HSP by inverse gas chromatography, is a valuable option. Inverse gas 
chromatography has been applied to investigate the solubility parameters of polymers,195,209–212 
surfactants,213,214, epoxidised soybean oil,215 triglycerides216 and liquid crystal systems.217–219 
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For measurement of solids, it is recommended for the samples to contain some amorphous 
fraction, so that the probe gases can enter the bulk. Otherwise, only surface interactions could 
skew the results for estimated solubility parameters. 
 
Using the inverse gas chromatography method, the material of interest is the stationary phase 
and is placed into a column. It is then characterised using diverse volatile probes (i.e. volatile 
solvents with known HSPs). The HSP of the material can then be calculated based on the 
retention data of the solvent probes.214 First, the retention times of the solvent probes are 
converted to specific retention volumes (Vg). These are then used to calculate the Flory-Huggins 
interaction parameter between the solvent and the sample using the following 
equation(Equation 28):220–222  
𝜒1,2
∞ = 𝑙𝑛 (
273.15
𝑀1.𝑉𝑔
° .𝑃1
° . 𝑅) −
𝑃1
°
𝑅.𝑇
(𝐵11 − 𝑉1
°) + 𝑙𝑛 (
𝜌1
𝜌2
) − (1 −
𝑉1
°
𝑉2
°)                                            (28) 
 
where 𝜒1,2
∞  is the Flory-Huggins interaction parameter between the material of interest and the 
solvent probe, 𝑀1 is the molecular mass, 𝑃1
° is the vapour pressure of the solvent probe at the 
measurement temperature calculated using the Antoine equation, 𝑉1
° is the molar volume of the 
probe, 𝑉2
° is the molar volume of the examined material, 𝐵11 is the second virial coefficient of 
the solvent probe calculated according to Voelkel and Fall,223 ρ1 and ρ2 are the densities of the 
solvent probe and material, respectively. The total solubility parameter is then calculated using 
Equation 29:210,213,224,225 
𝛿1
2
𝑅𝑇
−
𝜒1,2
∞
𝑉𝑖
=
2𝛿2
𝑅𝑇
𝛿1 − (
𝛿2
2
𝑅𝑇
+
𝜒𝑆
∞
𝑉𝑖
)                                                                                            (29) 
 
where δ1 is the total solubility parameter of the consecutive test solutes and δ2 the total solubility 
parameter of the material of interest, 𝜒𝑆
∞ is the entropic part of the Flory-Huggins interaction 
constant and is usually estimated in the range 0.2-0.4 or 0.6.212 By plotting the left hand side of 
the equation versus δ1, a straight line is obtained of which the slope and intercept are used to 
calculate δ2. 
 
Voelkel and Janas226 extended this original concept, introduced by Price and Shillcock217 to 
obtain partial solubility parameters from the linear relationships for solvent groups (n-alkanes 
for δ2d, polar solvents for δ2p and hydrogen bonding solvents for δ2h, while S is indicated as the 
value for the slope) according to Equations 30-32: 
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𝛿2𝑑 =
𝑆𝑛−𝑎𝑙𝑘𝑎𝑛𝑒𝑠
2
𝑅𝑇                                                                                                              (30) 
𝛿2𝑝 =
(𝑆𝑝𝑜𝑙𝑎𝑟𝑠−𝑆𝑛−𝑎𝑙𝑘𝑎𝑛𝑒𝑠)
2
𝑅𝑇                                                                                                (31) 
𝛿2ℎ =
(𝑆ℎ−𝑏𝑜𝑛𝑑𝑠−𝑆𝑛−𝑎𝑙𝑘𝑎𝑛𝑒𝑠)
2
𝑅𝑇                                                                                              (32) 
Using this approach Adamska and Voelkel212 determined the HSPs of di-n-butyladipat (Cetiol), 
caprylocaproyl macrogol-8 glycerides (Labrasol, Gattefosse) and polysorbate 80 (Tween 80) 
using inverse gas chromatography. Packing of columns with semi-solids and liquid compounds 
often require special preparation and here, the excipients were dissolved in a suitable solvent to 
coat on a solid support by slow solvent evaporation. By comparison, an alternative method with 
fewer assumptions has been used for some of the same excipients investigated by Adamska and 
Voelkel214 as described in Table 2. The method used has some parallels with the solubility 
approach described above. In this method the three partial parameters were iteratively and 
systematically changed to give the best fit between predicted and experimental values for the 
interaction parameter, 𝜒1,2
∞ , for all the solvent probes tested, hence no solvent probe families 
were needed. The predicted interaction constant was calculated according to Equation 33: 
𝜒1,2
∞ = 𝐶1 + 𝑉𝑚 ∙ 𝐶2 ∙ [4(𝛿1𝑑 − 𝛿2𝑑)² + (𝛿1𝑝 − 𝛿2𝑝)² + (𝛿1ℎ − 𝛿2ℎ)²]                              (33) 
where C1 and C2 are constants and Vm is the molar volume of the solvent probe. This approach 
is adopted in the software package “Hansen Solubility Parameters in Practice”, HSPiP.194 This 
software is helpful as it provides tools for many processes such as determining HSP from 
solubility data and, estimating HSP from the chemical structure as well as databases, which 
include HSP values for many polymers and excipients. The values obtained for polysorbate 80 
and caprylocaproyl macrogol-8 glycerides (Labrasol, Gattefosse) were somewhat different than 
the ones obtained by Adamska and Voelkel.214 This is possibly due to the use of different sample 
preparation methods and column packing material, which influences the retention volume 
determination. However, it should be also noted that it may be problematic to determine a 
solubility parameter for surfactants and other amphiphilic substances (e.g. some copolymers) 
by the use of only a single set of partial solubility parameters. Superstructures such as liquid-
crystalline phases are typically formed and probe gas molecules can interact with different 
microdomains, which is an issue of sample heterogeneity. 
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Table 2. Hansen solubility parameters obtained for materials using inverse phase gas 
chromatography compared using different data treatment. 
 
Material δd 
(MPa)1/2 
δp 
(MPa)1/2 
δh 
(MPa)1/2 
Remark Reference 
Cetiol 16.5 1.4 4.8 Inverse gas 
chromatography 
214 
Labrasol 18.0 0.8 3.2 
Tween 80 19.3 0.9 2.8 
PEG 2000 
(at 85°C) 
19.4 1.6 1.2 212 
Labrasol 18.3 5.8 7.2 Inverse gas 
chromatography 
followed by 
iterative 
calculation using 
HSPiP  
Internal 
Janssen data 
 
PEG 400 19.7 8.3 8.8 
Tween 80 19 5.3 5.6 
Olive oil 16.9 0.6 4.2 
 
 
Klar and Urbanetz195 investigated the solubility parameter for hypromellose acetate succinate 
(granular type M HPMCAS) by turbidimetric titration, inverse gas chromatography and seven 
different calculation methods. The total solubility parameter determined by turbidity was 24.7 
± 3.2 MPa1/2 for moderately hydrogen bonded solvents and 24.4 ± 0.3 MPa1/2 when determined 
by inverse gas chromatography. Furthermore, the partial HSPs that were determined by inverse 
gas chromatography and obtained data (17.69 , 12.06 and 11.7 MPa1/2 for dispersion, polar and 
hydrogen bonding respectively) showed good accordance with the value generated by the 
calculation methods, especially those calculated via the Hoy and Te Nijenhuis method, using 
experimentally determined molecular volumes,195 as well as the Janssen and Dow values 
determined from solubility data, see Table 1.  
In summary, even though the practice and the theory to determine solubility parameters by 
inverse gas chromatography has a long tradition, there are new theoretical and practical 
developments.216,227. For future applications, it is interesting to evaluate different calculations 
methods for inverse gas chromatography. The use of the Flory-Huggins interaction parameters 
is quite abundant but the theory was developed initially for polymers so that small molecules 
may be better described by, for example, by the Bragg-Williams interaction parameters.213  
 
3.3.6  Other experimental methods to determine solubility parameter 
Besides the typical methods described in the section above, a number of other analytical 
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techniques have been reported in the literature used to determine the solubility parameter. These 
include swelling,228–233 turbidity,195,233–236 ultraviolet spectroscopy, and differential scanning 
calorimetry (DSC) as well as differential scanning microcalorimetry (µDSC).237  
 
Gee described238 the swelling of rubber in various liquids to derive its solubility parameter, an 
approach which has also been applied in more recent studies. For example, Eroǧlu et al.232 and 
Çavuş et al.228 measured the weight of a polymer before and after addition of different solvent 
systems with known solubility parameters by gravimetry and then defined the solubility at the 
point where optimal swelling was observed. Furthermore, Çavuş et al.228 also investigated the 
swelling of PVC and found good correlations to the theoretical calculation of the solubility 
parameter based upon the van Krevelen- Hoftyzer and Hoy methods.228 The simplicity of the 
method is highly attractive but the swelling must be of course detectable.  
 
For turbidimetric titration, a polymer (or another relevant excipient) is dissolved in an 
appropriate solvent. A second solvent that is miscible with the first solvent but acts as anti-
solvent for the polymer is then added until precipitation occurs. Shu and co-workers234,235 
developed a method whereby the solubility parameter could be determined from these data. As 
described above Klar and Urbanetz195 showed good correlation between the solubility 
parameter for HPMCAS determined by inverse gas chromatography and turbidity titration. In 
addition, Schenderlein et al.233 reported the turbidity titration to be more precise relative to the 
swelling approach when investigating different proportions of lactide to glycolide for poly(d,l-
lactide-co-glycolide) (PLGA).  
 
Carvalho SP et al.237 used several methods to determine the solubility parameter for 
naphthalene, phenanthrene and pyrene and reported UV-vis as the most suited method for a 
wider molar mass range. For compounds with a low molar mass determination of the vapour 
enthalpy by DSC was argued to be better based on the similar results and a lower quantity of 
compound consumption, whereas the µDSC method still required some optimisation. 
Miecszkowski205 used refractive index in several solvents to determine the partial solubility 
parameter for polystyrene and compared these experimental results together with calculations 
according to the Van Krevelen approach. Ravindra et al.206 derived the solubility parameter of 
chitosan from intrinsic viscosity, surface tension, and the dielectric constant for data 
comparison including different group contribution calculations. The average of the calculation 
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methods yielded 43.1 MPa1/2 for chitosan, while the experimental data provided 41.5 MPa1/2, 
39.8 MPa1/2, and 37.0 MPa1/2 when determined by viscosity, surface tension, and dielectric 
constant, respectively. This demonstrates the variation that might be seen across methods. All 
of the mentioned approaches have their specific assumptions and limitations both with 
experimental design and data evaluation. 
 
3.3.7 Group contribution methods to calculate partial solubility parameters 
The partial solubility parameters describe the ability of a molecule to interact with another 
molecule via intermolecular forces. Given that molecules contain several structural 
fragments/groups that can contribute to such molecular forces and volume, group contribution 
methods are meaningful to estimate solubility parameters based only on the chemical structure. 
The most frequently applied methods are the approaches described by Hoy,239 Fedors,240 and 
Van Krevelen and Hoftyzer,241 however newer approaches have also been reported, e.g. by 
Stefanis and Panayiotou.164,242 An example of solubility parameter calculation is given for 
lacidipine according to Hoftyzer/Van Krevelen (Table 3). Group contribution calculations are 
attractive as they require pure in silico approach, which demands less computation time 
compared to, for example, molecular dynamics simulations. 
 
Table 3. Example of the parameters required for solubility parameter calculation for lacidipine 
according to Hotfyzer and Van Krevelen (modified from Forster 243). Whereas z indicates the 
functional group, Fdi is the group dispersion component giving δd, F2pi is the group polar 
component, Ehi the hydrogen bonding component and V the molar volume. 
 
Groupz Fdi F2pi Ehi ƩZV/cm3 mol-1 
(7) CH3 2940 0 0 234.5 
(2) CH2 540 0 0 32.2 
(1) NH 160 210 3100 4.5 
(1) C -70 0 0 -19.2 
(1) CH 80 0 0 -1.0 
(4) C = 280 0 0 -22 
(1) Phenylene 1270 110 0 52.4 
(2) HC = 400 0 0 27 
(3) COO 1170 1470 21000 54 
(1) Ring (6) 190 - - 16 
Ʃ 6960 1790 24100 378.4 
 
 
A solubility parameter from calculations or modelling is typically a bulk property of a liquid or 
of a supercooled melt. For that reason, it is essential to know whether a compound or polymer 
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is completely amorphous or contains crystalline parts, which may affect precision of the 
calculation. Computational concepts assume values for atomic or group contributions to the 
total cohesive energy. Most of the computational methods are related to the molar volume Vm 
of a substance, thus Vm has to be either known or calculated. Therefore, some researchers 
published values of group contributions to Vm, since in some cases reliable values of solubility 
parameters can be calculated best, when using two complementary methods. Whereas, other 
concepts e.g. the concept by Hoy, are suited to be combined Vm ascertained by experimental 
techniques.239 Especially for high molecular materials as polymers, experimental determined 
Vm can provide more precise values for solubility parameters, although an experimental 
determined Vm is not recommended in all cases. For example, the method proposed by Fedors 
can only yield concise results when using the correlated calculation concept for Vm, since Vm of 
Fedors’ method is often different to other calculations or experimentally determined Vm. Based 
on such differences it would be pragmatic approach to use different in silico methods to work 
with the median of these predictions.190,206 
 
 
Based on these group contribution components the partial solubility parameters can be 
calculated; 
𝛿𝑑 =  
∑ 𝐹𝑑𝑖
𝑉
=
6960
378.4
= 18.4 𝑀𝑃𝑎1/2                                                                                         (34) 
 
𝛿𝑝 =  
√∑ 𝐹𝑝𝑖
2
𝑉
=
√1790
378.4
= 0.11 𝑀𝑃𝑎1/2                                                                                     (35)    
 
𝛿ℎ = √
∑ 𝐸ℎ𝑖
𝑉
= √
24100
378.4
 = 7.98 𝑀𝑃𝑎1/2                                                                                 (36) 
 
From which the total solubility parameter can be calculated: 
𝛿𝑡 = √𝛿𝑑
2 + 𝛿𝑝2 + 𝛿ℎ
2 = √18.42 + 0.112 + 7.982 = 20.1 𝑀𝑃𝑎1/2                                     (37) 
The ease of the calculations has seen group contribution approaches being widely adopted, e.g. 
Shah and Agrawal244 used the Van Krevelen and Hoftyzer method to estimate the partial 
solubility parameters for a number of lipid excipients, including. Dynasan 114, Capmul MCM, 
Migloyol 812N and others. This approach has also been used for the calculation of solubility 
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parameters for drug substances,184,185,190,196,243 which are often compared to experimentally 
obtained data. Besides the classical group contribution methods it is in principle also possible 
to employ, for example, the COSMO-RS245 approach, molecular dynamics simulations,246 or 
quantitative structure property relationships. Future research may compare such a modern 
approach to classical group contribution methods for pharmaceutical dataset. 
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3.4  Applications of solubility parameters in pharmaceutics 
3.4.1  Organic solvent selection 
Knowledge of solubility in pure solvents and solvent mixtures is crucial for designing the 
crystallisation process of drug substances. The first step in finding the optimal crystallisation 
conditions is usually a solvent screening. To minimise time and resource investment, it would 
be desirable to conduct in silico screenings using solubility parameters or other modelling 
approaches to reach educated first guess.247 For this purpose, the use of solubility parameters is 
simpler than more advanced and complex theoretical models such as COSMO-RS (conductor-
like screening model for real solvents), which is computation intensive, and PC-SAFT 
(perturbed-chain statistical associating fluid theory), which requires extensive parameter 
determination.247,248 Thus, in silico solubility parameter determination is not the only way to 
rank solvents for further experiments however, it is significantly more straightforward, 
especially when considering group contribution methods. 
 
Furthermore, solvent selection can be essential when considering these processes. For example, 
Rogers and Marangoni249 reported that changes in solvent chemistry affected nucleation and 
crystal growth events and therefore defined the physical properties of obtained crystals. In 
addition, solvent selection can change, solvent−gelator compatibility, affecting the degree of 
undercooling, chemical potential, kinetics of gelation, and crystal morphology. These 
parameters are all inter-related and can be correlated to partial solubility parameters. Liu et 
al.,219 studied crystallisation behaviour of two anhydrous as well as the monohydrate form of 
piroxicam. Interestingly, additives with a similar hydrogen bonding pattern to piroxicam 
facilitated crystallisation of anhydrous form I. It was argued that such additives would affect 
the formation of the different molecular clusters in the supersaturated solution. As a 
consequence, these additives had a higher ability to influence the nucleation of the different 
polymorphs. These data suggested that the HSP could indeed be used for preliminary screening 
of additives for the solid form control of piroxicam during the crystallisation processes.219 Zhu 
et al.250 used the partial solubility parameters to select the optimum solvent system for aerogels, 
which are open-porous predominantly mesoporous solids with a wide range of applications, 
including oil-spill clean-up and CO2 capture. A HSP based search method was used to target a 
specific gel system and because the solvent in this case had a functional influence, its selection 
was of crucial importance.250 Solubility parameters can also be used for defining extraction 
processes, as described by Masurel et al.251 for the removal of tar from flue gas, but also other 
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publication focus on the use of solubility parameters for liquid extraction,252–255 even though 
the applications are not necessarily pharmaceutical. In particular, the partial solubility 
parameters seem to have several applications within the space of organic solvent selection for 
either crystallisation or extraction. These processes are especially important for the final steps 
of drug substance manufacture and even though a solubility parameter approach, however more 
can be done to harness the power of the HSP in the area of pharmaceutical solvent selection.  
 
3.4.2 Co-crystal and salt screening  
Solubility as well as dissolution rate can be significantly influenced by the selection of a suitable 
solid-state form. Generally high solubility and fast dissolution rate is realised by usage of an 
amorphous solid-state form.256 However, a direct use of the amorphous form, e.g. in a capsule 
or tablet, bears the risk of uncontrolled conversion to the crystalline solid-state form, which has 
inferior solubility and dissolution behaviour. Therefore, amorphous APIs are not normally used 
directly but stabilised by suitable formulation techniques,257 which will not be discussed in this 
section. Instead, we focus on optimisation of solubility and dissolution by choosing 
advantageous crystalline solid-state forms. Generally, these comprise pharmaceutical salts, 
polymorphs – including pseudo-polymorphs such as hydrates and solvates – and co-crystals. 
Optimisation of aforementioned properties by polymorph selection comes with the same risks 
as discussed for the amorphous form. Selection of metastable polymorphs increases solubility, 
but bears the risk of uncontrolled conversion to the thermodynamically stable form. Therefore, 
a thermodynamically stable polymorph is typically chosen for clinical development, and only 
in rare cases or when there is limited knowledge of the APIs polymorph landscape, is the 
metastable form selected. Examples of cases where metastable polymorphs have been used in 
clinical development can be found in the literature.258–260 Additionally, compared to the 
amorphous state, metastable polymorphs provide a much lower increase in solubility, which is 
why they are less attractive to develop. A schematic summary of the enthalpic processes 
involved in the dissolution process is given in Figure 3. 
For this reason, optimisation of solubility, dissolution rate and consequently bioavailability can 
be best realised by selecting an appropriate pharmaceutical salt or co-crystal. Even though salt-
selection is well established in the pharmaceutical industry, co-crystals have also emerged 
during recent years as part of more educated solid form engineering. 
A comprehensive summary of salt-selection is given by Stahl261 as well as Neau.262 Historically, 
there have also been a few publications which summarize the use of pharmaceutical salts.263–
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267  
 
Figure 3 Enthalpic processes involved in the dissolution process. 
 
From such analysis, it is clear that hydrochlorides historically represented the most frequently 
used pharmaceutical salts for basic APIs and the same was true for sodium if acidic APIs were 
used. However, in recent decades, it has been clearly recognised that these “one-fits-all” 
counterions did not always lead to the desired properties intended by the salt formation. This is 
in line with the observation that new drug candidates entering clinical development, in addition 
to newly approved drugs, exhibit significantly lower solubility (BCS class II and IV) and 
require more individualized solutions to optimize their physicochemical behaviour. This does 
not only include abovementioned solubility and dissolution aspects, but also further parameters 
such as hygroscopicity, melting point, chemical and physical stability as well as crystal habit. 
Several examples of optimizing such properties can be found in the literature.268–271 In many 
cases, sulfonate salts such as e.g. mesylates, tosylates, napsylates, edisilates showed far better 
performance with regards to increased solubility and dissolution rate272 compared to other salt 
forms. Lower dissolution rate of the parent (either free base or free acid) compared to 
pharmaceutical salts can be easily explained by the presence of ions in the crystal lattice of a 
pharmaceutical salt, leading to stronger interactions between the crystal lattice and water as the 
dissolution medium. However, a similar explanation as to why, for example, sulfonate salts 
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generally show excellent dissolution rate so far is not available. This phenomenon remains 
unexplained at least by simple chemical reasoning. 
However, there are other more systematic approaches to improve solubility by usage of 
pharmaceutical salts, which are based on mechanistic understanding: as solubility depends on 
crystal lattice energy, and high lattice energy will generally result in low solubility, reducing 
the lattice energy represents a means to improve solubility. For pharmaceutical salts, Coulomb 
interactions contribute with a major part to the lattice energy. Use of large, “non-coordinating” 
counterions with low charges (one positive charge or one negative charge) are useful in 
designing such pharmaceutical salts with improved solubility.273 In the extreme case, such 
pharmaceutical salts do not even represent solid APIs anymore, but become liquids.274–277 As 
stability can be more challenging for such ionic liquids compared to solids due to increased 
mobility, this certainly has to be assessed critically. Moreover, toxicological assessment and 
regulatory acceptance represent the major hurdles for the use of such non-coordinating ions in 
humans, as none of these salt formers are currently used in human beings or “generally regarded 
as safe” (GRAS) by the FDA.278 Therefore, this promising conceptual work on non-
coordinating ions has not yet led to approved drugs on the market nor in clinical development. 
From a more practical standpoint, several aspects must be considered for selection of 
pharmaceutical salts or co-crystals. The process steps include salt- or co-former screening and 
physicochemical characterisation with a typical focus on solubility and dissolution rate but also 
regarding chemical and physical stability while considering toxicological aspects of the selected 
salts or co-formers. This screening stage represents the starting points for the selection of a salt 
or co-crystal, respectively. Earlier, such screening was carried out as a typical synthesis process 
in lower gram-scale. Today salt or co-former screening is conducted on the lower mg-scale 
which saves API and allows conductance of such screens earlier during the research process. 
For this purpose, different screening approaches exist in the pharmaceutical industry. A salt or 
co-crystal screening might be carried out in an automated way using robotic systems that 
employ different solvents and solvent mixtures according to a fixed protocol. Alternatively, salt 
or co-crystal screens can be based on a rationale, non-automated process where small-scale 
crystallisation trials are performed and crystallisation is closely observed. This allows 
information to be obtained sequentially from one experiment to another. Even though for a 
single trial, larger amounts of API are required compared to the automated approach a repetition 
of unsuccessful experiments is avoided. A useful comparison of different screening approaches 
can be found in the literature for salt selection.279 
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Following initial screening of possible salt and co-crystal formation, characterisation of solid 
state properties, including melting point, hygroscopicity and stability is important; as well as 
analysis of solubility, dissolution and supersaturation. The aforementioned steps to salt and co-
crystal formation offer different opportunities to use solubility parameters. One application is 
certainly the selection of organic solvents or anti-solvents for solid form screening, which is in 
line with the previous section. Other applications of partial solubility parameters are selection 
of ionic liquids even though they are still currently quite toxic or not sufficiently characterised 
leading to regulatory hurdles in pharmaceutical development. More important therefore, are 
applications to the field of co-crystals where it has been attempted to predict formation based 
on HSP.280 A recent study conducted co-crystal search of itraconazole during which the HSP 
was used to rank different amino acids as potentially suitable co-formers.281 In spite of such 
reports, there are also typical limitations of solubility parameters because they cannot account 
for specific aspects of the crystal lattice. There are currently methods in structural informatics 
that can use the Cambridge Structural Database to assist in silico screening of the energy 
landscape of possible crystals. These approaches together with other computational methods 
used in pharmaceutical solid state chemistry have been recently reviewed in an excellent 
book.282 Therefore, partial solubility parameters can be applied successfully in the field of salt 
and co-crystal screening, however in cases where details of a crystal lattice energy landscape 
should be considered, alternative methods of solid state modelling are recommended. 
 
3.4.3  Solubility parameter concept in lipid-based formulations  
Lipid based formulations have been an important part of the toolbox to formulate low water-
soluble compounds for over 50 years. Additionally, an increased prevalence of such poorly 
soluble drug candidates in the last two decades has also intensified the interest in lipid-based 
drug delivery systems (LBDDS). The biopharmaceutical advantages of LBDDS include the 
potential to enhance bioavailability, decrease pharmacokinetic variability as well as food 
effects, promote lymphatic absorption, and support controlled drug release.283 
 
A key element of LBDDS is that the drug substance is dissolved within the lipid excipients 
before administration, hereby presenting the drug in a pre-solubilised state in the 
gastrointestinal tract. The level of solubility in the LBDDS is, hence, important to achieve the 
above-mentioned biopharmaceutical advantages. Therefore, options to predict and rank drug 
solubility in lipid excipient mixtures are of high interest to guide LBDDS formulation 
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development. Generally, the solubility in lipid excipients is determined experimentally; 
however, these experiments are costly, time-consuming, resource-intensive and the 
experimental protocols vary substantially between different research groups.284 Also, LBDDS 
are often mixtures of different excipients, e.g. lipids, surfactant and co-solvents, so the number 
of typical solubility studies required can be very extensive.284,285 Recently, the utility of 
empirical models to predict drug solubility in lipids has been explored, using multivariate data 
analysis with several molecular descriptors.284–286 A disadvantage of any such multivariate 
approach is that the size and quality of the calibration dataset highly influences the accuracy of 
the prediction. Thus, an alternative to complex computational models, is the HSP approach that 
has been proposed to guide lipid-excipient selection. Dumanli et al.287 used the HSP to rank 
compound solubility and miscibility in/with lipids. The required solubility parameters can be 
obtained either from experiments or from calculations as previously outlined in section 2. For 
lipid-based excipients, vapour pressure and boiling point determinations, miscibility of 
reference liquids (with known cohesive energy), inverse gas chromatography, and calculations 
using group contribution methods are of particular interest to determine HSP.288 Solubility 
parameters have been commonly employed for this purpose, especially for characterisation and 
release of raw materials for cosmetics289–291 and in the oil and textile industry.292 However, 
there are not many applications of solubility parameters for lipid-based systems in the 
pharmaceutical field. Most studies determine the solubility parameter using theoretical group 
contribution approaches and often only consider simple mixtures, i.e. compound A in oil B.46,244 
De La Peña-Gil and co-workers293 investigated methods to predict and calculate HSP of 
complex lipidic mixtures (i.e. vegetable oils) by using the HSPiP software.194 Two approaches 
were used to determine HSPs. In one approach it was assumed that each functional group (fatty 
acids, fatty acids + glycerol and fatty acid methyl esters) present in triglycerides, had an additive 
contribution to the dispersion, dipole-dipole, and hydrogen bonding interactions. Therefore, the 
composition of triglycerides was divided into different functional groups and each component 
of the total HSP (δt) was calculated (i.e. δd, δp and δh). The second approach assumed that 
vegetable oils are mixtures of simple triacylglycerols in the same mass fractions as the fatty 
acids.293 
Two studies by Shah and Agrawal244,294 investigated the utility of HSP as a predictor for optimal 
carrier and solvent system selection:294 firstly to describe the solubility behaviour of a drug 
(ciprofloxacin HCl) and lipid excipients and secondly, for the design of solid lipid nanoparticles 
(SLNs).244 Both studies used the Van Krevelen/Hoftyzer group contribution approach to 
Application of the solubility parameter concept to assist with oral delivery of poorly water-soluble drugs 
- a PEARRL review 
 
 
62 
 
calculate the HSP for different solvents, polymers and lipids by using the Molecular Modeling 
Pro software. Calculation of the solubility parameter was based on at single repeating polymeric 
unit for the polymers whilst, for lipids consisting of mixture of glycerides the calculation was 
carried out based on an average predominant ratio.294 With the Van Krevelen approach, the 
molar attraction constant (F) was calculated and all the extended HSPs determined. The 
calculated values of the total HSP were matched between different lipids, organic solvents and 
drug compounds and when similar values were observed then the systems were considered 
miscible. Shah and Agrawal244 validated the mathematical model used by experimental testing 
of drug solubility in the selected excipients and solvents. Both studies244,294 succeeded in 
qualitatively predicting the solubility of ciprofloxacin HCl in different lipids and subsequently 
the solubility of lipids in various organic solvents by using the HSP determination/calculation. 
This approach resulted in identifying the most promising lipid candidates for maximum drug 
loading in SLN formulation consisting of glyceryl monocaprylate and glycerol monostearate 
40-55. These studies demonstrate the possibility of using the HSP for optimal selection of 
excipients in designing SLNs and qualitative prediction of excipient-drug compatibility.  
 
Another application of the HSP was suggested by Li et al.295 to estimate the compatibility 
between materials to facilitate the design of polymer-lipid hybrid nanoparticles (PLN). 
Specifically, the enthalpies of mixing for a drug-polymer complex (i.e. verapamil in dextran-
sulfate-sodium) and 15 different lipids including triglycerides, fatty acids, glycerol esters and 
mixtures of glycerol esters were predicted by accounting for the volume fractions of 
components in the mixture. The study also used the Van Krevelen/Hoftyzer group contribution 
approach to calculate HSP and showed the suitability of the HSP theory in the screening of lipid 
carriers for PLN design of verapamil.295 
 
While useful to determine how a lipid or lipid mixtures may behave as solvent(s) and the 
possibility to predict how some compounds solubilize in lipids, the HSP concept has also some 
limitations. Firstly, the concept only considers the energies derived from direct contact of 
components and does not account for the entropy effects and the free volume of, for example, 
amorphous solids.244 The free volume is defined as an empty space in a solid or liquid that is 
not occupied by the molecules. Generally, amorphous solids are inefficiently packed and 
present a considerable amount of free volume compared to ordered materials. Additionally, it 
was mentioned before as a disadvantage that a given crystalline solid-state form is not 
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accounted for. By contrast, experimental HSP determinations are generally conducted with the 
most stable polymorph. Studies have suggested that HSP calculations based on group 
contribution methods provide accurate predictions if materials with similar structures are 
compared, as the calculation does not account for the dependencies on conformation, 
concentration and specific intermolecular interactions that might occur in binary mixtures.46 
Finally, another limitation of the theoretical model is that it disregards specific self-association 
of molecules, which is also the case with further thermodynamic approaches other than SAFT 
(statistical associating fluids theory) calculations.  
The HSP approach within LBDDS has only been investigated to a limited extend, potentially 
due to the variability and complexity of the lipid excipient composition and the multitude of 
drug excipient interactions. However, there are further pharmaceutical applications that are to 
some extent linked to lipids in general such as intestinal drug absorption,296 skin penetration of 
topically applied drugs,297 and prediction of drug-nail interactions.298 The available studies 
suggest that partial solubility parameters have the potential to be a useful tool in early 
development of LBDDS. 
 
3.4.4 Solid dispersions 
3.4.4.1 Amorphous solid dispersions  
Modification of the solid drug form to increase solubility and dissolution rate has been 
mentioned before (section 3.2.).In this endeavour, the high energy that the amorphous state can 
provide is especially interesting.38,161,299,300 However, the amorphous state is 
thermodynamically unstable and tends to revert to a crystalline polymorph. The amorphous 
drug state can be stabilised by solid dispersion,20,301 complexation with large (e.g. 
cyclodextrins)302 or small molecules,303 and spatial confinement (e.g. absorption on 
silica).304,305 
Solid dispersions involving the immobilisation of amorphous API in polymer have been studied 
extensively in the literature109,301,306,307 and are one of the most widely employed approaches to 
formulate an amorphous drug form. Amorphous solid dispersions (ASD) is an umbrella term 
for different types, which can be glass solution, glass suspension and solid solutions of drug in 
the carrier.301,308 Drug-polymer miscibility is key to consider when formulating solid 
dispersions89,309 and to obtain a single phase system, both the API and the carrier have to be 
miscible. Such miscibility can be calculated using advanced thermodynamic models, such as 
the previously mentioned PC-SAFT and COSMO-RS theories or the simpler Flory-Huggins 
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model may be applied.310 The advantages of suitable prediction accuracy of advanced 
thermodynamic approaches have to be balanced against drawbacks like either extensive 
computation time or the need for parameters that have to be based on extensive experimentation. 
This makes the simpler solubility parameter approach very attractive and either the total 
Hildebrand solubility parameter can be considered or partial solubility parameters. Thus, HSP 
has been extensively used to identify drug-excipient miscibility with a general rule of thumb 
that molecules with similar δ values are assumed to be miscible.89,102,190,280 This method 
considers the dispersion and polar interactions of a system as well as the hydrogen bond 
contributions of the test molecules. We emphasise again that HSP hereby addresses the main 
limitation of the conventional Hildebrand solubility parameter, which does not discriminate the 
different partial contributions to cohesive energy density.160  
However, ASD formulation miscibility has been investigated with both the Hildebrand28 as well 
as the Hansen243,311–313 approach. It was proposed by Greenhalgh and co-workers89 that systems 
with a difference in solubility parameters from 1.6 to 7.0 MPa0.5 present no miscibility 
problems. However, substances with a difference of 10.8 to 18.0 MPa0.5 were considered 
immiscible. Further practical measurements showed that systems with a difference of 1.6 to 7.5 
MPa0.5 could be considered miscible in the molten stage. Systems with a difference of 7.4 to 15 
MPa0.5 were slightly immiscible in the liquid state. Total immiscibility was observed in systems 
with differences greater than 15 MPa0.5.89 
With the Hansen approach similar observations were made when testing the miscibility of 2 
drugs in 11 excipients.243 Systems that were predicted to be miscible using the Greenhalgh 
values formed glass solution via hot melt extrusion while those combinations that were 
predicted to be immiscible formed solid dispersions in which the amorphous drugs was 
dispersed in crystalline carriers. On the other hand, when the Hildebrand approach was utilised 
in combination with logP, pKa and Tg considerations, amorphous miscibility between additives 
and polymers failed to be predicted for systems in which acid-base interactions took place.28 
Systems which were predicted to be immiscible, but showed acid-base interactions, still resulted 
in ASD formulations. Contrastingly, this approach accurately predicted miscibility and ASD 
formation for systems produced via a solvent evaporation method without acid-base 
interactions. This underlines again that the Hildebrand concept with a single value for total 
solubility parameter cannot adequately account for specific or hydrogen bonding interactions. 
 
As mentioned previously, the HSP concept offers a 3-D solubility parameter concept that can 
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be visualized in the Hansen space (Figure 1). A way to project a 3-D solubility parameter in a 
two-dimensional plane was proposed by Bagley et al.314 It was argued that the thermodynamic 
contribution to the solubility parameter of the polar and dispersion interactions are often similar, 
and therefore a combined solubility parameter (v2) can be derived from Equation 8 to yield the 
following Equation:314 
 𝛿d
2 + 𝛿p
2 = 𝛿v
2
                                                                                                                   (39) 
The plot of δv versus δh, simplifies the 3-D Hansen space into the 2-D plane, which is referred 
to as a Bagley plot. Analogues to the previously discussed Hansen space, it is assumed that 
molecules in vicinity of each other are more likely to be miscible.190,309 The Bagley plot has 
been utilised to evaluate and predict miscibility between molecules using the Ra(v) parameter, 
which gives an idea of the ‘area of miscibility’ around a molecule, and should be ≤5.6 MPa1/2 
for miscibility. This parameter is analogous to the Ra  in Equation 21 but uses the simplification 
of Equation 39 to a drug polymer system: 
𝑅a(v)2 = [4(𝛿v2 − 𝛿v1)2  +  (𝛿h2 − 𝛿h1)2]                                                                                  (40) 
Bagley plots are highly versatile and have been used to investigate the miscibility of polymers 
in solvents,241 drugs in excipients102,190,309 and polymers in polymers.315 It is important to 
consider the selected method when calculating solubility parameters, as different methods can 
give rise to different Bagley plots, which was highlighted by Meaurio and colleagues.315  
These theoretical considerations were applied to ASD formations by different authors.102,309 
One study tested 84 drug molecules for their miscibility in PEG and demonstrated a good 
correlation between the group of drugs forming ASDs with PEG with the plot region around 
PEG derived from theoretical solubility parameter calculation.309 Alhalaweh et al.102 compared 
experimentally derived miscibility data of indomethacin and excipients with predicted 
miscibility data. The Bagley plots of these data sets were almost identical and the predicted data 
showed a good correlation to the ASD formation.  
Another prerequisite for the formation and stability of successful ASDs is that the change in the 
free energy of the system upon mixing should be negative. Because ideal mixing increases the 
entropy of the system, the entropy contribution should facilitate mixing. Consequently, it is the 
enthalpy contribution that may prevent free mixing energy ΔGm to be negative. In drug-polymer 
systems the Flory-Huggins equation has been adapted to align with the lattice-based equation 
(41) used for the dissolution of polymers in solvents316–319 as previously described in Equation 
5.  
𝛥𝛨m = 𝑉dp𝜑d𝜑p(𝛿d − 𝛿p)2                                                                                                     (41) 
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where subscript d and p describe drug and polymer respectively, while ΔHm can, also, be given 
by the van Laar expression according to Equation 42: 
𝛥𝛨m = 𝜒dp𝜑d𝜑p𝑅𝑇                                                                                                                 (42) 
From Equation 42 it can be seen that the value of the drug-polymer interaction parameter, dp, 
could be a surrogate for the enthalpy of the system, for given conditions. By combining 
equations (41) and (42), the drug-polymer interaction parameter can be given by Equation 43 
(neglecting β) which is in line with the previously discussed Equation 6: 
 𝜒dp =
𝑉dp(𝛿d−𝛿p)2
𝑅𝑇
                                                                                                                    (43) 
Where Vdp is volume of mixture, φd, φp are volume fractions of drug and polymer, δd, δp are 
solubility parameters of drug and polymer. 
Similar to the total (or Hildebrand) solubility parameter, the HSP has also been linked to the 
drug-polymer interaction parameter (dp) by consideration of partial contributions to cohesive 
energy density.241 
The drug-polymer interaction parameter has been used widely for the investigation of binary 
mixtures especially, miscibility based on a negative ΔGm.. Although this parameter can be 
determined by melting point depression,90,317,319,320 there are also some studies that use the 3-D 
solubility parameter approach309,319,320 to investigate drug-excipient miscibility in a more 
quantitative way. Such construction of a phase diagrams shows the differentiation of single and 
two phase system at equilibrium (binodal line) and kinetic decomposition of metastable 
mixtures (spinodal line) can be estimated.18,321 It is attractive to construct entire phase diagrams 
but this objective is more ambitious than use of the solubility parameters to simply rank 
excipient selection based on rules of thumb, such as based on the proximity of drug and 
excipient representations in the Hansen space or Bagley plot. A key strength of the solubility 
parameter is that such approaches are in general rather simple. A more ambitious quantitative 
calculation of entire phase diagrams can suffer from the simplifications of the thermodynamic 
approach as well as from lacking prediction of solubility parameter estimates. Phase diagrams 
constructed via solubility parameters might therefore be better considered as a first 
approximation only.  
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3.4.5  Mesoporous silica 
Recent developments suggests mesoporous silica as a new and promising material to formulate 
poorly water-soluble drugs with the intent to increase dissolution rate and solubility.305,322–326 
Loaded mesoporous silica is prepared via adsorption of API from a concentrated organic 
solution followed by evaporating the solvent. This adsorption into the porous network stabilises 
the API in the amorphous state, due to steric effects. Upon administration, this amorphous API 
is then released and the dissolution is increased.323 
Utilisation of the solubility parameter in the development of amorphous mesoporous silica is 
still largely unemployed without commercial formulations that are globally on the market. This 
represents a key gap in the literature, as solubility parameters can guide the selection of suitable 
solvent to maximize the penetration efficiency of API into mesoporous silica, which was 
demonstrated by Hideo Hata and co-workers.327 They showed that, of six different solvents 
used to incorporate taxol onto mesoporous silica, only two resulted in effective loading of the 
API. They concluded that solubility parameter was a key factor in this observation; where 
solvents that interacted strongly with taxol resulted in the most effective loading, whereas those 
with weak interaction showed poor loading efficiency. Such interaction can be determined 
using solubility parameter approach.327 However, the range of solvents suitable for use with 
formulation development is limited. Those solvents that show the strongest solubilisation power 
are often seen as ‘no-go’ solvents based on ICH guidelines.328 Therefore, most instances of 
mesoporous silica use in the literature are carried out with either ethanol, acetone or 
dichloromethane, with even the latter being less utilised due to toxicity considerations.305 The 
ICH list certainly limits solvent selection but not to the extent as it is currently reflected in the 
literature on mesoporous silica so there is potential to access a wider range of solvents by 
employing with a rank-order based protocol based on in silico solubility parameter calculation. 
 
ASD systems have proved to be a useful formulation tools in battling the solubility issues of 
pharmaceutical molecules. However, because of their limitations in stability, miscibility of the 
system is of crucial importance for a successful formulation. This makes the identification of 
tools to evaluate miscibility in the development phase, not only useful, but imperative. Herein 
the application of solubility parameter concepts to assess miscibility has been reviewed and 
discussed in the previous section 3.4.1. It should be emphasised again that a consideration of 
partial solubility parameters is preferred to a simple comparison of total (i.e. Hildebrand) 
solubility parameters. Moreover, the need of a complete database for partial solubility 
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parameter either for drug and polymer was highlighted when using HSP. A limited number of 
data is not only available with respect to experimentally determined values but also for group 
contributions as used for in silico prediction of solubility parameters. The latter limitation can 
be especially troublesome in case of HSP estimation for more complex drug molecules. 
Application of the modified solubility parameter approach was applied by Piccinni329 and even 
though the usefulness for early excipient ranking was recognised, it was also emphasised that 
physical screening tests should not be replaced by the in silico method until more robust 
prediction methods are available. This supports what was discussed in the previous sections 
that solubility parameters can be calculated in silico to rank excipients for a subsequent 
experimental screening. Such a screening phase can therefore be designed in a more focused 
and cost-effective way rather that be entirely replaced.  
 
3.4.6 Application of solubility parameters in the formulation of nano- and 
microparticulate systems 
One of the most used methods for dissolution improvement of poorly water-soluble drugs is 
particle size reduction. The decrease in size increases the surface to volume ratio, which 
accelerates dissolution kinetics. Especially interesting here are sizes well below 1μm, which 
have the highest potential increase the kinetic drug solubility330,331 in addition to the dissolution 
rate enhancement. Thus, by bringing particle size to the nanoscale, solvation pressure increases 
and facilitates the disruption of the intra-solute bonds thus promoting solubilisation.332 
Micronisation and nanosizing methods can be grouped into two categories: the top-down 
methods that entails size reduction of bigger particles by the use of shear forces and the bottom-
up methods that involve the isolation of drug particles after recrystallisation from a highly 
supersaturated drug solution.331 Although traditional micronisation techniques, such as dry-
milling, are still being used, bottom-up approaches are becoming increasingly sophisticated, 
gaining merit as techniques that can circumvent typical process limitations.333 These limitations 
may involve unwanted amorphisation, disruption of the crystal lattice and unpredictable particle 
size distributions.334 However, bottom-up approaches also face their individual limitations. Due 
to the fact that they rely on the controlled precipitation of particles from supersaturated 
solutions, miscibility and solubility considerations should be taken into account for the optimal 
choice of formulation combinations. 
 
Moreover, technical developments in both top-down (e.g. “pearl” milling and high-pressure 
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homogenisation) and bottom-up techniques (e.g. new-generation spray dryers, supercritical 
fluid technology and freeze drying) have broadened the availability of nanosizing approaches. 
As nanoparticles exhibit high surface cohesive energies, they are especially prone to 
aggregation,335,336 making their stabilisation indispensable. The use of various stabilizers, often 
surfactants and/or polymers, has been reported. It is proposed that they work by sterically or 
ionically stabilizing the surface of nanoparticles, in order to limit aggregation.337 The choice of 
appropriate stabilizers seems to greatly depend on the physical characteristics of the surface of 
drug molecules.338 Consequently, the need for reliable tools to estimate possible candidates for 
nanoparticle formulations is evident.  
Several attempts for nano- and micronised formulations have been reported in literature using 
a variety of materials including proteins, lipids and polymers.339 We considered here not only 
the classical top-down and bottom-up approaches but more broadly reviewed also micro- and 
nanoparticle formation. Calculated solubility parameters are used eventually here as an early 
evaluation of miscibility of solvent-solute combinations as well as miscibility between 
molecules. However, evidence of using solubility parameters later during formulation 
development is very limited. To the best of our knowledge only few relevant literature 
references exist, i.e. where a solubility parameter approach has been used for choosing the 
appropriate lipids in drug-polymer-lipid nanoparticles,295 for choosing the drug-polymer 
combinations for the construction of polymeric micelles and for predicting drug loading.340,341 
Furthermore, Mahmud et al.341 and Dwan’Isa et al.340used the HSP to calculate the Flory-
Huggins interaction parameter of drug-polymer combinations (χdp) and considered it as a 
measure of miscibility.83 Dwan’Isa et al. tested 19 drugs for their interactions with a diblock 
co-polymer (MePEG-b-(PCL-co-TMC)), while Mahmud et al. studied the interactions of one 
anticancer drug (curcubitacin I) against a variety of core-forming polymers. In both studies, the 
calculation of the dp parameter was able to reveal the optimal drug-polymer combinations, as 
well as to predict the drug loading capacity of the polymer micelle formulations. Even though 
the calculation of the interaction parameter provided a reasonably accurate method for the 
qualitative prediction of drug solubilisation in the polymeric micelles, a definite rank-order of 
combination miscibility among the variations tested could not be achieved, which may be 
attributed to the limitations of the Flory-Huggins theory as well as lacking accuracy of 
estimating the interaction parameter. Simplifications included the disregard of polymer 
molecular weight and polymer solvent interactions.83 Nevertheless, the calculations of the HSP 
and the Flory-Huggins interaction parameter have been proven to be adequate tools for the 
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primary selection of potentially miscible nano- and microparticulate systems, which helps in 
reducing the number of early screening experiments.  
 
3.5  Conclusions 
Solubility parameters have proven to be useful in diverse scientific fields and this review has 
outlined the different applications concerning oral delivery of poorly water-soluble compounds. 
These compounds typically require bioenabling formulation for successful development and 
solubility parameters can help, for example with ranking of solvents and excipients to achieve 
a more focused formulation development. Herein, predictions based on chemical structure are 
particularly interesting since only limited compound is available in early development. Despite 
the usefulness of applying solubility parameters in pharmaceutics, there are also some gaps. 
Especially drugs in a solid crystalline state or also rather complex molecules in general may 
result in erratic predictions of solubility parameters. However, it is promising that new 
theoretical developments have been reported that present conceptual improvements. Moreover, 
experimental methods like high-throughput solubility testing or greater availability of inverse 
gas chromatography will help in generating more data. Important is to obtain more comparative 
data of experimental and computational methods to better learn about variability of results. This 
can in turn help to further improve in silico predictions of solubility parameters and a just 
accepted article has been following this research direction.94 Therefore, it can be expected that 
solubility parameters will also in the future rank among the mostly used thermodynamic 
approaches in pharmaceutics
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4 Towards a better understanding of solid 
dispersions in aqueous environment by a 
fluorescence quenching approach 
 
 
Summary 
Solid dispersions (SDs) represent an important formulation technique to achieve 
supersaturation in gastro-intestinal fluids and to enhance absorption of poorly water-soluble 
drugs. Extensive research was leading to a rather good understanding of SDs in the dry state, 
whereas the complex interactions in aqueous medium are still challenging to analyze. This 
paper introduces a fluorescence quenching approach together with size-exclusion 
chromatography to study drug and polymer interactions that emerge from SDs release testing 
in aqueous colloidal phase. Celecoxib was used as a model drug as it is poorly water-soluble 
and also exhibits native fluorescence so that quenching experiments were enabled. Different 
pharmaceutical polymers were evaluated by the (modified) Stern-Volmer model, which was 
complemented by further bulk analytics. Drug accessibility by the quencher and its affinity to 
celecoxib were studied in physical mixtures as well as with in SDs. The obtained differences 
enabled important molecular insights into the different formulations. Knowledge of relevant 
drug-polymer interactions and the amount of drug embedded into polymer aggregates in the 
aqueous phase is of high relevance for understanding of SD performance. The novel 
fluorescence quenching approach is highly promising for future research and it can provide 
guidance in early formulation development of native fluorescent compounds. 
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4.1  Introduction  
Solid dispersion (SD) is a widely employed approach to orally deliver poorly water-soluble 
drugs. The compound is mostly formulated in an amorphous high-energy state, which should 
be kinetically stabilized throughout the targeted shelf-life of the product. Especially critical for 
poorly soluble compounds is dispersion in aqueous medium, which comes naturally with the 
oral route of administration and bears a risk of drug crystallization from the amorphous state 
(Newman, 2015). To fully benefit from SD formulations, physical instability must be therefore 
hindered, for example, by using polymers 20,38,109,301 The results of most studies indicate that 
polymers decrease the crystallization tendency of an amorphous drug due to a reduction of 
molecular mobility 52, as well as by breaking of the interconnections between drug molecules 
and the formation of specific drug-polymer interaction 342,343 These molecular interactions and 
their biopharmaceutical consequences are of major interest within the field of SDs. A majority 
of research focuses on drug-polymer interactions in the dry bulk state employing Fourier 
transform infrared (FT-IR), Raman spectroscopy, differential scanning calorimetry (DSC), X-
ray powder diffraction (XRPD) and solid state NMR spectroscopy 23,344,345. Among the different 
characterization techniques to study the dry state of SDs, transmission electron microscopy was 
also deemed as highly relevant. 346–349  
It seems more complex to understand and study drug excipient interactions upon aqueous 
dispersion because there is often a complex phase separation involved. Indeed, previous studies 
reported that in contact with an aqueous solution simulating the gastro-intestinal media, SDs 
rapidly disperse and thereby provide a broad range of drug and excipient assemblies 4,11,18,101,350 
Release from these particles and colloids provide the free drug concentration that is the true 
supersaturation driving absorption. 18,100 The above investigations were conducted not only in 
simulated intestinal medium but also in mere buffer systems because simulated intestinal media 
make the interpretation more difficult due to the various colloidal states present even without 
dispersing ASDs.103. Already aqueous solution of lipophilic drug alone can exhibit complex 
behavior where a critical transition leads to a drug-rich and water-rich phase, which is known 
as a liquid-liquid phase separation (LLPS). 105,351,352 In this context, different authors 4,104,353,354 
have employed fluorescence probes as marker for the polarity of the molecular environment. 
The study reported by Tho et al. (2010) is one of few reports on fluorescence as a tool in SD 
analysis. 355 Solid drug particles were differentiated from a liquid and drug rich phase and nano- 
as well as micro-sized solid particles were formed (isolated and analyzed by X-Ray) on 
Towards a better understanding of solid dispersions in aqueous environment by a fluorescence 
quenching approach 
 
 
73 
 
dispersion of SDs in buffer media. 355  Moreover, Frank et al., 2012b reported a phase separation 
phenomenon during the dissolution of a commercial SD, including the formation of solid 
amorphous particles, which were isolated, dried, and analyzed by XRPD. 11 
 Given the wide range of established applications of fluorescence in the life sciences, it is rather 
surprising that fluorescence methods have not been more harnessed in pharmaceutical analysis 
of SDs. A notable exception is the very recent work on fluorescence lifetime and steady-state 
fluorescence spectra measurements, which were successfully employed to differentiate and 
characterize phase transformations in supersaturated aqueous solutions of poorly water-soluble 
drug 125. Interesting is in the context of fluorescence analysis of poorly soluble compounds also 
another work that employed pyrene to elucidate a drug dissolution enhancement effect of stevia-
G. 356 Moreover, a study on fluorescence resonance energy transfer (FRET) is noteworthy, 
which aimed at differentiation of compound distribution in SD as either in the form of molecular 
dispersion or as larger amorphous clusters.357 Fluorescence analysis is highly sensitive and can 
provide valuable information of a probe molecule regarding its immediate environment (i.e. 
polar molecules in polar solvents), rotational diffusion, distances between the sites on 
biomolecules, conformational changes, and binding interactions. It seems that fluorescence 
analysis could be further exploited in the field of solid dispersions and it may particularly help 
with the scientific challenges of analyzing the formulations on release in aqueous media. 
In aqueous dispersion, the evolving complex multiphase systems of SDs are inherently difficult 
to study. There are different approaches reported in the literature to study release from SDs 313, 
but no single technique alone appears to be sufficient to characterize both the solid particles as 
well as the aqueous colloidal phase that is formed during release. The evolving phases from 
SDs could therefore be analyzed separately using complementary analytical approaches. This 
work reports on a fluorescence analysis to assess the drug-polymer interactions in the aqueous 
colloidal phase on drug release. In particular, we introduce a method based on fluorescence 
quenching and size-exclusion chromatography to investigate such systems. Celecoxib (CX), a 
native-fluorescent poorly soluble compound was studied in physical mixtures with various 
polymers (at different concentrations) as well as with SDs where the 1:1 (w/w) CX: polymer 
ratio was selected in order to have a high drug loading. The combined analysis of the (modified) 
Stern-Volmer plots and size-exclusion chromatography enabled unique insight into how the 
selection of polymer affected the accessibility of drug by the quencher as well collisional 
affinity in the aqueous colloidal phase. Such information is highly attractive to learn about the 
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molecular interactions of drug with formulation components that take place during the 
dissolution in the aqueous colloidal phase. 
 
4.2 Materials and methods 
4.2.1  Materials 
Celecoxib (CX) was purchased from AK scientific, Inc. (USA), hydroxypropyl methyl cellulose 
acetate succinate, L grade (HPMCAS-LG) was obtained from Shin-Etsu AQOAT, 
polyvinylpyrrolidone vinyl acetate (PVP VA64) and Soluplus® were purchased from BASF, 
Poloxamer 188 and potassium iodide (KI) were purchased from Sigma Aldrich. PD MidiTrap 
G-25 M was purchased from GE healthcare life science. All solutions were prepared using Mill-
Q water (18.2 MΩ cm−1). 
4.2.2  Methods  
4.2.2.1 Preparation of solid dispersions and physical mixtures 
SDs were prepared by using a solvent evaporation method as described in literature (Chiou and 
Riegelman, 1969). Briefly, CX and polymer were taken in ratio of 50:50 (w/w) and dissolved 
in an adequate amount of methanol. The solvent was then rapidly evaporated under reduced 
pressure using a mild heating bath (up to about 50 °C) to form a uniform solid mass. The co-
precipitate was crushed and desiccated under vacuum for 24 h, then pulverized and vacuum 
desiccated again for a day. In case of the physical mixtures, CX and the different polymers were 
mixed in a ratio of 90:10, 80:20, 70:30, 50:50 and 30:70 (w/w) by trituration with a pestle-
mortar, and were then stored in a desiccated environment. CX based SDs and physical mixtures 
were prepared using HPMCAS-LG, PVP VA64, Poloxamer 188 and Soluplus. 
4.2.2.2  Powder x-ray diffraction (XRPD) 
Powder X-ray diffraction was used to characterize the solid form of the physical mixtures and 
of SDs at ambient temperature using a Bruker D2 PHASER (Bruker AXS GmbH, Germany) 
with a PSD-50 M detector and EVA application software version 6. Samples were prepared by 
spreading powder samples on PMMA specimen holder rings from Bruker. Measurements were 
performed with a Co Kα radiation source at 30 kV voltage, 10 mA current and were scanned 
from 10–35 2θ with 2θ being the scattering angle at a scanning speed of 2θ /min. 
4.2.2.3  Differential scanning calorimetry (DSC) 
A DSC 4000 System, from PerkinElmer (Baesweiler, Germany) was calibrated for 
Towards a better understanding of solid dispersions in aqueous environment by a fluorescence 
quenching approach 
 
 
75 
 
temperature and enthalpy using indium. Nitrogen was used as the protective gas (20 mL/min). 
Samples (approximately 5 mg) were placed in 40 μL aluminum pans with pierced aluminum 
lids. The midpoint glass transition temperatures (Tg), was determinate by a single-segment 
heating ramp of 5 °C/min from 25 °C to a maximum temperature of 200 °C. All DSC 
measurements were carried out in triplicate. 
 
4.2.2.4 Dynamic light scattering (DLS) for particle sizing 
The size of the obtained aggregates was measured with NanoLab 3D (LS instruments, 
Freiburg, Switzerland) equipped with a 45 mW at 685 nm, vertically polarized laser, having 
the detector at 180° with respect to the incident beam at 37 ± 0.1 °C. Disposable polystyrene 
cuvettes of 1 cm optical path length were rinsed several times (at least five) with the solutions 
to be analyzed and finally filled with the same solution under a laminar flow hood to avoid 
dust contamination. At least three independent samples were taken, each of which was 
measured 10 times. Measurements were done in auto correlation mode and the obtained 
values are reported as an average ± standard deviation (STDV). Each measurement had a 
duration of 30 seconds with the laser intensity set on 100%. For the fitting of the correlation 
function, third order cumulant fits were performed with the first channel index and the decay 
factor being 15 and 0.7 and analyzed according to the cumulant method (Frisken, 2001).  
 
4.2.2.5 Diffusing wave spectroscopy (DWS) 
DWS RheoLab (LS Instruments AG, Fribourg, Switzerland) was used as optical technique for 
microrheological measurements as reported previously. 118 The theory of DWS-based 
microrheology was already explained in detail in our previous work. 153 The DWS was 
calibrated prior to each measurement with a suspension of polystyrene particles, PS, 
(Magsphere Inc., U.S.A) in purified water (10 wt. %). The PS particles have a mean size of 
250±25 nm with a solid content of 0.5 wt. % in dispersion. This suspension was filled in 
cuvettes with a thickness L of 5 mm prior to measuring for 60 s at 25 ◦C. The value of the 
transport mean free path, l* (microns) was determined experimentally as reported 
previously.358 The transmission count rate was measured several times until a constant value 
was reached and the cuvette length, L, was considerably larger than the obtained values for l* 
(L ≫ l) ensuring diffusive transport of light. The transport mean free path of the sample l* is 
needed for the determination of the correlation intensity function and thus for the 
microrheological characterization. Viscosity measurements were performed on 0.5 mg/mL 
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HPMCAS-LG, PVP VA64, Soluplus and Poloxamer 188 solutions in PBS at pH 6.5. Thus, 
0.5 wt. % polystyrene (PS) nanoparticles were added to the clear samples to ensure the correct 
regime (guarantee a L/l* ratio larger than 7). 118 5 mm quartz cuvettes were employed and data 
acquired for 60 s and each sample was measured 5 times. The viscosity measurement of 
polymer solutions was determined in a broad frequency range by DWS, where an average 
reference viscosity (expressed as G’’/frequency) at high frequencies (from 100000 to 150000 
rad/s) is reported in table S1. 
 
4.2.2.6 Preparation of aqueous colloidal phase 
10 mL of PBS at pH 6.5 were added to 10 mg of freshly prepared SD or physical mixture of 
CX and different amounts of polymers. The obtained mixtures were kept under stirring (400 
rpm) at 37 °C for 4 hours in the dark. The time period was arbitrarily selected to represent a 
pseudo-equilibrium that is of physiological relevance for the absorption process. The aqueous 
phase of the dispersed samples containing the solubilized CX and polymer was then collected 
as supernatant (called here aqueous colloidal phase, ACP) and separated from the above 
mentioned mixtures. Subsequently, an aliquot from the ACP was taken out and used for further 
experiments. The amount of solubilized drug and its concentration in the ACP (CX 
concentration in aqueous phase) was based on high- performance liquid chromatography 
(HPLC) and calculated by using a calibration curve (both HPLC method and calibration curve 
are shown in SI). Measurements were carried out in triplicate (n=3) and the results are shown 
(Table 1 to 5). It has to be noted that such percentage values refer to the solubilized amount of 
drug in the aqueous colloidal phase (in the pseudo-equilibrium after 4 h), while the residual part 
of the total drug amount was unreleased in a solid phase. 
4.2.2.7 Fluorescence quenching experiments 
Fluorescence quenching experiments on the above mentioned ACP were performed using 
iodide (I-) as collisional quencher. All fluorescence experiments were carried out at room 
temperature on solutions with optical densities smaller than 0.05 to minimize inner filter effects. 
Fluorescence quenching experiments were performed by adding small aliquots of 1 M KI 
(containing small amount of Na2S2O4 to avoid the oxidation of the quencher) solution to the 
samples.  
Table 1. Physical mixtures of CX and HPMCAS-LG used for fluorescence quenching 
experiments. 
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Drug-
polymer 
ratio 
(w/w) 
CX concentration in 
aqueous phase 
(µg/mL) 
% Dose in 
aqueous 
phase 
KD (1/M × s) 
a
 fa 
b
 R2 
c
 
100:0 2.3 ± 1.1 0.5 ± 0.2 17.9 ± 0.7 1 ± 0.02 0.991 
90:10 9.1 ± 3.2 1.8 ± 0.6 7.1 ± 0.3 1 ± 0.01 0.996 
80:20 7.1 ± 1.0 1.4 ± 0.2 6.8 ± 0.2 1 ± 0.02 0.997 
70:30 6.8 ± 1.5 1.3 ± 0.3 0.21  ± 0.002* 0.52  ± 0.027 0.998** 
50:50 7.4 ± 1.3 1.5 ± 0.3 0.15  ± 0.002* 0.32  ± 0.023 0.996** 
30:70 10.2 ± 1.9 2.0 ± 0.4 0.15  ± 0.003* 0.32  ± 0.030 0.993** 
a 
Quenching constant (± standard error obtained by the fitting, SE), 
b 
accessible fraction (± SE) 
and 
c
Coefficient of determination (i.e. R-squared) of the Stern-Volmer plot fitting. * Quenching 
constant of accessible fraction (Ka, 1/M, ± SE). ** R2 of the modified Stern-Volmer plot fitting. 
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Table 2. Physical mixtures of CX and PVP VA 64 used for fluorescence quenching experiments. 
Drug- 
polymer 
ratio 
(w/w) 
CX 
concentration 
in aqueous 
phase ( g/mL) 
% Dose in aqueous 
phase 
KD (1/M × s) 
a
 fa 
b
 R2 
c
 
100:0 2.3 ± 1.1 0.5 ± 0.2 17.9 ± 0.7 1 ± 0.02 0.991 
90:10 13.5 ± 0.5 2.7  ± 0.1 8.0 ± 0.3 1 ± 0.01 0.987 
80:20 17.4 ± 2.6 3.5  ± 0.5 8.1 ± 0.4 1 ± 0.03 0.982 
70:30 15.7 ± 0.8 3.1 ± 0.2 8.6 ± 0.5 1 ± 0.04 0.979 
50:50 16.8 ± 2.9 3.3 ± 0.6 9.0 ± 0.5 1 ± 0.03 0.983 
30:70 15.4 ± 0.9 3.0 ± 0.2  9.0 ± 0.6 1 ± 0.04 0.990 
a Quenching constant (± SE), b accessible fraction (± SE) and c R2 of the Stern-Volmer plot 
fitting.  
 
 
 
Table 3. Physical mixtures of CX and Soluplus used for fluorescence quenching experiments. 
Drug-
polymer 
ratio 
(w/w) 
CX 
concentration 
in aqueous 
phase ( g/mL) 
% Dose in aqueous 
phase  
KD (1/M × s) 
a
 fa 
b
 R2 
c
 
100:0 2.3 ± 1.1 0.5 ± 0.2 17.9 ± 0.7 1 ± 0.02 0.991 
90:10 5.0 ± 2.3 1 ± 0.4 9.7 ± 0.4 1 ± 0.03 0.987 
80:20 6.8 ± 2.2 1.8 ± 0.4 9.5 ± 0.2 1 ± 0.01 0.982 
70:30 6.6 ± 1.2 1.7 ± 0.2 9.8 ± 0.4 1 ± 0.02 0.991 
50:50 5.8 ± 2.8 2.0 ± 0.6 7.9 ± 0.3 1 ± 0.04 0.991 
30:70 8.1 ± 1.2 2.0 ± 0.2 7.4 ± 0.5 1 ± 0.04 0.988 
a Quenching constant (± SE), b accessible fraction (± SE) and c R2 of the Stern-Volmer plot 
fitting 
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Table 4. Physical mixtures of CX and Poloxamer 188 used for fluorescence quenching 
experiments. 
Drug-
polymer 
ratio 
(w/w) 
CX 
concentration 
in aqueous 
phase ( g/mL) 
% Dose in aqueous 
phase  
KD (1/M × s) 
a
 fa 
b
 R2 
c
 
100:0 2.3 ± 1.1 0.5 ± 0.2 17.9 ± 0.7 1 ± 0.02 0.991 
90:10 19.4 ± 1.8 3.8 ± 0.4 16.4 ± 0.4 1 ± 0.01 0.997 
80:20 16.5 ± 1.2 3.3 ± 0.2 15.3 ± 0.2 1 ± 0.02 0.993 
70:30 24.2 ± 4.3 4.8  ± 0.9 14.7 ± 0.5 1 ± 0.03 0.986 
50:50 32.9 ± 5.3 6.6  ± 1.1 15.5 ± 0.4 1 ± 0.03 0.982 
30:70 28.8 ± 4.4 5.7  ± 0.9 15.6 ± 0.6 1 ± 0.04 0.985 
a Quenching constant (± SE), b accessible fraction (± SE) and c R2 of the Stern-Volmer plot 
fitting 
 
 
 
Table 5. CX solid dispersions (drug-polymer ratio 50:50, w/w) used for fluorescence quenching 
experiments. 
CX SDs CX 
concentration 
in aqueous 
phase ( g/mL) 
% Dose in 
aqueous phase 
Ka (1/M) 
a
 fa 
b
 R2 
c
 
HPMCAS-LG 28.8 ± 0.5  5.7 ± 0.1 0.038 ± 0.006  0.33 ± 0.07 0.990 
PVP VA 64 38.0 ± 0.7 6.7  ± 1.0 0.020 ± 0.001 0.45 ± 0.06 0.999 
Soluplus 6.1 ± 0.8 1.2 ± 0.2 0.017 ± 
0.0004 
0.86 ± 0.01 0.999 
Poloxamer 
188 
40.1 ± 2.5 8.2 ± 0.5 16.2* ± 
0.6433 
1 ± 0.04 0.990 
a Quenching constant (± SE) of the accessible fraction, b accessible fraction (± SE) and c R2 of 
the modified Stern-Volmer plot fitting. * Quenching constant (KD, 1/M × s ± SE). 
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Decrease of the CX fluorescence intensity was monitored at 380 nm by exciting at 250 nm 
using Greiner® UV-transparent microplates and a SpectraMax® M2 plate reader (Molecular 
devices, San Jose, CA, USA). Quenching of fluorescence is described by the Stern-Volmer 
equation and quenching data were presented as plots of F0/F versus quencher concentration 
[KI], were F0 and F are the fluorescence intensity in absence or in presence of the quencher, 
respectively. 121 The plot of F0/F versus [KI] is expected to be linearly dependent upon the 
concentration of quencher and it yields an intercept of one on the y-axis and a slope equal to 
the Stern-Volmer quenching constant KD (1/M × s) when the quenching process is dynamic. 
The KD is given by kq×τ0 where kq is the bimolecular quenching constant and τ0 is the lifetime 
of the fluorophore in the absence of quencher. When the Stern-Volmer plots deviate from 
linearity toward the x-axis (i.e. downward curvature) a modified Stern-Volmer equation (Eq.1) 
was used to calculate the amount of accessible fraction (fa) and its affinity to the quencher (Ka, 
1/M) 121 A plot of F0/(F0-F) versus 1/ [KI] yields fa–1 as the intercept on the y-axis and (fa ×Ka)–
1 as the slope. The KD, Ka and fa values are the coefficient of the curves obtained from six 
point’s linear regression and the coefficient of determinations, i.e. R-squared (R2) of the fittings 
are reported in the Tables. Each fitted value was reported as mean  standard error (SE) that 
was obtained by the regression analysis using Sigma Plot (Systat Software, Inc. San Jose, CA, 
USA). 
 
𝐹0/∆𝐹 = 1/(𝑓𝑎 × 𝐾𝑎 × [𝐾𝐼]) + 1/𝑓𝑎  (1) 
 
4.2.2.8 Size exclusion chromatography 
0.5 mL of the ACP containing only the solubilized CX and polymer was filtered at room 
temperature through a PD MidiTrap G-25 M, a Sephadex G-25 packed column. According to 
size exclusion chromatography (SEC), small molecules (such as the free CX) that are able to 
enter into the resin pores are retained longer in the column, while large molecules (such as 
aggregates) which are bigger than the pore size are eluted firstly. Therefore, this technique 
enables to discriminate between free drug and the drug embedded in aggregates. The elution 
profile was retrieved plotting either the value of the mean count rate (Kcps), obtained by DLS 
measurements or the percentage of CX present in the fractions eluted from the column vs the 
elution volumes (mL). The percentage of CX in the fractions (% CX) was evaluated according 
to Eq. 2.  
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% CX = (Ffr /Fnf) x 100 (2) 
% CX free = 100 - % CX-Polymer (3) 
Where Ffr is the fluorescence intensity value of the fractions eluted from Sephadex filtration 
and Fnf is the fluorescence intensity value before Sephadex filtration. The total percentage of 
CX embedded in polymer aggregates (% CX-Polymer) is given by the sum of the percentage 
of CX (% CX) present in the fractions where DLS shown presence of aggregates. On the other 
hand, the percentage of free CX (% CX free) was calculated according to the Eq. 3. All 
experiments were carried out consecutively (n=3) at room temperature, the % CX free is 
reported as mean ± STDV. 
 
4.3 Results 
4.3.1  Bulk characterization of physical mixtures and solid dispersions 
Prepared SDs were analyzed by powder X-ray diffraction (XRPD) at 25°C to verify the 
amorphous nature of the dispersions and the results were compared with those of the 
corresponding physical mixtures. As shown in Figure 1A, CX based SDs manufactured with 
HPMCAS-LG, PVP VA64, and Soluplus (at 50% (w/w) drug loading) were X-ray diffraction 
amorphous. However, the SD prepared with Poloxamer 188 showed diffraction peaks and a 
substantial crystallinity was verified in the physical mixtures as well as with pure drug. The 
SDs were further characterized by DSC to confirm the physical state of drug in the matrix. As 
shown in Figure 1B, the SD with HPMCAS-LG, PVP VA 64 and Soluplus display a single 
glass transition temperature (Tg) and the absence of a drug melting temperature (Tm). On the 
other hand, the SD based on Poloxamer 188 shows two different thermal events, one 
corresponding to melting of the eutectic mixture and the second to the Tm values indicate 
suspended CX present in the eutectic melt. As very different types of polymers were selected 
deliberately, it was expected that not all SDs of CX would result in an entirely amorphous 
system. 
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Fig. 1. Powder X-ray diffraction (XRPD) plots of CX alone (a), physical mixtures with 
HPMCAS-LG (b), PVP VA 64 (c), Soluplus (d), and Poloxamer 188 (e). CX solid dispersions 
(SD) are shown with HPMCAS-LG (f), PVP VA 64 (g), Soluplus (h), and Poloxamer 188 (i) 
(A). DSC thermograms of CX alone (a), SDs with HPMCAS-LG (b), PVP VA 64 (c), Soluplus 
(d) and Poloxamer 188 (e).  
 
4.3.2 Characterization of drug-polymer interactions 
Fluorescence quenching experiments were employed to gain information about the molecular 
environment of the model drug CX in the aqueous colloidal phase. The study of accessibility 
of drug to the quencher was therefore of interest in the physical drug-polymer mixtures as well 
as in SD formulations.  
The freshly prepared SDs or physical mixtures of CX with different amounts of polymers were 
added to PBS at pH 6.5 and kept under stirring at 37 °C for 4 hours in the dark. The duration 
was selected as physiologically-relevant time scale which typically allows a SD to reach a 
pseudo equilibrium. The obtained aqueous colloidal phase, containing the solubilized CX (CX 
concentration in aqueous phase) and polymers were used to study drug-polymer interactions 
that take place in the aqueous solution. Even though the study focused on this aqueous phase, 
one should keep in mind that this phase contained only a part of the dose since 4 h release (i.e. 
pseudo- equilibration) resulted in multiphase system in which some drug was either not released 
or it precipitated from supersaturation. Therefore, any given percentages in the fluorescence 
experiments are understood as relative to the drug amount solubilized in the aqueous phase. 
However, the exact amount of drug (CX concentration in aqueous phase) present in the aqueous 
colloidal phase (and the percentage of dose) used for quenching experiments were evaluated by 
HPLC and the results are shown in tables from 1 to 5. 
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Moreover, CX quenching is established to be dynamic and the fluorescence of the drug 
decreased linearly with the concentration of KI that is a commonly used collisional quencher 
(see SI, Figure S2).  
As shown in Figure 2A and summarized in Table 1, the quenching of fluorescence is described 
by the Stern-Volmer equation in the cases of CX alone (black circles) and the physical mixtures 
with 10 (black upper triangles) and 20 (white diamonds) % (w/w) of HPMCAS-LG. Thus, 
fluorescence quenching data, presented as plots of F0/F versus [KI], show a linear behavior. 
Already the presence of 10 or 20 w/w % polymer led to a decrease CX quenching as seen from 
decreased values of the quenching constant (KD). Interestingly, addition of 30 w/w % polymer 
or more (see Figure 2B) resulted in Stern-Volmer plots that clearly deviated from linearity. 
Indeed, CX quenching decreases by an increasing amount of HPMCAS-LG from 30 (white 
upper triangles) to 70 (black down triangles) w/w %. As shown in Figure 2C and summarized 
in Table 1, a modified Stern-Volmer equation was used to calculate the amount of accessible 
fraction (fa) and its affinity to the quencher (Ka). 
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Fig. 2. Physical mixtures: Stern–Volmer plots (A and B) and modified Stern–Volmer plots (C) 
for fluorescence quenching of CX in the presence of 0 (black circles), 10 (black upper triangles), 
20 (white diamonds), 30 (white upper triangles), 50 (white circles) and 70 (black down 
triangles) w/w % of HPMCAS-LG. 
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On the other hand, when in the physical mixture, HPMCAS-LG is replaced with PVP VA64, 
Soluplus, or, Poloxamer 188, the Stern-Volmer quenching plot did not deviate from linearity 
by a clear downward curvature (see SI, Figure S3) even not at highest polymer concentration 
(i.e. 70 w/w %). Similar as for HPMCAS-LG, was for PVP VA64 (Table 2) or Soluplus (Table 
3) that a decrease of the quenching constant (KD) was noted with added polymer in physical 
mixtures. By contrast, Poloxamer 188 did not exhibit any changes in the quenching of CX and 
the obtained KD values for different drug-polymer mixture ratios are comparable with the one 
for CX alone (Table 4). 
Moving from the physical mixtures to SDs of drug and polymer revealed that except for the 
Poloxamer 188 based SD, the Stern-Volmer plots deviated from linearity (downward curvature) 
for all the other formulations (see SI, Figure S4). As summarized in Table 5, the HPMCAS-LG 
based SD shows the lowest value of fa, while using Soluplus in SD, the accessible fraction rises 
up close to 0.9. As already mentioned in the case of Poloxamer 188, the obtained KD value 
(Table 5) was comparable with those obtained in the physical mixture and in the case of CX 
alone. This was different in the case of HPMCAS-LG (Figure 3) because the quenching 
constant in the physical mixtures was higher than in the SD while fa was about the same. 
Differences between SD and physical mixture were found also in the case of PVP VA64. As 
shown in Figure 4, in the case of the physical mixture, the quenching of fluorescence is 
described by the Stern-Volmer equation. This plot in case of SD deviated from linearity and the 
modified Stern-Volmer equation (inset Figure 4) was used to calculate the amount of accessible 
fraction (fa) and its affinity to the quencher (Ka). The same behavior was also observed in case 
of Soluplus (see SI, Figure S5). 
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Fig. 3. Modified Stern–Volmer plots for fluorescence quenching of CX with HPMCAS-LG as 
either SD (black circles) or physical mixture (white circles). 
 
 
Fig. 4. Stern–Volmer plots for fluorescence quenching of CX/ PVP VA 64 as either SD (black 
circles) or physical mixture (white circles). The inset in the figure shows the modified Stern–
Volmer plots for a comparative fluorescence quenching of CX/ PVP VA 64 SD 
 
After the fluorescence quenching experiments, the ACP was filtered through a Sephadex G-25 
packed column (Figure 5) to quantify the amount of free dug (% CX free) as well as the drug 
embedded in polymer aggregates (% CX-Polymer). Drug percentages obtained in the size 
exclusion chromatography experiments are again understood as relative to solubilized 
compound in ACP, which holds only for a part of the dose. 
Table 6. Solid dispersion (drug-polymer ratio 50:50, w/w) results from size exclusion elution 
profiles. 
CX solid dispersion   % CX free a Size (nm)b  
HPMCAS-LG 24 ± 6 2800 ± 45  
PVP VA 64 53 ± 10  2000 ± 75  
Soluplus 85 ± 5 615 ± 22  
Poloxamer 188 95 ± 4 850 ± 35  
a The values were obtained according to the equation 2, b Size analysis of fractions containing 
the CX embedded in polymer (% CX-Polymer) obtained by DLS. The % CX free and size 
measurements are reported as mean ± STDV (n=3). 
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As summarized in Table 6, the HPMCAS-LG based SD shows the lowest value of free drug, 
indicating that most of the drug is embedded in polymer aggregates. Moreover, the HPMCAS-
LG aggregates, analyzed by DLS, were the biggest with respect to the SD prepared with the 
other polymers. By contrast, in the case of SD of Poloxamer 188, the aggregates were about 
three times smaller than in the SD using HPMCAS-LG and almost the entire compound was in 
the free drug fraction. It has to be noted that the values of accessible fraction (fa in Table 5) and 
the values of percentage of free CX (% CX free in Table 6) were comparable for all the 
investigated SDs. 
 
4.4  Discussion 
Formulations based on SD technology generally target enhanced dissolution and sustained 
supersaturation of drug for optimal performance following oral administration.109 However, the 
aqueous formulation dispersion leads to phase changes and emergence of different particle 
species from which drug release takes place. The mechanisms of how polymers affect such drug 
release from SDs are still not thoroughly understood. Much current research is directly toward 
individual mechanistic aspects, for example how polymers can sustain drug supersaturation.359–
361 Interesting is further the mechanism that an enhanced dissolution rate was found to be partly 
due to the stabilization of drug in nanosized particles formed by precipitation.362,363 These 
different mechanisms of drug release provide a better understanding of drug-polymer 
interactions in aqueous environment. To gain such insights into the aqueous phase of SDs in a 
pseudo-equilibrium at a physiologically relevant time scale (4 h) was the primary objective of 
the present work. 
Celecoxib (CX) a Biopharmaceutics Classification System (BCS) class II drug was selected as 
model because it exhibits fluorescence. We introduced quenching analysis as a tool to explore 
drug-polymer interactions in SDs that take place in the aqueous colloidal phase during release, 
which was meant to complement existing analytics for this type of drug delivery systems.364 
First, we analyzed different SDs by means of XRPD and DSC to determine their amorphous 
nature.  
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Fig. 5. Elution profile obtained by SEC: Percentages of CX (A) and the mean count rate, 
expressed by Kcps (B) present in the eluted fractions were plotted vs the elution volumes. CX 
SD with HPMCAS-L (black circles), PVP VA 64 (white triangles), Soluplus (black squares), 
and Poloxamer 188 (white circles). 
 
Within this work, the ratio between CX and polymer (50:50, w/w %) was selected arbitrarily to 
reflect a rather high loading. In the case of SDs prepared with HPMCAS-LG, PVP VA64, and 
Soluplus, no distinct peaks were observed in the diffraction patterns. The case of SD prepared 
with Poloxamer 188 was different (but in agreement with previous results in the literature 10, 
because peak positions similar to CX were evidenced, indicating that notable amounts of drug 
were crystalline. These results were confirmed by DSC studies. As shown in Figure 1B in the 
SD formulated with HPMCAS-LG, PVP VA64, and Soluplus, the absence of melting point (Tm) 
of CX and the presence of single peak of glass transition temperature (Tg) indicate the 
conversion of drug to an amorphous state and its miscibility with the polymer. A broad peak in 
the case of PVP VA64 SD is likely due to strong interaction between the carrier matrix and CX 
even though this effect may have been confounded by the presence of water. On the other hand, 
as already reported in literature,20 Poloxamer 188 and CX form an eutectic, which exhibits a Tm 
at 40 °C and the second broad peak at 88 °C was attributed to the excess amount of the 
suspended CX present in the molten eutectic. 
It has to be noted that the four polymers have been selected to cover a broad variety of 
excipients: from the most hydrophobic and negatively charged at pH 6.5 HPMCAS-LG, to the 
nonionic triblock copolymers Poloxamer 188 that shows a rather high water solubility (>100 
g/l).365 Therefore it was already expected that not all of them would result in completely 
amorphous dispersions of CX. 
Fluorescence quenching was then used to obtain information about the environment that 
surrounds the model drug in the aqueous colloidal phase (ACP). Quenching of fluorescence is 
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presented as a Stern-Volmer plot where the ratio F0/F is plotted versus the quencher 
concentration [KI].121 The extrapolated quenching values, such as KD or fa, are independent 
from the absolute values of F and F0 and therefore also from the concentration of CX in ACP. 
However, the exact CX concentration in the ACP used for the quenching experiment was 
evaluated by HPLC. As already mentioned, it only contained a part of the dose because any 
pseudo-equilibrium of drug release from solid dispersion typically results in either some 
unreleased or precipitated drug in the course of supersaturation.306 Any given percentages in the 
fluorescence experiments are understood as relative to the drug amount solubilized in the ACP. 
The reference value of crystalline CX (4 h pseudo-equilibrium) was in line with literature.96 
The physical mixtures showed drug concentrations in ACP that were higher than solubility of 
pure CX, which was attributed to excipient solubilization effects (Tables 1 to 4). This effect was 
particularly notable for Poloxamer 188 (Table 4). As for SD formulations Table 5 indicates 
elevated concentrations of CX with exception of Soluplus. Perhaps the Soluplus (at least at the 
CX/polymer ratio used here) resulted in extensive drug precipitation after the equilibration time 
in accord with literature.366  An increase in Soluplus/ CX ratio could have decreased drug 
precipitation.367  
In the case of CX alone, the solubilized drug is totally accessible to the quencher and its 
fluorescence intensity decreased by increasing [KI]. However, when a polymer is added, 
different scenarios are observed and quenching measurements reveal important information 
about the polymer spatial arrangement around the drug.  
As already known from literature  and as experimentally evaluated herein, the presence of 
polymers at the same concentration used within this work (see SI, Figure S6) increases the 
viscosity of the system. 358 The quenching, a diffusion-limited process, is inversely proportional 
to the viscosity of the solution,368 since an increase of viscosity decreases the mobility of the 
quencher and therefore the number of collisions with the drug.369 
In the case of physical mixtures of CX with HPMCAS-LG, PVP VA64, and Soluplus either the 
drug-polymer interactions or the increase of viscosity could lead to a decrease in quenching 
efficiency. However, it has to be noted that even though Poloxamer 188, PVP VA64 and 
Soluplus solutions exhibit comparable viscosity values (0.83, 0.84 and 1.1 mPa s respectively), 
the extent of quenching did not decrease by using Poloxamer 188. Furthermore, the most 
viscous HPMCAS-LG (2.12 mPas s) displays a comparable decrease of quenching with the less 
viscous PVP VA64 (0.84 mPas s). This suggests that drug-polymer interactions predominantly 
contributed to the fluorescence quenching decrease, whereas viscosity was a factor of lesser 
Towards a better understanding of solid dispersions in aqueous environment by a fluorescence 
quenching approach 
 
 
90 
 
importance. 
 
Given that a polymer can form aggregates able to surround the drug, the latter would be totally 
protected from the quencher and hence quenching cannot occur. Additionally, two populations 
of drug in the aqueous phase can be present simultaneously: one which is accessible to quencher 
(fa) while the other one is inaccessible or buried in polymer aggregates. In this scenario, fa is 
the drug fraction that is not sequestered by the polymeric network. As a consequence, the more 
the polymer is able to bury the drug by forming aggregates surrounding it, the more the fa 
decreases. Interestingly, increasing the HPMCAS-LG concentration up to 30 % (w/w) in the 
physical mixture, the excipient was able to surround a fraction of CX. The drug interacting with 
polymer could have either become buried due to conformational change of the macromolecule 
or because of polymer aggregation. By contrast, the other polymers were not able, at least as 
physical mixtures, to protect CX from the quencher either by conformational change or by 
forming aggregates even not at a higher amount (70 %, w/w). CX was likely to interact with 
either hydrophobic side chains as well as via polar interactions, or hydrogen bonding with 
HPMCAS-LG.109 Especially the comparatively lipophilicity of polymer led in combination 
with the lipophilic model drug was likely to result in pronounced drug embedding. 51  
As known from the literature, electric charge either on the quenchers or on the polymers’ 
surface can have a dramatic effect on the extent of quenching. 370 In general, charge effects 
might be present with charged polymers such as HPMCAS-LG, and might be absent for neutral 
like PVP VA64.371 For instance, a negative charge on HPMCAS-LG could prevent a negatively 
charged quencher from coming in contact with the drug. However, it is clear from our results 
(see Table 1 to 4) that the decrease of quenching was not mainly due to the electrostatic 
repulsion, because the neutral PVP VA64 showed almost the same extent of quenching as the 
negatively charged HPMCAS-LG. 
Interestingly, except for Poloxamer 188, SDs in aqueous environment displayed at least two 
drug populations: one which is accessible to the quencher and the second that was inaccessible 
as it was buried in a polymeric conformation or in aggregated macromolecules. In the case of 
HPMCAS-LG (see Figure 3) the physical mixture showed a higher Ka as compared to SD. The 
quenching constant measures the stability of the quencher-fluorophore complex, and it is related 
to the accessibility of the fluorophore to the quencher, in particular to the separation distance 
within the excited-state complex, affected by diffusion and steric shielding of the 
fluorophore.372 Therefore, despite of the same values for fa (0.3 for both SD and physical 
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mixture), in the case of SD, the drug was bound to a microenvironment less suitable for the 
interaction with the quencher compared to the physical mixture. This was obviously the results 
of different spatial arrangement of drug in polymer matrix as the SD was prepared by a solvent-
evaporation method. This preparation must have facilitated a higher extent of polar interactions 
and hydrogen bonding of drug-HPMCAS-LG compared to physical mixture.373 However, also 
more frequent hydrophobic interactions (due to succinoyl substituent) could have occurred. 51 
In the case of PVP VA64 (Figure 4) and Soluplus (SI, Figure S5), the polymer was able to 
embed the drug only when it was formulated as SD. Even in this case, a possible explanation 
can be the capability of the polymer to strongly interact with the drug trough H-bonds between 
amide protons of CX and carbonyl C=O of polymers only in an amorphous state, as reported in 
literature. 374,375 
 
A problem of classical drug release studies from SDs is that drug free in aqueous solution or 
interacting colloids in different forms is typically not differentiated at all. Few research articles 
emphasized the different drug forms emerging from SDs in aqueous environment. 11,18,99 
Different analytical tools are in this context of interest to study how the drug is present in 
solution. While dialysis methods or ion selective electrodes can study free drug in solution, the 
asymmetric flow field flow fraction (AF4) is an approach to investigate colloidal and particulate 
forms that contain drug. 103,376,377  
In this study, the use of an SEC method enables to discriminate between the percentage of drug 
embedded in polymer aggregates (% CX-polymer) and the percentage of free drug (% CX free) 
present in the aqueous phase (i.e. ACP). As for the quenching experiments, it has to be kept in 
mind that a part of the initial drug was not in the colloidal aqueous phase and hence, the term 
free drug refers to the amount of solubilized drug in ACP, which was not buried or embedded 
in polymer aggregates. This should not be confused with the total amount of free CX relative 
to an initially administered dose. 
 As shown in Table 6, the HPMCAS-LG is able to entrap around 76 % of the drug (% CX-
polymer) and only 24% of CX is free (% CX free) according to Eq. 3. It has to be noted that the 
values of accessible fraction (fa in Table 5) and the values of percentage of free CX (Table 6) 
were comparable for all the investigated SDs. In the case of SD, the polymer aggregate 
protected the drug and therefore only the free fraction was reachable by the quencher.  
However, drug release is a dynamic process and different populations of drug can coexist. The 
amount of free CX present in the ACP, will change over time, since a percentage of it can be 
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either released or sequestered by the polymer. We considered a rather long but reasonable 
equilibration time for oral drug absorption so that the percentage of free CX would be either at 
or comparatively close to a pseudo- equilibration in the case of SDs. Studying the accessibility 
of the drug to a fluorescence quencher is a powerful and new method to investigate and 
elucidate the drug-polymer interactions upon drug release from SDs. In one formulated 
solubilization mechanism, the drug particles dissolve rapidly generating a highly supersaturated 
solution followed by the formation of drug nanoclusters within the polymer matrix. 363,378 It has 
been emphasized, for example by Ricarte et al. (who studied SDs of HPMCAS) that emergence 
of nanostructures from polymeric SDs can determine the kinetics of drug supersaturation. 349 
Accordingly, the present study suggests the presence of the polymer aggregates in the aqueous 
colloidal phase, which is able to interact and embed a solubilized drug fraction. We know that 
absorption is driven by free drug but it is unclear if buried drug in polymer from the aqueous 
solution phase is lost for absorption or if it merely acts as a reservoir of drug in the sink of 
absorption. It will be a matter of individual colloidal partitioning kinetics regarding how much 
of the drug in the solubilized form is finally available for intestinal permeation. 
 
4.5  Conclusions 
The molecular and supramolecular interactions of drug and excipients are of critical relevance 
for the performance of oral solid drug dispersions. Traditional release testing offers only limited 
characterization and more recent approaches attempted to better understand particles and 
colloids formed in aqueous environment. Various physical methods can be used to either study 
the solid phase that is typically formed on release from SDs or an aqueous colloidal phase is 
studied following a physiologically-relevant equilibration time. The current work introduced a 
fluorescence quenching method to study drug-polymer interactions in such an aqueous phase. 
Information was obtained regarding the accessible fraction of drug by the quencher and about 
the affinity to the quencher, which offered insights into molecular interactions with the polymer. 
An improved understanding of solubilization behavior was achieved by a comparison with 
results from size exclusion chromatography and dynamic light scattering. Depending on the 
polymer, a fraction of drug can obviously be buried in the macromolecule. This reduces free 
drug in solution, which leads to lower absorptive flux but also reduces the risk of undesired 
drug precipitation. Thus, it will depend on the partitioning kinetics of a given system between 
buried and free drug if such embedded drug can act as a favorable reservoir of drug absorption 
or if it adds to the dose fraction that is lost for absorption. There is certainly more research 
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needed but it seems that fluorescence quenching analysis can greatly contribute to a better 
understanding of drug -polymer interactions in vitro, which ultimately can guide development 
of oral solid dispersions.
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5 Biphasic drug release testing coupled with 
diffusing wave spectroscopy for mechanistic 
understanding of solid dispersion performance 
  
Summary 
Amorphous Solid dispersions (ASDs) represent an important formulation technique to achieve 
supersaturation in gastrointestinal fluids and to enhance absorption of poorly water-soluble 
drugs. Drug release from such systems is complex due to emergence of different colloidal 
structures and potential drug precipitation, which can occur in parallel to absorption. The latter 
drug uptake from the intestinal lumen can be simulated by an organic layer in a biphasic in vitro 
test, which was employed in this work to mechanistically study the release of ketoconazole 
from ASDs produced by hot melt extrusion using different HPMCAS grades. A particular aim 
was to introduce diffusing wave spectroscopy (DWS) to biopharmaceutical testing of solid 
dispersions. Results indicated that amorphous formulations prevented crystallization of the 
weakly basic drug upon transfer into the intestinal medium. Microrheological differences 
among polymer grades and plasticizers were revealed in the aqueous phase, which affected drug 
release and subsequently uptake into the organic layer. The results indicate that DWS can be 
employed as a new non-invasive tool to better understand drug release from solid dispersions. 
This novel light scattering technique is highly promising for future biopharmaceutical research 
on supersaturating systems such as solid dispersions. 
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5.1 Introduction  
Amorphous solid dispersions (ASDs) are one of the most widely employed methods to 
formulate poorly water-soluble drugs. To increase the apparent solubility and/or dissolution 
rate of a poorly soluble compound, it is encouraged to consider the amorphous form of a drug. 
The compound in an amorphous high-energy state is usually formulated in a polymer matrix 
system, which should be kinetically stabilized throughout the targeted shelf-life of the product. 
23 Thus, polymers should have a stabilizing function in the formulation to prevent drug 
crystallization in solid dispersions 20,38,109,301  by means of specific interactions with the active 
compound and via a general reduction of molecular mobility. 52,342,343 A large number of 
polymers employed for solid dispersion are water soluble in all pH conditions, but there are 
also enteric polymers that contain acidic groups that become ionized at higher pH to facilitate 
swelling and some water solubility. The latter group of polymers includes hydroxyl propyl 
methylcellulose acetate-succinate (HPMCAS) and methacrylate-based enteric coating polymer 
systems, such as the Eudragits. 23,30  
Biopharmaceutical classification system (BCS) class II drugs are characterized by low 
solubility and high permeability. 24,379,380 In addition, weakly basic drugs have higher solubility 
values in the acidic environment of the stomach compared with the more neutral environment 
of the small intestine, thereby leading to a susceptibility to precipitate in the intestine. 
Precipitation of poorly water soluble drugs can result in erratic absorption and decreased 
bioavailability. Although the rate of transfer from stomach to the intestine will affect 
precipitation rates, various authors have shown that the presence of an absorptive compartment 
under conditions simulating the environment in the small intestine is crucial for predicting the 
precipitation of a weak base. 381–384 Therefore, biphasic dissolution testing has been proposed, 
which includes dissolution of drug in an aqueous phase and drug partitioning into an organic 
phase. 382,385 The in vitro biphasic test use of a lipid layer, such as octanol or decanol, in 
dissolution testing has been employed to act as a ‘quasi-sink’ since unionized drug can partition 
from the aqueous layer into this organic compartment to mimic drug absorption in the intestine. 
This allows to study simultaneously how a drug is released and taken up. 
The dissolution of drug in the aqueous phase determines the amount of drug available for 
partitioning into the organic phase, which acts as a sink. 350,382,385,386 Such two phase dissolution 
tests can offer several advantages due to the presence of a second layer reflecting drug 
absorption from the intestine. First of all, in the presence of the organic layer, the dissolution 
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profile of the dosage form can be different compared to single phase dissolution systems. A key 
aspect of the biphasic dissolution is that it mimics the in vivo absorptive sink following drug 
release. The molecularly dissolved drug provides the driving force for partitioning into the 
organic layer and the concentration of the drug in the organic phase is a marker of in vivo 
absorption. This is supported by recent studies in which drug concentrations in the organic layer 
of a biphasic test were found to correlate with in vivo drug absorption. 385,387 These findings are 
encouraging even though the degree of correlation may depend on the used drug, formulation 
as well as test conditions. 
 
A particular advantage of biphasic release testing is that direct in-situ determination of drug 
concentration in the organic phase is often less challenging than analytics in the aqueous phase. 
This is because of the lack of turbidity compared to the aqueous phase in which particles can 
originate from non-dissolving excipients or precipitated drug.  
 
Apart from analytics of drug concentrations, it would be of interest to monitor physical changes 
occurring during drug release from a formulation. In particular, measurement of polymer 
swelling and microrheology upon dissolution testing presents an unmet research need in drug 
release analysis from solid dispersions. This study introduces diffusing wave spectroscopy 
(DWS) to ultimately gain a deeper understanding of drug release from polymeric matrices. 
DWS is an optical technique based on light scattering that investigates the microrheological 
properties of the fluid based on the intensity correlation function. DWS is a fast and non-
contacting method in which the sample is probed by a laser beam over a large frequency range 
that is partially inaccessible to classical mechanical rheology. It has been just recently 
introduced into pharmaceutics to characterize lipid-based formulation, but to the best of our 
knowledge, this is the first time it has been used for amorphous solid dispersions. 118,153 
Ketoconazole (KCZ), a poorly soluble drug and a weakly basic drug (basic pKa = 2.9 & 6.5, 
log P =3.9), was selected as a model compound. Similar to other such bases, KCZ is rather 
soluble in acidic gastric fluid, but precipitates in human upper intestine 388 as well as in 
simulated intestinal media 30,380. In order to reduce or avoid precipitation in the intestinal 
environment, HPMCAS was employed since it is a polymer that dissolves at pH values higher 
than 5.5. A number of researchers have highlighted the unique properties of HPMCAS since 
the polymer is partially ionized above pH 5.5 and therefore becomes a hydrated polyelectrolyte. 
18 The presence of the charges influences polymer conformation in solution; on one hand it 
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inhibits the formation of big polymer coils, while on the other hand, HPMCAS facilitates the 
stabilization of small drug/polymer aggregates that allow the drug to stay in solution. 18 These 
unique characteristics make HPMCAS a particularly interesting candidate for ASDs.  
The aim of this article is to assess the performance of the KCZ ASDs employing a biphasic 
dissolution test further incorporated a pH shift and to correlate it with microrheology and in 
particular the swelling of the polymer dispersion by using DWS.  
 
5.2 Materials and methods 
5.2.1  Materials 
Ketoconazole (KCZ) was purchased from BOCSI, Inc. (USA), hydroxypropyl methyl cellulose 
acetate succinate (HPMCAS) L,M,H grades were obtained from Shin-Etsu Chemical Company 
(Tokyo, Japan) (Table 1), triethyl citrate (TEC), sodium chloride, sodium acetate trihydrate and 
sodium dihydrogen phosphate monohydrate was purchased from Sigma Aldrich, (St.Louis MO, 
USA). The lipid Gelucire 50/13 (Stearoyl macrogol-32-glycerides) was kindly donated by 
Gattefossé (Luzern, Switzerland). FaSSIF V2 was purchased from Biorelevant.com. (UK) All 
solutions were prepared using Mill-Q water (18.2 MΩ cm−1).  
 
Table 1. Characteristics of HPMCAS L, M and H grades 
Grade MeO HPO Acetyl (%) Succinoyl 
(%) 
Dissolving pH 
AS-L  20.0–24.0 5.0–9.0 8 15 >=5.5 
AS-M  21.0–25.0 5.0–9.0 9 11 >=6.0 
AS-H  22.0–26.0 6.0–10.0 12 7 >=6.5 
      
 
5.2.2 Preparation of solid dispersions and physical mixtures 
ASDs were prepared by using a hot melt extrusion (HME) method as described in the literature. 
389,390 Briefly, KCZ, polymer and plasticizer (Gelucire 50/13 or TEC) were employed in a ratio 
of 20:80:10 w/w and mixed with the spatula. The different compositions of the extrudates were 
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prepared by the HME process using a Thermo Scientific Haake MiniLab II, which is a conical, 
co-rotating, twin- screw microcompounder (Thermo Electron, Karlsruhe, Germany). The 
premix was manually fed into the extruder hopper and the temperature of the barrel was set to 
150°C. The screw speed during the feeding step was 150 rpm. Subsequently, the extrudate 
strand was allowed to exit from the flat die by opening the bypass valve. The strands were then 
stored in the desiccator until analysis. Extrudate strands were pelletized using a Thermo 
Scientific Process 11 (Karlsruhe, Germany) producing pellets of 2mm employed for 
dissolution. 
5.2.3 Powder X-ray diffraction (PXRD) 
PXRD was used to characterize the solid form of the physical mixtures and of freshly prepared 
ASDs at ambient temperature using a Bruker D2 PHASER (Bruker AXS GmbH, Germany) 
with a PSD-50 M detector and EVA application software version 6. Samples were prepared by 
spreading pellets from HME or powder of the physical mixture or collected after filtration at 
the end of the USP II dissolution test on PMMA specimen holder rings from Bruker. 
Measurements were performed with a Cu K α radiation source at 30 kV voltage, 10 mA current 
and were scanned from 6–40 2θ with 2θ being the scattering angle at a scanning speed of 0.016 
2θ /min. 
5.2.4 Differential scanning calorimetry (DSC) 
A DSC 4000 System, from DSC 3 (Mettler Toledo, Greifensee, Switzerland) was calibrated for 
temperature and enthalpy using indium. Nitrogen was used as the protective gas (20 mL/min). 
Samples (approximately 5 mg) were placed in 40 μL aluminium pans with pierced aluminium 
lids. The midpoint glass transition temperature (Tg), was determined by a single-segment 
heating ramp of 10 °C/min from 25 °C to a maximum temperature of 200 °C. All DSC 
measurements were carried out in triplicate. 
 
5.2.5 Biphasic dissolution test 
The biphasic dissolution experiments were carried out using the inForm (Pion Inc., Billerica, 
MA) platform, with the experimental setup shown in Figure 1. The UV detection wavelengths 
for ionized (pH 2) KCZ were between 260 and 280 nm, for unionized (pH 6.8) KCZ between 
280 and 300 nm and in the organic layer the selected range was 285 -315 nm. A linear 
relationship (R2>0.99) was established between absorbance and concentration in each of the 
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media tested. KCZ formulations were added into the gelatin capsules and delivered via the 
sample holder into a cylindrical vessel (diameter 49.9mm, height 74.9mm). Crystalline KCZ 
and KCZ ASD formulation were delivered at a dose equivalent to 20mg of KCZ. Initially, 
samples were introduced into 36 mL of 0.01M acetate phosphate at pH 2. After 30 minutes to 
replicate the transition into the upper small intestine, a layer of decanol (40mL) and 4 mL of 10 
x concentrated FaSSIF V2 were added, with the pH of the aqueous layer adjusted to pH 6.8. 
The duration of the intestinal sector was 240 minutes. Concentration of KCZ in both layers was 
quantified every 2 minutes using two in situ multi-wavelength fiber optic UV dip probes. The 
pH was monitored throughout the experiment using an in situ pH probe and controlled to ± 0.1 
pH unit using 0.5M HCl or 0.5M NaOH. Temperature was monitored using the temperature 
probe and controlled to 37oC using a heating block. The stirring speed of the paddles was set to 
100 rpm. Stirring was temporarily stopped, while the layer of decanol was added into the vessel.  
 
 
Figure 1. Schematic representation of the biphasic dissolution setup 
 
5.2.6 USP II dissolution test 
In order to investigate polymer swelling in the aqueous layer with DWS, a dissolution testing 
using the same proportion between drug amount and the dissolution volume in the biphasic 
method was carried out using an Erweka USP II dissolution apparatus (Heusenstamm, 
Germany). Temperature was set to 370C and initial release testing was in 225 ml of 0.01M 
acetate phosphate buffer at pH 2 for the first 30 minutes, with a stirring speed of 100 rpm. After 
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30 minutes, undissolved pellets were withdrawn and transferred in 225 mL of biorelevant fasted 
state medium FaSSIF V2 at pH 6.8, with the temperature maintained at 37 0C ± 0.5 and stirring 
speed of 100 rpm. 24 The biorelevant media were prepared using FaSSIF V2 based on 
instructions from www.biorelevant.com. Gelatine capsules containing 225 mg of ASDs, 
equivalent to 45 mg of KCZ were tested. A 5 mL aliquot was withdrawn at appropriate time 
intervals and replaced with fresh dissolution media. Microrheology of withdrawn samples was 
determined using DWS as described in the following section. 
 
5.2.7 Diffusing wave spectroscopy (DWS) 
DWS RheoLab (LS Instruments AG, Fribourg, Switzerland) was used as optical technique for 
microrheological measurements. 118,391,392 The theory of DWS-based microrheology has already 
been explained in detail in previous works. 118,153 The DWS was calibrated prior to each 
measurement with a suspension of polystyrene particles, PS, (Magsphere Inc., U.S.A) in 
purified water (10 wt. %). The PS particles have a mean size of 250± 25 nm with a solid content 
of 0.5 wt. % in dispersion. This suspension was filled in cuvettes with a thickness L of 5 mm 
prior to measuring for 60 s at 37 ◦C. The value of the transport mean free path, l* (microns) was 
determined experimentally, as reported previously. 358 The transmission count rate was 
measured several times until a constant value was reached and the cuvette length, L, was 
considerably larger than the obtained values for l* (L ≫ l) ensuring diffusive transport of light. 
The transport mean free path of the sample l* is needed for the determination of the correlation 
intensity function and, thus for the microrheological characterization. Microrheological 
characterization (l* and complex viscosity) were performed on the samples withdrawn from the 
USP II dissolution test at different time points.  
Thus, 0.5 wt. % PS nanoparticles were added to the clear samples to ensure the correct regime 
(guarantee a L/l* ratio larger than 7). 118 Quartz cuvettes (5 mm) were used and data acquired 
for 60 s. Each sample was measured 5 times as previous measurements. The microrheological 
characterization of polymer solutions was measured in a broad frequency range by DWS, 
whereas an average of the complex viscosity, at high frequencies (90 000rad/s) was selected. 
 
5.2.8 Statistical analysis 
Analysis of the variance (ANOVA) and regression analysis were calculated using Statgraphics 
(v16.1.11, Statpoint Technologies, Inc., Warrenton, Virginia). A multi factor ANOVA was used 
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to assess possible effects of polymer grades, plasticizers, and time on drug uptake into the 
organic phase. A multi factor analysis of variance (ANOVA) was calculated with respect to the 
uptake of drug amounts into the organic phase, Q (%). Thus, effects of the polymer, plasticizer, 
time and their factor interactions on Q (%) were evaluated statistically. This analysis was 
focused on the organic layer due to its likely relevance for drug absorption and because of lack 
of particles, which avoided the analytical complication of turbidity that otherwise occurred in 
the aqueous phase. 
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5.3 Results 
5.3.1  In vitro characterization of crystalline KCZ 
Figure 2 shows the biphasic dissolution profile of KCZ in aqueous and organic phase, 
represented as drug concentration (µg/mL) versus time. Drug concentration reaches a peak in 
the gastric compartment after 0.5h, while at simulated intestinal conditions, the drug 
concentration decreased due to precipitation caused by the lower solubility at intestinal pH (pKa 
2.9 and 6.5). Precipitation of the drug was assessed using DWS. The parameter monitored was 
the transport mean free path l*, that can be viewed as a measure of sample turbidity. More 
specifically, l* is a critical length scale in the case of diffuse light propagation and is described 
as the distance a photon travels in the sample before its direction of propagation is randomized. 
Therefore, the lower the value of l*, the more turbid is a sample. In Figure 3, a decrease of l* 
indicated turbidity due to precipitated drug upon change to intestinal medium. X-ray 
diffractograms at 25°C (Figure 4b) revealed that after 4.5h of dissolution time, KCZ existed in 
a crystalline state when compared with the KCZ reference material (Figure 4a).  
 
 
Figure 2. Dissolution profile of KCZ in the biphasic dissolution test: aqueous profile (filled 
circles) and organic profile (opened circles). Broad error bars and the connecting dotted line are 
an indication of UV blackout occurring in the aqueous phase due to rapid KCZ precipitation.  
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Figure 3. Microrheological characterization of the aqueous dissolution profile of pure KCZ 
with DWS in the USP II apparatus 
 
 
Figure 4. KCZ raw material (a), ketoconazole precipitate after 4.5h of dissolution test at 37 
degrees (b) 
 
 
5.3.2 Bulk characterization of crystalline material and solid dispersions 
Prepared ASD, physical mixtures and raw materials were analyzed by PXRD at 25°C to verify 
the amorphous nature of the dispersions, and the results were compared with those of the 
corresponding physical mixtures. As shown in Figure 5, KCZ based ASDs manufactured with 
HPMCAS-L, HPMCAS-M and HPMCAS-H grade were amorphous at 20% (w/w) drug 
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loading. In contrast, physical mixtures and raw materials were crystalline, as expected. ASDs 
were further characterized by DSC (Figure 6) to confirm the solid form of the drug in the 
physical mixture and in the ASDs. All ASDs showed an absence of the KCZ melting peak, 
while the physical mixture had a melting peak of the drug (Tm).  
 
 
Figure 5. X-ray powder diffraction patterns of Gelucire (a) KCZ (b), physical mixtures of 
HPMCAS H, Gelucire, and KCZ (c) Physical mixtures of HPMCAS M, Gelucire, and KCZ (d), 
physical mixtures of HPMCAS L, Gelucire, and KCZ (e), physical mixtures of HPMCAS H, 
TEC, and KCZ (f), physical mixtures of HPMCAS M, TEC, and KCZ (g), physical mixtures of 
HPMCAS L, TEC, and KCZ (h), ASD HPMCAS H, Gelucire, and KCZ (i), ASD HPMCAS 
M, Gelucire, and KCZ (j), ASD HPMCAS L, Gelucire, and KCZ (k), ASD HPMCAS H, TEC, 
and KCZ (m), ASD HPMCAS M, TEC, and KCZ (n), ASD HPMCAS L, TEC, and KCZ (o). 
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Figure 6. DSC thermograms of ASD HPMCAS L, TEC and KCZ (a), ASD HPMCAS M, TEC, 
and KCZ (b), ASD HPMCAS H TEC and KCZ (c), ASD HPMCAS L, Gelucire, and KCZ (d), 
ASD HPMCAS M, Gelucire, and KCZ (e), ASD HPMCAS H, Gelucire, and KCZ (f), physical 
mixtures of HPMCAS L, TEC, and KCZ (g), physical mixtures of HPMCAS M, TEC, and KCZ 
(h), physical mixtures of HPMCAS H, TEC, and KCZ (i), physical mixtures of HPMCAS L, 
Gelucire, and KCZ (j), physical mixtures of HPMCAS M, Gelucire, and KCZ (k), physical 
mixture HPMCAS H, Gelucire, and KCZ(m), HPMCAS L (n), HPMCAS M (o), HPMCAS H 
(p), TEC(r), Gelucire (q), KCZ alone (t) 
 
5.3.3 Biphasic dissolution experiment of ASDs 
Figure 7a depicts dissolution profiles of six different ASDs formulation in the aqueous layer. 
As mentioned before the first 0.5h of the dissolution test were in a gastric environment and 
during this time, no relevant differences were observed between formulations. By contrast, in 
the intestinal sector, differences between formulations and polymer grades were observed. As 
a trend, the L polymer grade resulted in comparatively highest amounts of KCZ in solution, 
followed by the M and H grades even though the given plasticizers appeared to play a role as 
well. The absolute concentrations in the aqueous phase result in kinetics that is essentially 
confounded by the overlapping processes of drug release, supersaturation, and potential 
precipitation. It was therefore important to compare the concentrations profiles also with those 
obtained from the organic layer, simulating the amount of absorbed drug. Figure 7b 
demonstrates again clear differences between the formulations depending on polymer grade and 
plasticizer used. 
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Figure 7. Biphasic dissolution test in aqueous (a) and in organic layer (b). Mean (SD) (n=3) 
biphasic dissolution data of ASD Gelucire formulation (filled symbols) with L grade (triangle), 
M grade (square), H grade (circles) ASD TEC formulation (opened symbols) with L grade 
(triangle), M grade (square),H grade (circles). Some aqueous layer dissolution profiles appear 
not complete because of the strong turbidity blocking UV light reaching the detector.  
 
   
5.3.4 Microrheological characterization  
Analysis of biphasic dissolution test results revealed differences between grades of the 
HPMCAS polymer. The behavior of the different solid dispersions was further studied in a USP 
II dissolution vessel using DWS. This microrheological technique allowed even at low polymer 
concentrations to monitor the mechanical sample dynamics over a large range of time scales 
(10-7 s to 10s) and local displacements. Using DWS, it was possible to correlate the decrease of 
complex viscosity with an increase of KCZ concentrations over dissolution time in the aqueous 
layer. The dissolution test was performed at pH 6.8 using the same biorelevant medium FaSSIF 
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V2 and polymer concentration as compared to the biphasic in vitro experiment. Sample 
differences were specific for given grades and plasticizers, and the residue of the ASDs were 
studied by PXRD analysis after 4.5 h of dissolution which showed absence of crystalline drug 
precipitate. (Figure 8) In Figure 9 is shown that comparatively higher complex viscosity was 
noted in gastric conditions (0.5 h) with moderate differences between samples. More 
pronounced differences were seen depending on polymer grade and plasticizer following 
transfer into the intestinal medium. In Figure 10, it can be seen that values of l* generally 
decreased over time, which meant an increase in turbidity.  
 
 
Figure 8. Representative X-Ray diffraction patterns of KCZ precipitates in the USP II 
dissolution test. KCZ reference material a), crystalline pattern collected from the intestinal 
sector (in vitro) that refers to pure KCZ after 4.5h of dissolution at 37 0C b), amorphous patterns 
that refer to collected solid from ASDs in the intestinal sector (4.5 h, 37°C) that indicate absent 
crystallization c),d),e),e),f),g). 
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Figure 9. Mean (SD) (n=3) complex viscosity (η*) data versus dissolution time (h) for different 
grades of HPMCAS. Filled symbols indicate ASD Gelucire formulation L grade (triangle), M 
grade (square), H grade (circles) while opened symbols represent ASD with TEC L grade 
(triangle), M grade (square), H grade (circles).  
 
 
 
Figure 10. Mean (SD) (n=3) l* data versus dissolution time (h) for different grades of 
HPMCAS. Filled symbols indicate ASD Gelucire formulation L grade (triangle), M grade 
(square), H grade (circles) while opened symbols represent ASD with TEC L grade (triangle), 
M grade (square), H grade (circles). 
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5.3.5  Statistical analysis 
The statistical analysis revealed a significant influence of the polymer grades on drug release 
into the organic phase, as well as another effect of the plasticizer on drug release as indicated 
by the obtained p-values. (Table 2) The ANOVA table decomposes the variability of Q (%) 
organic phase into contributions due to various factors. Since type III sums of squares (the 
default) have been chosen, the contribution of each factor is measured having removed the 
effects of all other factors. Different factor effects as well as interactions were found to be 
significant with p-values lower than 0.05 (i.e. 95% significance level) regarding the drug 
amount taken up into the organic phase Q (%). (Table 2) Inspecting means of drug uptake into 
the organic layer provided highest values for L grade, then the M grade, and finally the H grade 
of HPMCAS. The interaction of polymer grade and dissolution time revealed that the above 
ranking was primarily due to the drug uptake at 4.5h. A comparison of the means for plasticizer 
effect showed on the average higher uptake for formulations containing Gelucire instead of 
TEC. 
 
Table 2. Analysis of variance for Q (%) organic phase - Type III sums of squares 
 
Source Sum of 
squares 
Df Mean 
square 
F-ratio p-value 
A:HPMCAS 
B:Plasticizer 
C:time (h) 
INTERACTIONS 
AB 
AC 
BC 
RESIDUAL 
TOTAL 
(CORRECTED) 
1605.5 
190.3 
15696.4 
 
17.9 
3212.0 
319.7 
294.7 
21336.6 
2 
1 
2 
 
2 
4 
2 
40 
53 
802.8 
190.3 
7848.2 
 
8.9 
803.0 
159.9 
7.4 
108.9 
25.8 
1065.2 
 
1.2 
109.0 
21.7 
0.0000 
0.0000 
0.0000 
 
0.3074 
0.0000 
0.0000 
 
 
Interesting was a regression of drug amounts in the organic layer versus the aqueous layer, 
which provided a correlation coefficient of r = 0.50 (p = 0.0002) if all data were considered and 
at the longest release time, the correlation was higher r4.5h = 0.83 (p < 0.0001). These 
correlations were expected to be less than unity because partitioning into the organic layer is 
governed by thermodynamic activity rather than drug concentrations or amounts. 
In the aqueous phase, the amount released can be compared versus the complex viscosity and 
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resulted in a correlation coefficient of r = 0.50 (p = 0.0001) and for the longest release time in 
r4.5h = 0.67 (p = 0.0024). Interestingly, a negative weak correlation was found for drug amounts 
released into the aqueous phase versus l* with r = -0.31 (p = 0.0222). This correlation 
coefficient became stronger for a consideration of endpoint data only, r4.5h = -0.73 (p = 0.0005).  
 
5.4 Discussion 
To cope with the biopharmaceutical challenges of poorly soluble drugs, one of the current 
research needs is to improve mechanistic understanding upon release, while another important 
need is to have suitable analytical methods to study these aspects. This work studied amorphous 
solid dispersions of KCZ in a biphasic in vitro test and introduced DWS to elucidate 
mechanisms of sustained drug release from ASD.  
From the data in Figure 7, it is apparent that the ASDs of KCZ displayed a dissolution behavior 
that was quite distinct from that of crystalline KCZ. (Figure 2) Crystalline KCZ completely 
dissolves in the gastric compartment (>99%) and upon transition into the intestinal medium, 
precipitation occurred. The dissolved amount in the aqueous phase readily partitioned into the 
organic layer, providing constant drug concentrations over the dissolution time (plateau is 
around 200 µg/mL). Obtained data suggested that drug precipitation in FaSSIF was relatively 
rapid compared to the partitioning rate into the organic layer. Precipitated fraction of the pure 
KCZ in the intestinal condition was found to be crystalline, in contrast to in vivo findings 
reported by Psachoulias et al. (2011) who found a limited fraction of amorphous precipitate.388 
(Figure 4). Furthermore, over predicted precipitation has been mentioned also by Ruff A et al. 
(2017) who studied formulated KCZ in an in vitro transfer model without an absorptive sink. 
Thus, it seems challenging to simulate a relevant degree of precipitation in vitro. 381 The present 
biphasic release test has here the advantage of an absorptive sink, but a direct correlation with 
in vivo data was beyond scope as the study focused on mechanistic understanding of the drug 
release performance from solid dispersion. 
A weak base KCZ was selected as a model compound and combined with the enteric coating 
polymer HPMCAS to form solid dispersions. Release performance was assessed using biphasic 
dissolution testing, while mechanistic aspects were investigated by means of DWS. Considering 
the obtained dissolution profiles of ASDs, it is possible to observe that at the end of the 
simulated gastric phase, the majority of the KCZ (about >75%) from the ASDs remained 
undissolved. Thus, all ASDs provide significantly lower concentrations of KCZ under gastric 
conditions when compared with the crystalline KCZ. This was due to the poor solubility of the 
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HPMCAS polymers at gastric conditions at pH 2. The initial low release of KCZ from the ASDs 
during this gastric phase was hence expected to be mostly caused by KCZ close to the surface 
of the ASDs since the bulk of the polymer matrix would hardly swell and dissolve in the acidic 
environment. After transition to intestinal conditions, KCZ released by the ASDs partitioned 
into the decanol layer, with the L type HMPCAS ASDs resulting in the greatest release of drug 
whilst the H grade HMPCAS ASDs showing the lowest release of drug, as presented in Figure 
7. Dissolution performance of each formulation is reflected with the mass of the residue 
collected at the end of the dissolution test. (Table 3) Indeed, H grade reported the highest solid 
amount undissolved (83.58 % of the ASD with TEC and 69.70% of ASD with Gelucire), while 
L grade presented the lowest solid amount (24.36% in ASD with TEC and just 3% in the ASD 
with Gelucire). In addition, ASDs using the Gelucire plasticizer showed a larger release of KCZ 
compared to the ASDs using TEC as a plasticizer. These higher concentrations of KCZ from 
the ASDs using Gelucire was a likely consequence of the surfactant properties of Gelucire 
resulting in greater solubilization of KCZ in the aqueous layer. 393 In accordance with the results 
in the aqueous layer, the partitioning rate into the organic layer differed greatly among the 
ASDs. The rank order of  KCZ released from the ASDs in the decanol layer reflects the 
dissolution performance of the ASDs in the aqueous layer. It can be therefore be summarized 
that avoidance of high release in the stomach medium and the observed sustained release in the 
intestinal medium  of the employed ASD formulations were advantageous to maximize 
absorptive drug uptake. This is in line with literature of other solid dispersions that a sustained 
drug release rate would lead to relatively longer induction times of crystallization, which 
thereby forms the basis of effective drug absorption. 11,99,374 
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Table 3. Outline of the calculated percentage (w/w) KCZ in each layer at the end of the biphasic 
dissolution experiment; formulations with Gelucire as plasticizer are indicated with Gel, while 
the others with triethyl citrate are indicated with TEC  
 
 
 
 
 
 
 
 
 
 
 
Since drug release and hence absorption is governed by rather complex mechanisms in the 
aqueous phase and the drug concentration in the aqueous phase is the driving force for 
partitioning into the organic layer, it was of interest to obtain complementary data to the kinetics 
of drug concentrations. We introduced DWS to gain knowledge about microrheological 
properties of the dispersed ASDs (such as the complex viscosity) and to study l* over the 
dissolution time. The mechanism of drug release from ASDs is typically governed by polymer 
swelling and the dissolution of the carrier in the solvent medium. 99,374 Such swelling and 
dissolution is dependent on ionization state of the polymer as well as on how close its solubility 
parameter is to that of the surrounding medium. 84 The selected carrier, HPMCAS is practically 
not soluble in gastric media, while it starts to dissolve and swell at pH values higher than 5.5 
depending on the ratio of succinoyl and acetyl moieties. (Table 1) The poor solvent conditions 
of the acidic medium would theoretically lead to undissolved dispersed polymer particles 
together with some initial polymer swelling. In addition, at lower pH values the polymer is not 
charged and the absence of repulsive charge might cause polymer particles aggregation. 18 Thus, 
large hydrophobic particles of the polymer and drug in the gastric conditions provide higher 
values of complex viscosity in the medium as evidenced by DWS. (Figure 9) The opposite 
situation is observed in FaSSIF, where the polymer exists as colloidal aggregates. 99 Indeed, in 
the simulated intestinal media, the colloidal nature of HPMCAS allows the drug to interact with 
hydrophobic moieties of the carrier providing drug polymer nanoaggregates and colloids as 
reported in literature. 18,349 The negative charge of the succinoyl groups present in the polymer 
 
Percentage of 20mg KCZ Dose (%) 
Formulation Organic layer  Aqueous layer Solid 
L Gel 66.24 30.88 2.88 
M Gel 51.72 28.41 19.87 
H Gel 22.34 7.96 69.70 
L TEC 53.38 22.26 24.36 
M TEC 42.44 16.32* 41.24 
H TEC 11.24 5.18* 83.58 
Crystalline 45.76 2.99** 51.25 
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matrix in intestinal media provide stable nanoaggregates due to the repulsive forces and prevent 
aggregation of the polymer in big colloids causing a decrease in the complex viscosity in the 
intestinal conditions compared to the gastric. 18,349,394,395 Indeed, it is well known that viscosity 
is influenced by the particle size and smaller colloidal size have a lower resistance to flow, 
therefore providing lower complex viscosity values in solution (Barnes, 2003) As reported in 
literature upon contact with water, Gelucire forms micelles and their presence in solution likely 
influenced the drop in complex viscosity observed for these formulations. 64 It is known that 
micelles increase the solubility and wettability of poorly soluble compounds and these might 
be the reason of higher drug release from ASDs Gelucire formulations. 65 The same trend in 
complex viscosity values were also evidenced in comparative experiments with just polymer 
and plasticizer matrix, indicating that drug had a relatively lower influence on the 
microrheology compared to the excipients alone (data not shown). Critical for drug release are 
the particles and colloidal assemblies that emerge from ASDs and a recent study reported on 
different accessible drug fractions in the aqueous phase of HPMCAS-based solid dispersions. 
396 This study about the accessible drug fraction used fluorescence and suggested that 
thermodynamic activity in such HPMCAS systems can clearly differ from nominal 
concentrations. 
The present DWS study further considered the mean free path l*, which has been used before 
to study microstructural changes in emulsion system. 118 The mean free path l* describes the 
optical characteristics of the sample. In this study it has been employed to describe the 
appearance of the turbidity during dissolution. In case of pure KCZ, a decrease of the l* values 
was observed during dissolution time probably due to the precipitation upon the transition into 
intestinal pH. The precipitation behavior of crystalline KCZ in the aqueous phase is also shown 
during the biphasic dissolution testing with the UV blackout. (Figure 2) Considering the 
dissolution of ASDs, an interesting finding is that in the case of ASDs, there was a drop in l* at 
the end of the dissolution test compared to the initial values in gastric medium. (Figure 10) In 
the former systems, the increase of the turbidity is due to the increase of the polymer drug 
nanoaggregates occurring during the dissolution time in the aqueous phase. Indeed, it can be 
observed that lower values of l* are provided with Gelucire formulations (L and M grade of the 
polymer) that are also performing better in the biphasic dissolution testing.  
Overall the obtained results support the idea that HPMCAS is a good candidate for ASD 
formulation development of especially weak basic drugs. Indeed, the major advantage of the 
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ASDs formulations is the sustained drug release from the polymer matrix when compared to 
the performance of the crystalline KCZ. (Figure 2)  
ASDs formulations with HPMCAS have been prepared employing solvent methods, but some 
researchers have also studied the utility of HPMCAS for HME. 50,312 Optimization of the 
process was meaningful to avoid degradation of drug or polymer in line with Sarode et al. 
(2014) who have investigated the stability of HPMCAS for HME. The present study 
accordingly extruded at a temperature (i.e. 150°C) that was deemed as uncritical from a 
degradation viewpoint, which was enabled by adding suitable plasticizers (i.e. Gelucire 50/13 
or TEC). Process optimization might be critical for the miscibility of the system and therefore 
for the stability of the formulations. All ASDs formulations appear miscible at the molecular 
level, presenting just one single Tg. (Figure 6) Miscibility is an important factor for physical 
drug stability and all ASDs presented the drug in the amorphous form. (Figure 5) Even though 
ASDs can be technically produced by employing both TEC or Gelucire as plasticizer, the release 
results favored ASDs with the PEGylated lipid Gelucire. Increased drug release from these 
formulations might be due to the multiple interactions between the drug and polymer/lipid 
matrix compared to the polymer/TEC carrier. (Figure 7) 65,390,397  
 
5.5 Concluding remarks 
Solid drug dispersions form complex and heterogeneous systems upon aqueous dispersions. 
Coarse as well as colloidal drug/polymer particles evolve and impact on drug release that in 
turn drives absorptive flux. Traditional release testing often neglect important aspects like an 
absorptive sink and they offer only limited physical characterization. More recent approaches 
attempted to better understand emerging particles that are formed in aqueous environment. The 
current work used a biphasic dissolution test with a pH shift method and introduced DWS as 
novel analytical tool to gain a deeper understanding of the dissolution process from ASDs. 
Information about the polymer matrix was obtained regarding the polymer swelling in aqueous 
media and differences between the grades and plasticizers were highlighted. The 
microrheological correlations with drug release provided valuable aspects that were in previous 
research neglected due to lack of data. More results of further solid dispersions should clarify 
how broadly the identified correlations hold but already now it can be concluded that DWS is 
a promising tool for in vitro testing of ASDs and potentially also further supersaturating 
formulations.
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6 Broadband Diffusing Wave Spectroscopy reveals 
microstructuring of polymer-drug system  
 
 
 
Summary 
Microstructuring during a phase transition and crystallization in particular is critical for the 
physico-chemical properties of polymeric drug carriers and of the final dosage form. Extensive 
research has been dedicated to study polymeric matrices in drug delivery and despite of 
substantial progress, there are still unmet challenges such as a non-invasive mechanical analysis 
since classical rheological methods typically disturb the samples especially during a phase 
transition. This paper employs Diffusing Wave Spectroscopy (DWS) over a broad frequency 
band to study polymer-drug systems in a non-invasive way. Eutectic mixtures of polyethylene 
glycol (PEG) were investigated using two model drugs. While fenofibrate was barely 
interacting with the polymer, flurbiprofen provided a compound showing distinct molecular 
interactions with the carrier. Mechanical spectra were obtained during cooling of the molten 
polymer-drug systems. In conclusion, broadband DWS provided a better mechanistic 
understanding of the polymer-drug interactions and of macromolecular structuring during 
cooling of the eutectic melts. Such findings are relevant for a rationale design of pharmaceutical 
formulations during development and such knowledge would be also important for 
manufacturing to achieve drug products with reproducible quality characteristics. 
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6.1 Introduction  
The rheological properties of pharmaceutically important materials such as polymer melts, 
colloids, gels, and dispersions are central to many fields of formulation development and 
manufacturing. Most mixtures exhibit complex rheological behavior since formulations include 
abundant polymers of different kinds.398 Polymers that melt into a liquid are called to be 
thermoplastic and they are often processed by extrusion or molding. Polymeric crystallization 
may start when nuclei develop in a stochastic way and grow to a critical size in the cooling 
melt. Studies over the past two decades have provided important information on shear-induced 
crystallization and anisotropy in the direction of shear and show that crystallization proceeds as 
the nuclei grow into crystallites until all the melt has solidified.399 When neighboring crystallites 
grow and segments of the chains forming these crystallites can no longer be incorporated into 
the crystalline domains, then amorphous regions start to form. This process is depending on the 
cooling rate so that a low cooling rate grants polymer chains more time to arrange or incorporate 
themselves into crystallites.399  
 
Crystallization in synthetic polymers typically produces polycrystalline aggregates that are 
called spherulites given their spherical morphology. These spherulites are radially symmetric 
arrays of fibrillary crystallites ranging in diameter from less than one micron to several 
millimeters.400 In pharmaceutical systems, previous research revealed that interactions between 
the polymer and a drug can influence the crystallization behavior of the polymeric matrix.36 
Indeed, molecular drug- polymer interaction can occur already in the molten state and may not 
be easily evidenced in the solid state.401,402 Especially difficult is to study the crystallization 
process because such a phase transition is easily perturbed by the analytical method thereby 
leading to experimental bias. 
Mechanical rheology has a long tradition in the study of polymer melts.403 Shear stress 
controlled rheometers with high sensitivity allow measurement in the linear visco-elastic 
regime (LVR). Current rheological research on polymer crystallization attempts to combine the 
mechanical experiment with monitoring techniques such as nuclear magnetic resonance 
(NMR), small-angle X-ray scattering or dynamic optical microscopy.404 However, any 
mechanical rheometry is not contact-free and it can be problematic to measure within the LVR 
when very dynamic changes occur such as during polymer crystallization. Shear stress 
controlled oscillatory measurements are further limited because of a narrow range of accessible 
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high frequencies (with a maximum of about 100 Hz) and most important for the herein system, 
by the flow induced crystallization.135,405  
 
Modern microrheology based on Diffusing Wave Spectroscopy (DWS) has significantly 
extended the range of experimentally accessible frequencies and it is possible to measure non-
ergodic samples such as gels and semi-crystalline materials in a non-invasive 
way.130,131,406DWS has been used previously in the field of Pharmaceutics to study self-
emulsifying formulations, emulsions as well as solid drug dispersions.118,153,391,396,407 
The present research explores, for the first time, the effects of crystallization in a pharmaceutical 
polymeric system using DWS. Two eutectic systems with polyethylene glycol (PEG) and 
fenofibrate or flurbiprofen were employed as models.36,408 This polymer type is hydrophilic 
with a crystalline lattice structure and can form eutectic mixtures with an active pharmaceutical 
ingredient (API). Specific interactions between PEG and a drug can suppress the crystalline 
polymer lattice to some degree during cooling of the molten blend. The model mixtures were 
selected for their ability to either specifically interact with PEG (e.g. flurbiprofen) or as a model 
for which no specific interactions are known (e.g. fenofibrate).35,36 A particular aim of this DWS 
pioneer study in polymer crystallization was to obtain insights into structure formation of the 
solidifying molten matrices upon cooling. This is not only of interest from a formulation 
perspective but also regarding manufacturing such as by hot melt extrusion. 
 
6.2 Materials and methods 
6.2.1 Materials 
Fenofibrate was purchased from AK Scientific (30023 Ahern Ave Union City CA,USA), while 
poly(ethylene glycol) 6000, PEG was obtained from Sigma Aldrich (Riedstr. 2 D89559 
Steinheim 497329970). Flurbiprofen was supplied by Acros Organics (New Jersey USA) and 
uniform Ti02 particles were obtained from LS Instruments (Fribourg, Switzerland). 
6.2.2 Methods 
6.2.2.1  Preparation of the eutectic mixtures 
Eutectic mixtures were prepared by using the melting method as described in the literature.301 
Briefly, the PEG 6000 binary mixtures contained 24% (w/w) fenofibrate or alternatively 33% 
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(w/w) of flurbiprofen. These concentrations were obtained from previous DSC measurements, 
(i.e. as mixtures with one endothermic event) as reported in the literature.36 The physical 
mixture was blended with a spatula in a metallic pan and heated up to 90°C to assure complete 
melting. The obtained molten mixture was then cooled down to room temperature and kept in 
a desiccator before analysis. The heat exposure during preparation and analysis of the eutectic 
mixtures was not expected to cause any drug degradation of the two rather stable compounds 
in line with previous reports that employed hot melt extrusion.409,410 The obtained molten 
mixture in the present work was then cooled down to room temperature and kept in a desiccator 
before analysis. Characteristics and compositions for various drug-PEG eutectic  
systems are described in Table 1.  
 
Table 1. Characteristics and composition for various Drug-PEG eutectic systems 
 
 
6.2.2.2 Powder x-ray diffraction (XRPD) 
Powder X-ray diffraction was used to characterize the solid form of the physical mixtures and 
of solid dispersions at ambient temperature using a Bruker D2 PHASER (Bruker AXS GmbH, 
Germany) with a PSD-50 M detector and EVA application software version 6. Samples were 
prepared by spreading powder samples on PMMA specimen holder rings from Bruker. 
Measurements were performed at 25°C with a Cu Kα radiation source at 30 kV voltage, 10 mA 
current and were scanned from 6-40 2θ, with 2θ being the scattering angle at a scanning speed 
of 2 °/min.  
  
Compound 
Molecular 
weight 
(MW) 
Tm 
(°C) 
Hf 
(kJ/m
ole) 
Molar 
volume 
(cm3/mol) 
cLogP 
(n-
octanol/water
) 
Experimental 
eutectic 
composition 
with PEG 6000 
(%) 
References 
Fenofibrate 361 80.2 34.0 310.7 4.43 24 35 
Flurbiprofe
n 
244 114.7 28.0 263.5 4.12 33 408 
PEG 6000 58-
63 
- - - 
-  
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6.2.2.3  Differential scanning calorimetry (DSC) 
A DSC 3 system (Mettler Toledo, Greifensee, Switzerland) was calibrated for temperature and 
enthalpy using indium. Nitrogen was used as the protective gas (200 mL/min). Samples 
(approximately 5 mg) were placed in 40 μL aluminium pans with pierced aluminium lids. The 
melting point (Tm) was determined by a single-segment heating ramp of 10 °C/min from 25 °C 
to a maximum temperature of 200 °C. All DSC measurements were carried out in triplicate.  
 
6.2.2.4  Fourier transform infrared spectroscopy 
Attenuated total reflection Fourier transform infrared (ATR-FTIR) spectra of pure compounds 
and SDs were acquired in the 4000–600 cm-1 range using a Cary 680 Series FTIR spectrometer 
(Agilent Technologies, Santa Clara, USA) equipped with an attenuated total reflectance 
accessory. A scanning range of 4000–600 cm was selected with 42 scans and a resolution of 4 
cm. The spectra were evaluated using the software ACD/Spectrus Processor 2016.1.1 
(Advanced Chemistry Development Toronto, Canada). 
 
6.2.2.5 Diffusing wave spectroscopy (DWS) 
6.2.2.5.1 Measuring principle: 
DWS is a light scattering technique that requires turbid samples to study the dynamic properties. 
In the transmission geometry, the sample is illuminated by an expanded laser light source and 
the transmitted light is analyzed on the opposite side.129 The colloidal scattering particles can 
be present inside the sample, such for example oil droplets in emulsion, or they can be added 
in case of transparent sample such as, for example by dispersing titanium dioxide. Light 
detectors measure the intensity of the scattered light. The fluctuations of scattered light are 
characterized by the normalized intensity autocorrelation function (eq.1):129 
 
g(2)(t)=<I(t0)I(t0+t)>/<I>
2 (1) 
 
where the quantity <I> is the average intensity, while t represents the lag time.  
Using the Siegert relation (eq.2), the intensity correlation function and the field autocorrelation 
are related:  
 
g(2)(t)=1+׀g(1)(t)׀2 (2) 
 
where  is an instrumental factor given by the collection optics. Once the field correlation 
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function and l* have been measured, the mean square displacement (MSD, <r2(t)>) of a 
sample can be calculated employing (eq.3)135,136: 
  
g(2)(t)-1 ∝ |∫ 𝑃(𝑠)𝑒𝑥𝑝 [−
1
3
𝑘2 < 𝛥𝑟2(𝑡) >
𝑠
𝑙∗
]  𝑑𝑠
∞
0
|
2
  (3) 
 
where k = 2πn/λ is the optical wavenumber including n as the refractive index of the medium 
and λ is the laser wavelength. P(s) represents the distribution of the photon trajectories of length 
s in the sample of thickness L, while l* is the transport mean free path which characterizes the 
typical step length of the photon random walk. 
The data obtained for the MSD were analyzed employing the function proposed by Bellour and 
coworkers411: 
< ∆𝑟2(𝑡) >= 6𝛿2 (1 − 𝑒
−(
𝐷0
𝛿2
𝑡)
𝛼
)
1/𝛼
(1 +
𝐷𝑚
𝛿2
𝑡 ) (4) 
 
Where δ2 represents the amplitude of particle motion, t is the lag time, Do and Dm are the short 
and long-time diffusion coefficient while α is an additional parameter introduced to take into 
account the broad spectrum of relaxation times at the plateau onset time. 
Eq. 4 has been recently extended to better describe the region of longer relaxation times in case 
of pharmaceutical emulsions.412 On the other hand eq. 4 can also be simplified for other 
systems. Bellour et al. suggested the following eq. 5 for particles that are harmonically bound 
(i.e. “entrapped”) to exhibit Brownian motion around a stationary mean position:  
< ∆𝑟2(𝑡) >= 6𝛿2 (1 − 𝑒
−𝐷0
𝛿2
𝑡) (5) 
 
It is here possible to approximate the displacement value of the plateau with 6 2. The present 
work determined this plateau value based on the obtained MSD at the estimated inflection point. 
 
6.2.2.5.2 Experimental setup:  
All samples were measured in transmission mode using a DWS RheoLab instrument (LS 
Instruments AG, Fribourg, Switzerland). The theory of DWS-based microrheology was already 
explained in detail in our previous work.153 In brief, the laser light was scattered from the ground 
glass and collimated by a single lens before illuminating the sample. To avoid time consuming 
measurements at low frequencies, the instruments uses the so-called echo technique. The echo 
completes the data set to obtain the ICF over a broad range of lag times. In the echo mode the 
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ground glass rotates during the measurement producing different illumination speckle 
pattern.118 This feature is particularly important when working with non-ergodic samples, such 
as emulsions, gels and semi-crystalline polymers.118,153 Samples were analyzed using a 5mm 
thickness cuvette. To ensure turbidity of the molten polymer and of the solid dispersion, 4.5 mg 
of titanium dioxide tracer particles with mean diameter of 360 nm were added and mixed with 
2 g of sample. The mixture was poured into the cuvette to fill it up to 15-20 mm. The 
measurements were set in slow rotation mode at 300s with 30 s of echo mode. Five 
measurements of each temperature were done with two independent samples. The average of 
ten measurements is presented in all graphs. 
 
6.2.2.6  Hot stage cross polarized microscopy  
An assessment of the crystal nucleation and growth was based on polarized light imaging using 
a heating stage coupled with a microscope Axioskop 2 mot (upright). The latter had a 
Hamamatsu 5810 3CCD video camera and was equipped with phase contrast, polarized filters, 
and DIC. Physical mixtures were molten at 85° degrees and the crystallization was studied using 
a remained constant magnification throughout the whole measurement (scale bars are displayed 
in every image). 
 
6.2.2.7  Molecular visualization by docking 
To qualitatively analyze and depict drug interactions with the polymer, molecular docking was 
conducted. Chemical structures were obtained from the ChemicaElectrica Gateway (v. 4.01) 
and loaded into Molecular Modeling Pro Plus (v.8.2.1.) (both programs by Norgwyn 
Montgomery Software Inc., North Wales, USA). A relatively shorter chain for polyethylene 
glycol (i.e. PEG 400) was selected as model and this structure was drawn together with either 
the drug fenofibrate or flurbiprofen. Following a molecular mechanics minimization of the 
conformational energy (using the MM2 algorithm), partial charges of the molecules were 
calculated based on a semi-empirical quantum mechanical method (using a Complete Neglect 
of Differential Overlap, CNDO approach). Starting from 6 Angstroms distance between the 
molecular Van der Waals surfaces, a grid search algorithm proposed a molecular docking 
configuration of minimized energy. A relative permittivity of 18 was selected to approximate 
the PEG environment.413 The final molecular association was depicted as combined wire frame 
and space filled model. 
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6.3 Results  
6.3.1  Solid state characterizations 
Raw materials and the eutectic mixtures of PEG 6000 with either fenofibrate or flurbiprofen 
were characterized initially. Solid state analysis such as by DSC, PXRD and FT-IR was 
performed to determine the physical state of the raw materials and of the eutectic mixtures as 
well as to study interactions in both the molten and solid state. 
While the composition of eutectic mixtures and the respective melting point are presented in 
Table 1, the molecular docking of the two compounds with the carrier employed is presented 
in Fig. 1.  
 
Fig. 1. Molecular docking of PEG 6000 with fenofibrate (A) and flurbiprofen (B) 
 
Fig. 2. Differential Scanning Calorimetry (DSC) (A) and Powder X-ray diffraction (XRPD) (B) 
plots of fenofibrate (a), flurbiprofen (b), PEG c) PEG –fenofibrate SD (d) and PEG- flurbiprofen 
SD (e). 
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The DSC thermograms of pure PEG 6000, fenofibrate and flurbiprofen, as well as of their 
eutectic mixture are shown in Fig. 2A. The analysis of pure PEG 6000 shows that the onset of 
the endotherm occurs at 58 °C, having a peak at 62.5 °C. While the pure drug fenofibrate had a 
melting point of 80.2 °C and flurbiprofen’s melting point was 114 °C, the endothermic event 
of the eutectics was much lower compared to the raw materials. The eutectic composition for 
PEG and fenofibrate has been determined previously to comprise 24% (w/w) of drug and it was 
independent of the molecular weight of the carrier.414 Due to a strong hydrogen bonding, the 
eutectic composition for PEG and flurbiprofen was much higher with 33% (w/w) of API and 
strongly influenced by the molecular weight of the polymer.36,408 As eutectic systems, the 
crystallinity of the pure drugs was affected in mixture regarding form as well as extent, thereby 
resulting in the observed DSC endotherms. The molecular interaction of the two model drugs 
with a PEG chain was also visualized based on molecular modeling (i.e. molecular docking of 
API to a polymer chain). 
Fig. 1 depicts the hydrogen bond that is formed in the case of flurbiprofen whereas no such 
strong interaction was possible in case of fenofibrate with PEG. 
The crystalline state of the raw materials and of the eutectics was analyzed further by PXRD. 
As observed in Fig. 2B, raw material and eutectics present distinct Bragg peaks, indicating a 
crystalline nature. When comparing the spectra of the raw flurbiprofen with that of the eutectic 
mixture, a slight shift in the location of the peaks was observed.  
 
Fig. 3. FT-IR of flurbiprofen (gray solid line), solid dispersion with flurbiprofen (gray dots), 
fenofibrate (black solid line), solid dispersion with fenofibrate (black dots). 
 
The interaction between flurbiprofen and PEG 6000 was further evaluated by FT-IR. 
Broadband Diffusing Wave Spectroscopy reveals microstructuring of polymer-drug system  
 
 
124 
 
Pronounced shifts in the absorption bands of FT-IR are visible in Fig. 3 when comparing the 
spectra of flurbiprofen and fenofibrate as raw material and those obtained from the respective 
eutectic formulations. It can be seen that the carbonyl stretching band of flurbiprofen’s carboxyl 
moiety at 1700 cm-1 band has shifted to a higher frequency in the eutectic mixture. It has been 
argued that flurbiprofen is able to both donate and accept hydrogen bonds via the carboxyl 
moiety depending on the molecular weight of the polymer.36 It is likely that flurbiprofen is able 
to donate hydrogen bonds with PEG 6000, while it might also accept hydrogen bonds with 
much lower molecular weight PEG considering a more relevant influence of hydroxyl groups 
present at the chain ends.415 This is according to the expected molecular interaction based on 
molecular docking (Fig. 1) and the previously reported changes in FT-IR spectroscopy in 
mixtures of flurbiprofen and PEG.36,408 Such a shift was not observed in the case of the 
fenofibrate and the eutectic mixture of this drug. There were also not pronounced changes in 
the lower wave number vibrations in case of the pure fenofibrate compared to that of the eutectic 
mixture. This was again different for the system of flurbiprofen where at relatively lower wave 
numbers, some changes were observed in the spectra; especially a peak at 696 cm-1 that was 
shifted towards lower wavenumber (630 cm-1) for the solid dispersion of flurbiprofen with PEG. 
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6.3.2  DWS 
Analysis of polymer crystallization and macromolecular structuring was a central aim of this 
study. Recent progress in DWS allows measuring at changing temperatures in a dynamic way 
so that a solidification of eutectic melts with and without drug could be analyzed. 
Fig. 4. Microrheological characterization of PEG 6000: ICF (A), MSD (B), complex viscosity 
(C) and MCR (D). 
 
Fig. 4A presents the intensity correlation function (ICF) of PEG 6000 from 85 °C to 48 °C. At 
85 °C when the polymer was completely molten, the intensity correlation function decayed to 
zero. Upon cooling, such decay occurred at longer lag time, and this abrupt shift was due to 
high viscosity increase that was expected by polymer nucleation and crystal growth since PEG 
6000 is a semi-crystalline polymer at room temperature. The major changes in intensity 
correlation function were observed between 49 and 48 °C and the shift in lag time is displayed 
in Fig. 4B, where MSD is plotted. At relatively high temperature, the system was liquid and the 
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MSD was linearly increasing with lag time, while with temperature decreased, the MSD was 
reaching a plateau. Such a plateau means that tracer particles exhibit limited Brownian motion 
as they become entrapped. Complex viscosity versus the frequency is presented in Fig.4C. 
While at high temperature, the polymer was behaving as a Newtonian system with constant 
viscosity across a broad range of frequencies, this was different at lower temperatures, for which 
viscosity was changing with frequency thereby suggesting a structuring in the course of 
polymer crystallization leading to shear thinning. Mean count rate (MCR) represents the 
average intensity of light (proportional to the number of photons arriving at the detector) that is 
an indicator of sample transparency. At the higher end of measured temperatures, MCR was 
around 300 kHz, whereas with the onset of polymer crystallization there was a strong decrease 
of the MCR, indicating an increase of turbidity. (Fig. 4D). This provided a sensitive analytical 
approach to the macroscopic appearance of the polymer that was transparent at 85°C but white 
at room temperature. In PEG 6000 is a semi-crystalline polymer and the increase of turbidity 
was due to the crystallization of the polymer occurring around 48 °C. 
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Fig. 5.  Microrheological characterization of solid dispersion of PEG 6000 and fenofibrate: ICF 
(A), MSD (B), complex viscosity (C) and MCR (D). 
 
The molten physical mixture of PEG 6000 and fenofibrate was then heated to 85 °C Fig. 5A 
compares the intensity correlation function (ICF) upon cooling to lower temperatures and 
45.4°C can be identified as the temperature of crystallization. Thus, at 85 °C when the polymer 
was completely molten, the ICF decayed to zero, whereas the ICF started to no longer reach 
zero upon cooling. ICFs were shifted to higher values of lag time(s) and the viscosity was 
increasing. The major changes in intensity correlation function for the eutectics were observed 
between 46 and 45.4 °C. The shift in lag time is depicted in Fig. 5B, where MSD is plotted 
versus lag time. At high temperature for which the system is liquid, the MSD was increasing 
linearly with lag time, while upon decreasing the temperature, the MSD was reaching a plateau. 
Changes of the complex viscosity versus temperature are presented in Fig.5C. Similar to pure 
PEG 6000, the molten polymer mixture had a constant viscosity over the measured frequency 
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range, whereas at lower temperatures, there was a decrease of viscosity over the frequency 
range suggesting again shear thinning as previously observed with pure PEG 6000. Further 
analysis of the fenofibrate and PEG 6000 mixture is given by Fig. 5D that shows the decrease 
of the MCR over the temperature for this eutectic system. At higher temperatures, MCR was 
approximately 300 kHz and a strong decrease of the MCR, indicated an increase of turbidity in 
the course of matrix crystallization. The onset of crystallization was occurring at a temperature 
of about 45 °C and MCR reached approximately 220 kHz when the sample was completely 
solidified. 
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Fig. 6. Microrheological characterization of solid dispersion of PEG 6000 and flurbiprofen: ICF 
(A), MSD (B), complex viscosity (C) and MCR (D). 
 
Finally, the model of the strongly interacting mixture was analyzed using PEG 6000 in 
combination with flurbiprofen. The molten mixture at 85 °C showed again an ICF that was 
decaying to zero. However, with a decrease of temperature there was again a shift to higher lag 
times, indicating a higher viscosity of the system as it can be seen in Fig.6A. For this eutectic 
mixture, no solidification was observed even close to the body temperature (38° C) in line with 
what has been reported before.36 Again, the MSD provided again insights into the 
microstructure via the mean average distance that tracer particles were travelling. (Fig. 6B). In 
the liquid state, tracer particle were able to perform Brownian motion and therefore, there was 
a linear increase of MSD versus lag time. For a nearly constant MSD, tracer particles were 
apparently confined around their mean positions. When considering Fig 6C, the systems does 
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not exhibit an ideally viscous behavior at high temperature; therefore, an apparent shear 
thickening may have caused the observed frequency changes at 85°C, while cooling of the 
system was leading to a rheological behavior suggesting shear thinning similar to the previously 
analyzed samples. Such cooling led again to a strong decrease of MCR values due to the 
occurrence of crystallites as shown Fig 6D.  
 
Fig. 7. Comparison of the apparent cage size (named as 6 2) in pure PEG, SD of fenofibrate 
and SD of flurbiprofen close to their solidification temperature. 
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Fig. 8. Hot stage cross polarized light microscopy of PEG 6000 (A), SD of fenofibrate (B) and SD of 
flurbiprofen (C) 
 
Since all samples showed a plateau regime of MSD, a comparison for this apparent confinement 
of the tracer particles due to microstructuring of the solidifying polymer matrix. Following the 
approach of Bellour et al.411 (Eq. 5) for the present case of polymeric melts, the given 
confinement of the tracer particles can be plotted as a kind of “cage size” as displayed in Fig. 
7. The dimension of this apparent confinement of tracer particles was biggest for polymer alone, 
followed by the eutectic mixtures with fenofibrate and finally that with flurbiprofen. The data 
of DWS were finally complemented by studies using hot stage cross polarized microscopy and 
the results are presented in Fig.8A, B and C respectively. As mentioned before, polymer drug 
interaction play a significant role in polymer chain folding during the crystallization and as 
highlighted in the Fig. 8C, the crystalline structure of the SD with flurbiprofen in the solid state 
appeared to be different compared to the polymer alone or also compared to the SD with 
fenofibrate that was less interacting with the polymer matrix. It is evident that the crystalline 
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structure was in the latter case rather disrupted in line with previous reports in the 
literature.401,408,414 
 
6.4 Discussion 
Crystallization of polymers is a complex topic and the classical of Hoffmann-Lauritzen theory 
provides a basic understanding of how polymeric chains exhibit surface crystallization into 
lamellae of a given thickness.416 Since these pioneer days, several more refined theoretical 
models involving multistep crystallization have been proposed and a very recent review in the 
journal Macromolecules comes to the conclusion that even these days, important theoretical 
questions remain unanswered.417 The theoretical complexity is of course even increased in 
presence of additives such as a drug and therefore, pharmaceutical research has mostly taken 
just a phenomenological approach to crystallization of polymeric drug formulations. However, 
any experimental study of a phase transition such as crystallization is also difficult because the 
analytics should not disturb the observed process, which is a concern with techniques such as 
mechanical rheology. The present work therefore used for the first time broadband DWS to 
study pharmaceutical eutectic model systems in the course of solidification upon cooling. 
 
Previous work suggested that flurbiprofen is strongly interacting with PEG while fenofibrate is 
not.36 Solid state characterization employing DSC, PXRD were performed and the results are 
shown in Fig. 2. Specific interactions such as hydrogen bonding between flurbiprofen and PEG 
6000 have been studied with FT-IR and presented in Fig 3. The current study found that drug-
polymer interaction played a key role in case of flurbiprofen during phase transition of the PEG-
based solid dispersion. It can be well imagined that strongly attached flurbiprofen would affect 
polymer chain flexibility and its bulkiness so that crystalline packing of lamellae would be 
affected. This qualitative view may explain the observed effects on polymer matrix 
crystallization in case of this strongly interacting eutectic system. The solid dispersion 
comprising PEG 6000 and fenofibrate exhibited ideal viscous behavior at high temperatures 
and the frequency spectrum suggested some viscoelastic behavior at lower temperatures. (Fig. 
4C and 5C). The high temperature regime can be imagined to hold for a typical melt with 
polymer chains that can arrange in random coils and thereby provide a rather homogenous 
system with practically ideal viscous behavior. Once polymer nucleation and growth occurs, 
the lamellar grow into crystallites and such spherulites can further aggregate. Since these 
aggregates provide suspended particles, there was turbidity noted as indicated by the MCR of 
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the DWS experiments. The frequency dependence of viscosity was analogues to shear thinning 
of a suspension and a recent study actually evaluated typical models of suspension rheology for 
such samples.418 The authors pointed to the analogy of particle hierarchy between aggregated 
crystallites and other polymeric nanocomposites. The latter nanocomposites are typically 
agglomerates of small aggregates and these again consist of primary nanoparticles. 
Analogously, crystal aggregates (spherulites) are aggregates of crystal lamellae consisting of 
several individual lamellae.  
 
Table 2. Temperatures and G’ G’ values at the intersection of curves 
 Temperature (°C) Frequency 
(rad/s) 
Moduli G’ G’’ 
(Pa) 
PEG 48.20 
48.00 
 
0.63 
0.70 
120.00 
150.60 
SD of 
fenofibrate 
45.60 
45.40 
 
2.69 
0.50 
19.54 
398.58 
SD of 
flurbiprofen 
38.40 
38.20 
 
0.12 
1.64 
151.40 
1958.76 
 
Aggregated polymeric crystals can exhibit mechanical rigidity and therefore elastic behavior. 
Determination of the solidification point is obtained using the crossover point of G’ and G’’ 
and the results presented in Table 2. Indeed, above the given crystallization temperature, 
samples were in molten state exhibiting G’’> G’, while upon solidification, there was 
dominance of the elastic modulus with G’ > G’’. (data not shown)  
Newtonian behavior at high temperatures was not found in case of the molten solid dispersion 
with flurbiprofen. (Fig. 6C) The changes along the differences frequencies suggested increasing 
viscosity at 85 °C, whereas upon cooling, data indicated again a shear thinning behavior. The 
latter behavior supports the view that occurrence of crystallites was leading to a suspension-
type of rheology. However, the behavior at 85°C in the melt is particularly notable since PEG 
6000 alone did not show such increased viscosity with frequency but was rather Newtonian. 
Polymers of higher molecular weight can show an increase of viscosity with rising frequency 
which is due to the entanglement of longer chains. Each detanglement is expected to require a 
specific relaxation time and for higher frequencies, transient bonds of entanglement would 
become permanent on the given time scale.419 Even though a strongly interacting small-
molecular drug like flurbiprofen would not greatly lengthen the chains of PEG 6000, the present 
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results still display some frequency dependency of the viscous melt caused by the presence of 
flurbiprofen.  
The presence of strong molecular interactions between a drug and PEG 6000 was also studied 
by Van Duong et al. (2017). They outlined the view that in the melt, PEG chains are locked in 
hydrogen bonding with drug molecules and therefore no more than one repeated unit of helical 
structure can be folded. The crystallization process for the considered systems is taking place 
in a relatively narrow temperature range, and this may occur especially when the system is 
homogeneously dispersed. The model assumes that in the course of chain folding, drug-polymer 
hydrogen bonds are disrupted leading to a segregation of API. Some drug remains hydrogen 
bonded to the surface of the folded lamellae and is part of drug-rich domains. Such solidified 
polymer systems are typically semi-crystalline and the extent of crystallinity as well as the given 
microstructure were previously mentioned to likely affect quality attributes such as drug 
release.36,401 
To gain a better understanding of how the presence of drug affected polymer crystallization, 
the average movement of the tracer particles as MSD grants insights into the microstructuring 
in the course of crystallization. The approach by Bellour et al. 411 has been previously used to 
describe other structured liquids such as a surfactant solution of worm-like micelles and it was 
qualitatively used in the present study to interpret the obtained data of the polymeric melts upon 
crystallization.411  When tracer particles exhibit a nearly constant MSD for a regime of 
frequencies (or lag times), then there is a kind of apparent entrapment given. The so-called 
“cage size” grants indirect insights into the structure of the matrix that is surrounding the used 
tracer particles. It is noteworthy that the MSD decreases in presence of polymer drug 
interaction, which is also reflecting by the apparent cage size at the inflexion point (named as 
6δ2 ) as presented in Fig.7. Given that tracer particles were embedded in a matrix of crystallizing 
and aggregating lamellae, the differences in apparent cage size may suggest how finely meshed 
these networks of lamellae were. This would support the view that the strongly interacting 
flurbiprofen perturbs polymer crystallization thereby leading to relatively smaller lamellae 
compared with pure PEG 6000 or its SD with fenofibrate. Indeed, the presence of flurbiprofen 
attached to the PEG via hydrogen bonding would inhibit the crystallization of the polymer, 
because it induces defects in the PEG crystalline network, hindering it from growing and 
structuring in line with results depicted in Fig.8. The present findings show that 
microstructuring of polymer in presence of drug can be studied not only by small-angle X 
scattering but also with novel microrheological tool such as broadband DWS.420,421 
These findings help us to understand the microstructuring during phase transition of the 
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polymer and of eutectic mixtures at high frequencies and in a non-invasive conditions. In 
addition, physicochemical properties and pharmaceutical performance of PEG-based solid 
dispersion depend on the drug-polymer interactions. Disruption of the crystalline lattice has 
also expected implications of drug release in that a relatively lower matrix crystallinity typically 
shows faster drug release compared to an eutectic system with a higher degree of crystallization. 
Therefore, the given microstructure is central for the quality attributes of the given SD 
formulations and present work may find applications in formulation development as well as in 
process development of a eutectic drug product. 
 
6.5 Conclusions 
The physico-chemical properties of polymeric drug carriers and of the final dosage form depend 
on the micro structuring during the crystallization process in case of polymer eutectics. DWS 
and MSD were employed to study macromolecular structuring during cooling of the PEG-based 
mixtures with two model drugs, fenofibrate and flurbiprofen. While the first compound was 
barely interacting with the polymer, flurbiprofen provided a distinct molecular interaction with 
the carrier. This interaction already present in the molten state was changing the rheological 
behavior of the otherwise pure polymer melt. The crystallization of polymer was monitored by 
studying complex viscosity and MSD parameters from DWS. Indirectly it was possible to gain 
insights into how lamellae may crystalize and aggregate in the different formulations. Given 
the importance of the microstructure of such eutectic systems on different pharmaceutical 
quality attributes, the present findings are of high relevance also for practical formulation 
development. Compared to classical rheological measurements where the directions of the 
crystallizing lamellae are influenced during the measurements, DWS offers insights into the 
microstructuring of crystallizing lamellae based on contact-free measurements over a broad 
frequency range. Such mechanistic analysis and understanding of microstructuring under non-
invasive conditions is not only relevant for eutectic systems. Other solid drug dispersions could 
be studied in the future too and tracer particles should be added whenever a system does not 
provide sufficient light scattering on its own. Therefore, DWS is a quite versatile tool to study 
the solidification behavior of drug-excipient mixtures, which is important to properly 
understand phase behavior and microstructuring of pharmaceutical formulations. 
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Final remarks and outlook 
Solid dispersion technology is one of the most employed technologies to enhance the 
performance of poorly soluble drugs. It employs not just polymer but also other excipients to 
enhance the solubility and dissolution rate of low solubility APIs. The selection of an 
appropriate excipient for the formulation is still challenging and involves a lot of trial and errors. 
Different approaches to characterize amorphous solid dispersions have been already presented. 
Indeed, solid-state analytical characterizations are widely employed to discern between the 
amorphous and crystalline physical state of the API, explore the system thermodynamics, 
changes and the effect of multicomponent systems within the amorphous solid dispersion. 
However, many aspects of solid dispersions are still unknown; in this regard, novel approaches 
for solid dispersion characterization can deepen our understanding of processes such as drug-
polymer interaction during manufacturing, or upon water dispersion. This thesis aims to 
introduce two novel approaches for solid dispersion characterizations such as Diffusing Wave 
Spectroscopy (DWS) and Fluorescence Spectroscopy. 
 
DWS is an advanced light scattering technique, which provides microrheological knowledge 
employing dispersed particles in a solvent. The main advantages of this technique are the 
broadband frequencies and low viscosity measurements in a non-invasive way. For the first 
time, it has been introduced in the solid dispersion field and it has been applied to 
mechanistically study the dissolution process from different solid dispersion formulations. It 
allowed us to measure very low viscous media during the dissolution process for example in 
Chapter 4 and correlate it to the dissolution mechanism. The polymer type employed in this 
study forms colloids upon water dispersion, and through viscosity measurements, it was 
possible to deepen our knowledge about the dissolution mechanism of complex solid 
dispersions mixtures.  
 
Also, fluorescence spectroscopy together with size-exclusion chromatography aimed to study 
drug-polymer interactions that emerge upon water dispersion of the solid dispersion (Chapter 
4). In this study celecoxib, a native fluorescent drug was combined with four different polymers; 
drug-polymer interactions in the physical mixture or solid dispersion were compared. The 
results of this study outline the amount of drug embedded into polymer aggregates and the 
amount of free drug in solution, which is the true supersaturation driving absorption. 
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Drug release from solid dispersions was also the topic in Chapter 5. For this purpose, different 
grades of HPMCAS were prepared and tested in a biphasic in vitro dissolution test. DWS was 
introduced to study microrheological differences among polymer grades and plasticizers in the 
aqueous phase; polymer swelling and drug-polymer nanoaggregates affected drug release and 
the uptake in the organic layer. DWS outlined its potential in the biopharmaceutical research 
on supersaturating systems, such as solid dispersions. 
The last chapter emphasized the use of DWS for drug development and manufacturing, 
employing a fusion method. In Chapter 6 the microstructuring upon cooling of two different 
solid dispersions was studied and compared to the pure matrix. DWS highlighted differences in 
microstructuring upon cooling in the presence of and in the absence of molecular interaction.  
 
This thesis offers interesting and promising characterization approaches for the formulation of 
solid dispersions, which can guide early formulation development of drug delivery systems. 
DWS, for example, might be used in the characterization for differently gelling drug delivery 
systems or in combination with fluorescence spectroscopy to gain a better understanding of the 
swelling and drug release mechanism.
  
138 
 
 
7 Bibliography: 
1. Shah, N. H., Sandhu, H., Choi, D. S., Chokshi, H. & Malick, A. W. Amorphous Solid 
Dispersions (Theory and Practice). (Springer New York, 2014). 
2. Butler, J. M. & Dressman, J. B. The developability classification system: application of 
biopharmaceutics concepts to formulation development. J. Pharm. Sci. 99, 4940–4954 
(2010). 
3. Hu, J., Johnston, K. P. & Williams, R. O. Nanoparticle Engineering Processes for 
Enhancing the Dissolution Rates of Poorly Water Soluble Drugs. Drug Dev. Ind. 
Pharm. 30, 233–245 (2004). 
4. Taylor, L. S. & Zhang, G. G. Z. Z. Physical chemistry of supersaturated solutions and 
implications for oral absorption. Adv. Drug Deliv. Rev. 101, 122–142 (2016). 
5. Viernstein, H., Weiss-Greiler, P. & Wolschann, P. Solubility enhancement of low 
soluble biologically active compounds - Temperature and cosolvent dependent 
inclusion complexation. Int. J. Pharm. 256, 85–94 (2003). 
6. Van Den Mooter, G. The use of amorphous solid dispersions: A formulation strategy to 
overcome poor solubility and dissolution rate. Drug Discov. Today Technol. 9, e79–e85 
(2012). 
7. Baird, J. A., Van Eerdenbrugh, B. & Taylor, L. S. A classification system to assess the 
crystallization tendency of organic molecules from undercooled melts. J. Pharm. Sci. 
99, 3787–3806 (2010). 
8. Zografi, G. & Newman, A. Interrelationships Between Structure and the Properties of 
Amorphous Solids of Pharmaceutical Interest. J. Pharm. Sci. 106, 5–27 (2017). 
9. Janssens, S. & Van den Mooter, G. Review: physical chemistry of solid dispersions. J. 
Pharm. Pharmacol. 61, 1571–1586 (2009). 
10. Homayouni, A., Sadeghi, F., Nokhodchi, A., Varshosaz, J. & Afrasiabi Garekani, H. 
Preparation and characterization of celecoxib solid dispersions; comparison of 
poloxamer-188 and PVP-K30 as carriers. Iran. J. Basic Med. Sci. 17, 322–331 (2014). 
11. Frank, K. J. et al. The amorphous solid dispersion of the poorly soluble ABT-102 
forms nano/microparticulate structures in aqueous medium: Impact on solubility. Int. J. 
Nanomedicine 7, 5757–5768 (2012). 
12. Vasanthavada, M., Tong, W. Q., Joshi, Y. & Kislalioglu, M. S. Phase behavior of 
amorphous molecular dispersions I: Determination of the degree and mechanism of 
solid solubility. Pharm. Res. 21, 1598–1606 (2004). 
13. Miyazaki, T., Yoshioka, S., Aso, Y. & Kojima, S. Ability of polyvinylpyrrolidone and 
polyacrylic acid to inhibit the crystallization of amorphous acetaminophen. J. Pharm. 
Sci. 93, 2710–2717 (2004). 
14. Qian, F., Huang, J. & Hussain, M. A. Drug-polymer solubility and miscibility: Stability 
consideration and practical challenges in amorphous solid dispersion development. J. 
Pharm. Sci. 99, 2941–2947 (2010). 
15. Mori, Y. et al. Theoretical and practical evaluation of lowly hydrolyzed polyvinyl 
alcohol as a potential carrier for hot-melt extrusion. Int. J. Pharm. 555, 124–134 
(2019). 
16. Guzmán, H. R. et al. Combined use of crystalline salt forms and precipitation inhibitors 
to improve oral absorption of celecoxib from solid oral formulations. J. Pharm. Sci. 96, 
2686–2702 (2007). 
17. Craig, D. Q. M. M. The mechanisms of drug release from solid dispersions in water-
soluble polymers. Int. J. Pharm. 231, 131–144 (2002). 
 139 
 
18. Friesen, D. T. et al. Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-
Dried Dispersions: An Overview. Mol. Pharm. 5, 1003–1019 (2008). 
19. Succinate-based, H. M. A. et al. Spray-Dried Dispersions : An Overview. 5, 1003–1019 
(2008). 
20. Serajuddln, A. T. M. M. Solid dispersion of poorly water-soluble drugs: Early 
promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 88, 1058–
1066 (1999). 
21. Kwon, J. et al. Spray-dried amorphous solid dispersions of atorvastatin calcium for 
improved supersaturation and oral bioavailability. Pharmaceutics 11, (2019). 
22. Guns, S. et al. Comparison between hot-melt extrusion and spray-drying for 
manufacturing solid dispersions of the graft copolymer of ethylene glycol and 
vinylalcohol. Pharm. Res. 28, 673–682 (2011). 
23. Newman, A. Pharmaceutical Amorphous Solid Dispersions. (John Wiley & Sons, Inc., 
Hoboken, New Jersey, 2015). 
24. Amidon, G. L., Lennernäs, H., Shah, V. P. & Crison, J. R. A theoretical Basis for a 
Biopharmaceutical Drug Classification:The Correlation of in Vitro Drug Product 
Dissolution and in vivo bioavailability. Pharm. Res. 12, 413–20 (1995). 
25. Rosenberger, J., Butler, J., Muenster, U. & Dressman, J. Application of a Refined 
Developability Classification System. J. Pharm. Sci. 108, 1090–1100 (2019). 
26. Rosenberger, J., Butler, J. & Dressman, J. A Refined Developability Classification 
System. J. Pharm. Sci. 107, 2020–2032 (2018). 
27. Wu, C. Y. & Benet, L. Z. Predicting drug disposition via application of BCS: 
Transport/absorption/ elimination interplay and development of a biopharmaceutics 
drug disposition classification system. Pharm. Res. 22, 11–23 (2005). 
28. Yoo, S. U., Krill, S. L., Wang, Z. & Telang, C. Miscibility/stability considerations in 
binary solid dispersion systems composed of functional excipients towards the design 
of multi-component amorphous systems. J. Pharm. Sci. 98, 4711–4723 (2009). 
29. Descamps, M. & Willart, J. F. Perspectives on the amorphisation/milling relationship 
in pharmaceutical materials. Adv. Drug Deliv. Rev. 100, 51–66 (2016). 
30. Warren, D. B., Benameur, H., Porter, C. J. H. & Pouton, C. W. Using polymeric 
precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A 
mechanistic basis for utility. J. Drug Target. 18, 704–731 (2010). 
31. Vasconcelos, T., Sarmento, B. & Costa, P. Solid dispersions as strategy to improve oral 
bioavailability of poor water soluble drugs. Drug Discov. Today 12, 1068–1075 (2007). 
32. Hancock, B. C. & Parks, M. What is the True Solubility Advantage for Amorphous 
Pharmaceuticals? Pharm. Res. 17, 397–404 (2000). 
33. Hancock, B. C. & Zografi, G. Characteristics and Significance of the Amorphous State 
in Pharmaceutical Systems. J. Pharm. Sci. 86, 1 (1997). 
34. Vo, C. L.-N., Park, C. & Lee, B.-J. Current trends and future perspectives of solid 
dispersions containing poorly water-soluble drugs. Eur. J. Pharm. Biopharm. 85, 799–
813 (2013). 
35. Law, D. et al. Properties of rapidly dissolving eutectic mixtures of poly(ethylene 
glycol) and fenofibrate: The eutectic microstructure. J. Pharm. Sci. 92, 505–515 
(2003). 
36. Vippagunta, S. R., Wang, Z., Hornung, S. & Krill, S. L. Factors affecting the formation 
of eutectic solid dispersions and their dissolution behavior. J. Pharm. Sci. 96, 294–304 
(2007). 
37. Newa, M. et al. Preparation, characterization and in vivo evaluation of ibuprofen 
binary solid dispersions with poloxamer 188. Int. J. Pharm. 343, 228–237 (2007). 
38. Leuner, C. Improving drug solubility for oral delivery using solid dispersions. Eur. J. 
 140 
 
Pharm. Biopharm. 50, 47–60 (2000). 
39. Sethia, S. & Squillante, E. Solid dispersion of carbamazepine in PVP K30 by 
conventional solvent evaporation and supercritical methods. Int. J. Pharm. 272, 1–10 
(2004). 
40. Okonogi, S., Oguchi, T., Yonemochi, E., Puttipipatkhachorn, S. & Yamamoto, K. 
Improved dissolution of ofloxacin via solid dispersion. Int. J. Pharm. 156, 175–180 
(1997). 
41. Bhattacharya, S. & Suryanarayanan, R. Local mobility in amorphous pharmaceuticals - 
Characterization and implications on stability. J. Pharm. Sci. 98, 2935–2953 (2009). 
42. Kissi, E. O. et al. Glass-Transition Temperature of the β-Relaxation as the Major 
Predictive Parameter for Recrystallization of Neat Amorphous Drugs. J. Phys. Chem. B 
122, 2803–2808 (2018). 
43. Dedroog, S., Pas, T., Vergauwen, B., Huygens, C. & Van den Mooter, G. Solid-state 
analysis of amorphous solid dispersions: Why DSC and XRPD may not be regarded as 
stand-alone techniques. J. Pharm. Biomed. Anal. 178, 112937 (2019). 
44. Lehmkemper, K., Kyeremateng, S. O., Heinzerling, O., Degenhardt, M. & Sadowski, 
G. Long-Term Physical Stability of PVP- and PVPVA-Amorphous Solid Dispersions. 
Mol. Pharm. 14, 157–171 (2017). 
45. Xiang, T. X. & Anderson, B. D. Effects of Molecular Interactions on Miscibility and 
Mobility of Ibuprofen in Amorphous Solid Dispersions With Various Polymers. J. 
Pharm. Sci. 108, 178–186 (2019). 
46. Huynh, L., Neale, C., Pomès, R. & Allen, C. Computational approaches to the rational 
design of nanoemulsions, polymeric micelles, and dendrimers for drug delivery. 
Nanomedicine Nanotechnology, Biol. Med. 8, 20–36 (2012). 
47. Lübtow, M. M., Haider, M. S., Kirsch, M., Klisch, S. & Luxenhofer, R. Like Dissolves 
Like? A Comprehensive Evaluation of Partial Solubility Parameters to Predict 
Polymer-Drug Compatibility in Ultrahigh Drug-Loaded Polymer Micelles. 
Biomacromolecules 20, 3041–3056 (2019). 
48. Watts, Robert O. Williams III Alan B. Miller, D. A. Formulating Poorly Water Soluble 
Drugs. Formul. Poorly Water Soluble Drugs vol. 3 (2012). 
49. Van Duong, T. & Van den Mooter, G. The role of the carrier in the formulation of 
pharmaceutical solid dispersions. Part II: amorphous carriers. Expert Opin. Drug Deliv. 
13, 1681–1694 (2016). 
50. Tanno, F., Nishiyama, Y., Kokubo, H. & Obara, S. Evaluation of Hypromellose 
Acetate Succinate (HPMCAS) as a Carrier in Solid Dispersions. Drug Dev. Ind. 
Pharm. 30, 9–17 (2004). 
51. Ueda, K., Higashi, K., Yamamoto, K. & Moribe, K. The effect of HPMCAS functional 
groups on drug crystallization from the supersaturated state and dissolution 
improvement. Int. J. Pharm. 464, 205–213 (2014). 
52. Taylor, L. S. & Zografi, G. Spectroscopic Characterization of Interactions Between 
PVP and Indomethacin in Amorphous Molecular Dispersions. Pharm. Res. 14, 1691–
1698 (1997). 
53. Solanki, N. G. et al. Effects of Surfactants on Itraconazole-HPMCAS Solid Dispersion 
Prepared by Hot-Melt Extrusion I: Miscibility and Drug Release. J. Pharm. Sci. 108, 
1453–1465 (2019). 
54. Curatolo, W., Nightingale, J. A. & Herbig, S. M. Utility of 
Hydroxypropylmethylcellulose Acetate Succinate (HPMCAS) for Initiation and 
Maintenance of Drug Supersaturation in the GI Milieu. Pharm. Res. 26, 1419–1431 
(2009). 
55. Zhang, Q. et al. Effect of HPMCAS on recrystallization inhibition of nimodipine solid 
 141 
 
dispersions prepared by hot-melt extrusion and dissolution enhancement of nimodipine 
tablets. Colloids Surfaces B Biointerfaces 172, 118–126 (2018). 
56. Guyot, M., Fawaz, F., Bildet, J., Bonini, F. & Lagueny, A.-M. Physicochemical 
characterization and dissolution of norfloxacin/cyclodextrin inclusion compounds and 
PEG solid dispersions. Int. J. Pharm. 123, 53–63 (1995). 
57. Meng, F., Ferreira, R. & Zhang, F. Effect of surfactant level on properties of celecoxib 
amorphous solid dispersions. J. Drug Deliv. Sci. Technol. 49, 301–307 (2019). 
58. Han, R. et al. Insight into the Dissolution Molecular Mechanism of Ternary Solid 
Dispersions by Combined Experiments and Molecular Simulations. AAPS 
PharmSciTech 20, 10–20 (2019). 
59. Chaudhari, S. P. & Dugar, R. P. Application of surfactants in solid dispersion 
technology for improving solubility of poorly water soluble drugs. J. Drug Deliv. Sci. 
Technol. 41, 68–77 (2017). 
60. Siepmann, J. et al. Lipids and polymers in pharmaceutical technology: Lifelong 
companions. Int. J. Pharm. 558, 128–142 (2019). 
61. Jannin, V. & Cuppok, Y. Hot-melt coating with lipid excipients. Int. J. Pharm. 457, 
480–487 (2013). 
62. Damian, F. et al. Physicochemical characterization of solid dispersions of the antiviral 
agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14. Eur. J. Pharm. Sci. 
10, 311–322 (2000). 
63. Lee, K. H., Park, C., Oh, G., Park, J. B. & Lee, B. J. New blends of 
hydroxypropylmethylcellulose and Gelucire 44/14: physical property and controlled 
release of drugs with different solubility. J. Pharm. Investig. 48, 313–321 (2018). 
64. Kawakami, K., Miyoshi, K. & Ida, Y. Solubilization behavior of poorly soluble drugs 
with combined use of Gelucire 44/14 and cosolvent. J. Pharm. Sci. 93, 1471–1479 
(2004). 
65. Potluri, R. H. K., Bandari, S., Jukanti, R. & Veerareddy, P. R. Solubility enhancement 
and physicochemical characterization of carvedilol solid dispersion with Gelucire 
50/13. Arch. Pharm. Res. 34, 51–57 (2011). 
66. Cortes-Rojas, D. F., Souza, C. R. F. F., Chen, M. J., Hochhaus, G. & Oliveira, W. P. 
Effects of lipid formulations on clove extract spray dried powders: comparison of 
physicochemical properties, storage stability and in vitro intestinal permeation. Pharm. 
Dev. Technol. 23, 1047–1056 (2018). 
67. Khan, N. & Craig, D. Q. M. M. The influence of drug incorporation on the structure 
and release properties of solid dispersions in lipid matrices. J. Control. Release 93, 
355–368 (2003). 
68. Kasten, G., Löbmann, K., Grohganz, H. & Rades, T. Co-former selection for co-
amorphous drug-amino acid formulations. Int. J. Pharm. 557, 366–373 (2019). 
69. Sosnik, A. & Seremeta, K. P. Advantages and challenges of the spray-drying 
technology for the production of pure drug particles and drug-loaded polymeric 
carriers. Adv. Colloid Interface Sci. 223, 40–54 (2015). 
70. Paudel, A., Worku, Z. A., Meeus, J., Guns, S. & Van Den Mooter, G. Manufacturing of 
solid dispersions of poorly water soluble drugs by spray drying: Formulation and 
process considerations. Int. J. Pharm. 453, 253–284 (2013). 
71. Baird, J. A., Santiago-Quinonez, D., Rinaldi, C. & Taylor, L. S. Role of viscosity in 
influencing the glass-forming ability of organic molecules from the undercooled melt 
state. Pharm. Res. 29, 271–284 (2012). 
72. Mahlin, D., Ponnambalam, S., Heidarian Höckerfelt, M. & Bergström, C. A. S. S. 
Toward in silico prediction of glass-forming ability from molecular structure alone: A 
screening tool in early drug development. Mol. Pharm. 8, 498–506 (2011). 
 142 
 
73. Mahlin, D. & Bergström, C. A. S. S. Early drug development predictions of glass-
forming ability and physical stability of drugs. Eur. J. Pharm. Sci. 49, 323–332 (2013). 
74. Patil, H., Tiwari, R. V. & Repka, M. A. Hot-Melt Extrusion: from Theory to 
Application in Pharmaceutical Formulation. AAPS PharmSciTech 17, 20–42 (2016). 
75. Mendonsa, N. et al. Manufacturing strategies to develop amorphous solid dispersions: 
An overview. J. Drug Deliv. Sci. Technol. 55, 101459 (2020). 
76. De Brabander, C., Van Den Mooter, G., Vervaet, C. & Remon, J. P. Characterization of 
ibuprofen as a nontraditional plasticizer of ethyl cellulose. J. Pharm. Sci. 91, 1678–
1685 (2002). 
77. Repka, M. A., Majumdar, S., Battu, S. K., Srirangam, R. & Upadhye, S. B. 
Applications of hot-melt extrusion for drug delivery. Expert Opin. Drug Deliv. 5, 
1357–1376 (2008). 
78. Kelleher, J. F. et al. A comparative study between hot-melt extrusion and spray-drying 
for the manufacture of anti-hypertension compatible monolithic fixed-dose 
combination products. Int. J. Pharm. 545, 183–196 (2018). 
79. Dedroog, S., Huygens, C. & Van den Mooter, G. Chemically identical but physically 
different: A comparison of spray drying, hot melt extrusion and cryo-milling for the 
formulation of high drug loaded amorphous solid dispersions of naproxen. Eur. J. 
Pharm. Biopharm. 135, 1–12 (2019). 
80. Abreu-Villela, R., Schönenberger, M., Caraballo, I. & Kuentz, M. Early stages of drug 
crystallization from amorphous solid dispersion via fractal analysis based on chemical 
imaging. Eur. J. Pharm. Biopharm. 133, 122–130 (2018). 
81. Qian, F. et al. Is a distinctive single Tg a reliable indicator for the homogeneity of 
amorphous solid dispersion? Int. J. Pharm. 395, 232–235 (2010). 
82. Niederquell, A., Wyttenbach, N., Kuentz, M. & Panayiotou, C. Partial solvation 
parameters of drugs as a new thermodynamic tool for pharmaceutics. Pharmaceutics 
11, 1–17 (2019). 
83. Kennedy, J. W. Principles of Polymer Chemistry. Journal of the American Chemical 
Society vol. 76 (Cornell University Press, 1954). 
84. Jankovic, S. et al. Application of the solubility parameter concept to assist with oral 
delivery of poorly water-soluble drugs – a PEARRL review. J. Pharm. Pharmacol. 71, 
441–463 (2019). 
85. Hansen, C. M. The Three Dimensional Solubility Parameter and Solvent Diffusion 
Coefficient. Their Importance in Surface Coating Formulation. (Danish Technical 
Press, 1967). 
86. Kalam, M. A. et al. Solubility Measurement and Various Solubility Parameters of 
Glipizide in Different Neat Solvents. ACS Omega 5, 1708–1716 (2020). 
87. He, H. et al. Thermodynamic modelling and Hansen solubility parameter of N-
hydroxy-5-norbornene-2,3-dicarboximide in twelve pure solvents at various 
temperatures. J. Mol. Liq. 300, (2020). 
88. Venkatram, S., Kim, C., Chandrasekaran, A. & Ramprasad, R. Critical Assessment of 
the Hildebrand and Hansen Solubility Parameters for Polymers. J. Chem. Inf. Model. 
59, 4188–4194 (2019). 
89. Greenhalgh, D. J., Williams, A. C., Timmins, P. & York, P. Solubility parameters as 
predictors of miscibility in solid dispersions. J. Pharm. Sci. 88, 1182–1190 (1999). 
90. Marsac, P. J., Shamblin, S. L. & Taylor, L. S. Theoretical and Practical Approaches for 
Prediction of Drug–Polymer Miscibility and Solubility. Pharm. Res. 23, 2417–2426 
(2006). 
91. Guan, J. et al. Synergetic effect of nucleation and crystal growth inhibitor on in vitro-in 
vivo performance of supersaturable lacidipine solid dispersion. Int. J. Pharm. 566, 
 143 
 
594–603 (2019). 
92. Salem, A., Nagy, S., Pál, S. & Széchenyi, A. Reliability of the Hansen solubility 
parameters as co-crystal formation prediction tool. Int. J. Pharm. 558, 319–327 (2019). 
93. Turpin, E. R. et al. In Silico Screening for Solid Dispersions: The Trouble with 
Solubility Parameters and FH. Mol. Pharm. 15, 4654–4667 (2018). 
94. Niederquell, A., Wyttenbach N., Kuentz, M., Niederquell, A., Wyttenbach, N. & 
Kuentz, M. New prediction methods for solubility parameters based on molecular 
sigma profiles using pharmaceutical materials. Int. J. Pharm. 546, 137–144 (2018). 
95. Han, R. et al. Predicting physical stability of solid dispersions by machine learning 
techniques. J. Control. Release 311–312, 16–25 (2019). 
96. Gupta, P., Chawla, G. & Bansal, A. K. Physical Stability and Solubility Advantage 
from Amorphous Celecoxib: The Role of Thermodynamic Quantities and Molecular 
Mobility. Mol. Pharm. 1, 406–413 (2004). 
97. Price, D. J. et al. Approaches to increase mechanistic understanding and aid in the 
selection of precipitation inhibitors for supersaturating formulations – a PEARRL 
review. J. Pharm. Pharmacol. 71, 483–509 (2019). 
98. Frank, D. S. & Matzger, A. J. Effect of Polymer Hydrophobicity on the Stability of 
Amorphous Solid Dispersions and Supersaturated Solutions of a Hydrophobic 
Pharmaceutical. Mol. Pharm. 16, 682–688 (2019). 
99. Frank, K. J. et al. What is the mechanism behind increased permeation rate of a poorly 
soluble drug from aqueous dispersions of an amorphous solid dispersion? J. Pharm. 
Sci. 103, 1779–1786 (2014). 
100. Frank, K. J. et al. Amorphous solid dispersion enhances permeation of poorly soluble 
ABT-102: True supersaturation vs. apparent solubility enhancement. Int. J. Pharm. 
437, 288–293 (2012). 
101. Harmon, P., Galipeau, K., Xu, W., Brown, C. & Wuelfing, W. P. Mechanism of 
Dissolution-Induced Nanoparticle Formation from a Copovidone-Based Amorphous 
Solid Dispersion. Mol. Pharm. 13, 1467–1481 (2016). 
102. Alhalaweh, A., Alzghoul, A. & Kaialy, W. Data mining of solubility parameters for 
computational prediction of drug–excipient miscibility. Drug Dev. Ind. Pharm. 40, 
904–909 (2014). 
103. Kanzer, J. et al. In situ formation of nanoparticles upon dispersion of melt extrudate 
formulations in aqueous medium assessed by asymmetrical flow field-flow 
fractionation. J. Pharm. Biomed. Anal. 53, 359–365 (2010). 
104. Trasi, N. S. & Taylor, L. S. Thermodynamics of Highly Supersaturated Aqueous 
Solutions of Poorly Water-Soluble Drugs - Impact of a Second Drug on the Solution 
Phase Behavior and Implications for Combination Products. J. Pharm. Sci. 104, 2583–
2593 (2015). 
105. Sun, D. D., Wen, H. & Taylor, L. S. Non-Sink Dissolution Conditions for Predicting 
Product Quality and In Vivo Performance of Supersaturating Drug Delivery Systems. 
J. Pharm. Sci. 105, 2477–2488 (2016). 
106. Hate, S. S., Reutzel-Edens, S. M. & Taylor, L. S. Insight into Amorphous Solid 
Dispersion Performance by Coupled Dissolution and Membrane Mass Transfer 
Measurements. Mol. Pharm. 16, 448–461 (2019). 
107. Saboo, S., Mugheirbi, N. A., Zemlyanov, D. Y., Kestur, U. S. & Taylor, L. S. 
Congruent release of drug and polymer: A “sweet spot” in the dissolution of 
amorphous solid dispersions. J. Control. Release 298, 68–82 (2019). 
108. Ma, X. & Williams, R. O. Characterization of amorphous solid dispersions: An update. 
J. Drug Deliv. Sci. Technol. 50, 113–124 (2019). 
109. Baghel, S., Cathcart, H. & O’Reilly, N. J. Polymeric Amorphous Solid Dispersions: A 
 144 
 
Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, 
and Aqueous Solubilization of Biopharmaceutical Classification System Class II 
Drugs. J. Pharm. Sci. 105, 2527–2544 (2016). 
110. Medarević, D., Djuriš, J., Barmpalexis, P., Kachrimanis, K. & Ibrić, S. Analytical and 
computational methods for the estimation of drug-polymer solubility and miscibility in 
solid dispersions development. Pharmaceutics 11, 1–33 (2019). 
111. Ibrahim, M., Zhang, J., Repka, M. & Chen, R. Characterization of the Solid Physical 
State of API and Its Distribution in Pharmaceutical Hot Melt Extrudates Using 
Terahertz Raman Imaging. AAPS PharmSciTech 20, 1–8 (2019). 
112. Yang, F. et al. Rheology Guided Rational Selection of Processing Temperature to 
Prepare Copovidone-Nifedipine Amorphous Solid Dispersions via Hot Melt Extrusion 
(HME). Mol. Pharm. 13, 3494–3505 (2016). 
113. Ito, A. et al. Prediction of recrystallization behavior of 
troglitazone/polyvinylpyrrolidone solid dispersion by solid-state NMR. Int. J. Pharm. 
383, 18–23 (2010). 
114. Yang, F. et al. Rheological and solid-state NMR assessments of 
copovidone/clotrimazole model solid dispersions. Int. J. Pharm. 500, 20–31 (2016). 
115. Purohit, H. S. et al. Insights into Nano- and Micron-Scale Phase Separation in 
Amorphous Solid Dispersions Using Fluorescence-Based Techniques in Combination 
with Solid State Nuclear Magnetic Resonance Spectroscopy. Pharm. Res. 34, 1364–
1377 (2017). 
116. Saboo, S. & Taylor, L. S. Water-induced phase separation of miconazole-poly 
(vinylpyrrolidone-co-vinyl acetate) amorphous solid dispersions: Insights with confocal 
fluorescence microscopy. Int. J. Pharm. 529, 654–666 (2017). 
117. Wilson, V. et al. Relationship between amorphous solid dispersion In Vivo absorption 
and In Vitro dissolution: phase behavior during dissolution, speciation, and membrane 
mass transport. J. Control. Release 292, 172–182 (2018). 
118. Reufer, M. et al. Introducing diffusing wave spectroscopy as a process analytical tool 
for pharmaceutical emulsion manufacturing. J. Pharm. Sci. 103, 3902–3913 (2014). 
119. Lauer, M. E. et al. Atomic force microscopy-based screening of drug-excipient 
miscibility and stability of solid dispersions. Pharm. Res. 28, 572–584 (2011). 
120. Szente, V., Süvegh, K., Marek, T. & Zelkó, R. Prediction of the stability of polymeric 
matrix tablets containing famotidine from the positron annihilation lifetime 
distributions of their physical mixtures. J. Pharm. Biomed. Anal. 49, 711–714 (2009). 
121. Lakowicz, J. R. Principles of Fluorescence Spectroscopy Principles of Fluorescence 
Spectroscopy. Principles of fluorescence spectroscopy, Springer, New York, USA, 3rd 
edn, 2006. (Springer New York, 2006). doi:10.1007/978-0-387-46312-4. 
122. Purohit, H. S. & Taylor, L. S. Phase separation kinetics in amorphous solid dispersions 
upon exposure to water. Mol. Pharm. 12, 1623–1635 (2015). 
123. Purohit, H. S. & Taylor, L. S. Miscibility of Itraconazole-Hydroxypropyl 
Methylcellulose Blends: Insights with High Resolution Analytical Methodologies. Mol. 
Pharm. 12, 4542–4553 (2015). 
124. Tian, B., Tang, X. & Taylor, L. S. Investigating the Correlation between Miscibility 
and Physical Stability of Amorphous Solid Dispersions Using Fluorescence-Based 
Techniques. Mol. Pharm. 13, 3988–4000 (2016). 
125. Tres, F., Hall, S. D., Mohutsky, M. A. & Taylor, L. S. Monitoring the Phase Behavior 
of Supersaturated Solutions of Poorly Water-Soluble Drugs Using Fluorescence 
Techniques. Journal of Pharmaceutical Sciences vol. 107 94–102 (Elsevier). 
126. Ricarte, R. G. et al. Recent Advances in Understanding the Micro- and Nanoscale 
Phenomena of Amorphous Solid Dispersions. Mol. Pharm. 16, 4089–4103 (2019). 
 145 
 
127. Purohit, H. S. & Taylor, L. S. Phase Behavior of Ritonavir Amorphous Solid 
Dispersions during Hydration and Dissolution. Pharm. Res. 34, 2842–2861 (2017). 
128. Sivadasan, K. & Somasundaran, P. Polymer-surfactant interactions and the association 
behavior of hydrophobically modified hydroxyethylcellulose. Colloids and Surfaces 
49, 229–239 (1990). 
129. Furst, E. M. & Squires, T. M. Microrheology. (OUP Oxford, 2017). 
130. Pine, D. J., Weitz, D. A., Chaikin, P. M. & Herbolzheimer, E. Diffusing wave 
spectroscopy. Phys. Rev. Lett. 60, 1134–1137 (1988). 
131. Pine, D. J., Weitz, D. A., Zhu, J. X. & Herbolzheimer, E. Diffusing-wave spectroscopy: 
dynamic light scattering in the multiple scattering limit. J. Phys. 51, 2101–2127 (1990). 
132. Mason, T. G. & Weitz, D. A. Optical Measurements of Frequency-Dependent Linear 
Viscoelastic Moduli of Complex Fluids. Phys. Rev. Lett. 74, 1250–1253 (1995). 
133. Maret, G. Diffusing-wave spectroscopy. Curr. Opin. Colloid Interface Sci. 2, 251–257. 
134. Fluctuations, D. et al. Diffusing-wave spectroscopy : The technique and some 
applications Diffusing-Wave Spectroscopy : The Technique and Some Applications. 
(1993). 
135. Dasgupta, B. R., Tee, S.-Y., Crocker, J. C., Frisken, B. J. & Weitz, D. A. 
Microrheology of polyethylene oxide using diffusing wave spectroscopy and single 
scattering. Phys. Rev. E 65, 051505 (2002). 
136. Constantin, D., Knaebel, A., Bellour, M., Padding, J. T. & Boek, E. S. Microrheology 
of giant-micelle solutions. (2002). 
137. Narita, T. & Indei, T. Microrheological study of physical gelation in living polymeric 
networks. Macromolecules 49, 4634–4646 (2016). 
138. Veerman, C. et al. Gelation kinetics of β-hairpin peptide hydrogel networks. 
Macromolecules 39, 6608–6614 (2006). 
139. Schultz, K. M., Baldwin, A. D., Kiick, K. L. & Furst, E. M. Gelation of covalently 
cross-linked PEG-heparin hydrogels. Macromolecules 42, 5310–5315 (2009). 
140. Palmer, A., Xu, J. & Wirtz, D. High-frequency viscoelasticity of crosslinked actin 
filament networks measured by diffusing wave spectroscopy. Rheol. Acta 37, 97–106 
(1998). 
141. Xu, J., Viasnoff, V. & Wirtz, D. Compliance of actin filament networks measured by 
particle-tracking microrheology and diffusing wave spectroscopy. Rheol. Acta 37, 387–
398 (1998). 
142. Palmer, A., Mason, T. G., Xu, J., Kuo, S. C. & Wirtz, D. Diffusing wave spectroscopy 
microrheology of actin filament networks. Biophys. J. 76, 1063–1071 (1999). 
143. Rigato, A., Miyagi, A., Scheuring, S. & Rico, F. High-frequency microrheology reveals 
cytoskeleton dynamics in living cells. Nat. Phys. 13, 771–775 (2017). 
144. Moschakis, T., Murray, B. S. & Biliaderis, C. G. Modifications in stability and 
structure of whey protein-coated o/w emulsions by interacting chitosan and gum arabic 
mixed dispersions. Food Hydrocoll. 24, 8–17 (2010). 
145. Moschakis, T., Murray, B. S. & Dickinson, E. Particle tracking using confocal 
microscopy to probe the microrheology in a phase-separating emulsion containing 
nonadsorbing polysaccharide. Langmuir 22, 4710–4719 (2006). 
146. Blijdenstein, T. B. J., Hendriks, W. P. G., Van der Linden, E., Van Vliet, T. & Van 
Aken, G. A. Control of strength and stability of emulsion gels by a combination of 
long- and short-range interactions. Langmuir 19, 6657–6663 (2003). 
147. Blijdenstein, T. B. J., Veerman, C. & Van Der Linden, E. Depletion - Flocculation in 
oil-in-water emulsions using fibrillar protein assemblies. Langmuir 20, 4881–4884 
(2004). 
148. Xu, D., Aihemaiti, Z., Cao, Y., Teng, C. & Li, X. Physicochemical stability, 
 146 
 
microrheological properties and microstructure of lutein emulsions stabilized by 
multilayer membranes consisting of whey protein isolate, flaxseed gum and chitosan. 
Food Chem. 202, 156–164 (2016). 
149. Xu, D., Zhang, J., Cao, Y., Wang, J. & Xiao, J. Influence of microcrystalline cellulose 
on the microrheological property and freeze-thaw stability of soybean protein 
hydrolysate stabilized curcumin emulsion. LWT - Food Sci. Technol. 66, 590–597 
(2016). 
150. Eliot, C., Horne, D. S. & Dickinson, E. Understanding temperature-sensitive caseinate 
emulsions: New information from diffusing wave spectroscopy. Food Hydrocoll. 19, 
279–287 (2005). 
151. Liu, J., Verespej, E., Alexander, M. & Corredig, M. Comparison on the effect of high-
methoxyl pectin or soybean-soluble polysaccharide on the stability of sodium 
casemate-stabilized oil/water emulsions. J. Agric. Food Chem. 55, 6270–6278 (2007). 
152. Kim, H. S., Şenbil, N., Zhang, C., Scheffold, F. & Mason, T. G. Diffusing wave 
microrheology of highly scattering concentrated monodisperse emulsions. Proc. Natl. 
Acad. Sci. U. S. A. 116, 7766–7771 (2019). 
153. Niederquell, A., Völker, A. C. & Kuentz, M. Introduction of diffusing wave 
spectroscopy to study self-emulsifying drug delivery systems with respect to liquid 
filling of capsules. Int. J. Pharm. 426, 144–152 (2012). 
154. Hörter, D. & Dressman, J. B. Influence of physicochemical properties on dissolution of 
drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev. 25, 3–14 (1997). 
155. Zaheer, K. & Langguth, P. Formulation strategy towards minimizing viscosity 
mediated negative food effect on disintegration and dissolution of immediate release 
tablets. Drug Dev. Ind. Pharm. 44, 444–451 (2018). 
156. Silchenko, S. et al. In vitro dissolution absorption system (IDAS2): Use for the 
prediction of food viscosity effects on drug dissolution and absorption from oral solid 
dosage forms. Eur. J. Pharm. Sci. 143, 105164 (2020). 
157. D’Arcy, D. M. & Persoons, T. Understanding the Potential for Dissolution Simulation 
to Explore the Effects of Medium Viscosity on Particulate Dissolution. AAPS 
PharmSciTech 20, 1–13 (2019). 
158. Van Renterghem, J., Vervaet, C. & De Beer, T. Rheological Characterization of Molten 
Polymer-Drug Dispersions as a Predictive Tool for Pharmaceutical Hot-Melt Extrusion 
Processability. Pharm. Res. 34, 2312–2321 (2017). 
159. Sarabu, S. et al. Hypromellose acetate succinate based amorphous solid dispersions via 
hot melt extrusion: Effect of drug physicochemical properties. Carbohydr. Polym. 233, 
115828 (2020). 
160. Hansen, C. M. Hansen solubility parameter a user’s handbook. (CRC Press, 2007). 
161. Hancock, B., York, P. & Rowe, R. The use of solubility parameters in pharmaceutical 
dosage form design. Int. J. Pharm. 148, 1–21 (1997). 
162. Kuentz, M., Holm, R. & Elder, D. P. Methodology of oral formulation selection in the 
pharmaceutical industry. Eur. J. Pharm. Sci. 87, 136–163 (2016). 
163. Hildebrand, J. H. & Scott, R. L. Solubility of nonelectrolytes. (Dover, 1964). 
164. Stefanis, E. & Panayiotou, C. Prediction of Hansen Solubility Parameters with a New 
Group-Contribution Method. Int. J. Thermophys. 29, 568–585 (2008). 
165. Just, S., Sievert, F., Thommes, M. & Breitkreutz, J. J. Improved group contribution 
parameter set for the application of solubility parameters to melt extrusion. Eur. J. 
Pharm. Biopharm. 85, 1191–1199 (2013). 
166. Díaz, I., Díez, E., Camacho, J., León, S. & Ovejero, G. Comparison between three 
predictive methods for the calculation of polymer solubility parameters. Fluid Phase 
Equilib. 337, 6–10 (2013). 
 147 
 
167. Panayiotou, C., Mastrogeorgopoulos, S., Aslanidou, D., Avgidou, M. & 
Hatzimanikatis, V. Redefining solubility parameters: Bulk and surface properties from 
unified molecular descriptors. J. Chem. Thermodyn. 111, 207–220 (2017). 
168. Louwerse, M. J. et al. Revisiting Hansen Solubility Parameters by Including 
Thermodynamics. ChemPhysChem 18, 2999–3006 (2017). 
169. Bustamante, P., Peña, M. A. & Barra, J. The modified extended Hansen method to 
determine partial solubility parameters of drugs containing a single hydrogen bonding 
group and their sodium derivatives: benzoic acid/Na and ibuprofen/Na. Int. J. Pharm. 
194, 117–124 (2000). 
170. Bashimam, M. Hansen solubility parameters : A quick review in pharmaceutical aspect. 
J. Chem. Pharm. Res. 7, 597–599 (2015). 
171. Scatchard, G. Equilibria in Non-electrolyte Solutions in Relation to the Vapor 
Pressures and Densities of the Components. Chem. Rev. 8, 321–333 (1931). 
172. Hildebrand, J. H. & Wood, S. E. The Derivation of Equations for Regular Solutions. J. 
Chem. Phys. 1, 817 (1933). 
173. Biroa, J., Zeman, L. & Patterson, D. Prediction of the x Parameter by the Solubility 
Parameter and Corresponding States Theories. Macromolecules 4, 30–35 (1971). 
174. Barton, A. Handbook of solubility parameters and other cohesion parameters. (CRC 
Press, 1991). 
175. Brown, H. C. & Grayson, M. Homomorphs of 2,6-Dimethyl-t-butylbenzene 1,2. J. Am. 
Chem. Soc. 75, 20–24 (1953). 
176. Brown, H. C. et al. Strained Homomorphs. 1 14. General Summary. J. Am. Chem. Soc. 
75, 1–6 (1953). 
177. Blanks, R. F. & Prausnitz, J. M. Thermodynamics of Polymer Solubility in Polar and 
Nonpolar Systems. Ind. Eng. Chem. Fundam. 3, 1–8 (1964). 
178. Hansen, C.M., Skaarup, K. Independent calculation of the parameter components. J. 
Paint. Technol. 37, 511–515 (1967). 
179. Hansen, C.M., Beerbower, C. H. Solubility parameters. Kirk-Othmer Encyclopedia of 
Chemical Technology (1971). 
180. Hansen, C. M. 50 Years with solubility parameters—past and future. Prog. Org. 
Coatings 51, 77–84 (2004). 
181. Small, P. A. Some factors affecting the solubility of polymers. J. Appl. Chem. 3, 71–80 
(2007). 
182. Sorenson, P. Application of the acid/base concept describing the interaction between 
pigments, binders, and solvents. J. Paint Technol. 47, 31 (1975). 
183. Beerbower, A., Wu, P. L. & Martin, A. Expanded Solubility Parameter Approach I: 
Naphthalene and Benzoic Acid in Individual Solvents. J. Pharm. Sci. 73, 179–188 
(1984). 
184. Barra, J., Peña, M.-A. & Bustamante, P. Proposition of group molar constants for 
sodium to calculate the partial solubility parameters of sodium salts using the van 
Krevelen group contribution method. Eur. J. Pharm. Sci. 10, 153–161 (2000). 
185. Verheyen, S., Augustijns, P., Kinget, R. & Van den Mooter, G. Determination of 
partial solubility parameters of five benzodiazepines in individual solvents. Int. J. 
Pharm. 228, 199–207 (2001). 
186. Bustamante, P., Escalera, B., Martin, A. & Selles, E. A Modification of the Extended 
Hildebrand Approach to Predict the Solubility of Structurally Related Drugs in Solvent 
Mixtures. J. Pharm. Pharmacol. 45, 253–257 (1993). 
187. Jouyban, A. & Acree, W. E. Comments on “Prediction of Drug Solubility in Lipid 
Mixtures from the Individual Ingredients”. AAPS PharmSciTech 15, 83–85 (2014). 
188. Vay, K., Scheler, S. & Frieß, W. Application of Hansen solubility parameters for 
 148 
 
understanding and prediction of drug distribution in microspheres. Int. J. Pharm. 416, 
202–209 (2011). 
189. Muela, S., Escalera, B., Peña, M. Á. & Bustamante, P. Influence of temperature on the 
solubilization of thiabendazole by combined action of solid dispersions and co-
solvents. Int. J. Pharm. 384, 93–99 (2010). 
190. Kitak, T. et al. Determination of solubility parameters of ibuprofen and ibuprofen 
lysinate. Molecules 20, 21549–21568 (2015). 
191. Howell, J., Roesing, M. & Boucher, D. A Functional Approach to Solubility Parameter 
Computations. J. Phys. Chem. B 121, 4191–4201 (2017). 
192. Archer, W. L. Determination of Hansen solubility parameters for selected cellulose 
ether derivatives. Ind. Eng. Chem. Res. 30, 2292–2298 (1991). 
193. Janssen. Development of a semi-automated system for the determination of the Hansen 
solubility parameters of pharmaceutical excipients. Unpublished Data (2015). 
194. Abbott, S., Hansen, C., & Yamamoto, H. (2017). Hansen Solubility Parameters in 
Practice, HSPiP, a package of software, datasets and eBook. (2017). 
195. Klar, F. & Urbanetz, N. A. Solubility parameters of hypromellose acetate succinate and 
plasticization in dry coating procedures. Drug Dev. Ind. Pharm. 42, 1621–1635 (2016). 
196. Bustamante, P., Peña, M. A. & Barra, J. Partial solubility parameters of piroxicam and 
niflumic acid. Int. J. Pharm. 174, 141–150 (1998). 
197. Martin, A., Wu, P. L., Adjei, A., Beerbower, A. & Prausnitz, J. M. Extended Hansen 
Solubility Approach: Naphthalene in Individual Solvents. J. Pharm. Sci. 70, 1260–
1264 (1981). 
198. Van Dyk, J. W., Frisch, H. L. & Wu, D. T. Solubility, solvency, and solubility 
parameters. Ind. Eng. Chem. Prod. Res. Dev. 24, 473–478 (1985). 
199. Segarceanu, O. & Leca, M. Improved method to calculate Hansen solubility parameters 
of a polymer. Prog. Org. Coatings 31, 307–310 (1997). 
200. Kent, D. J. & Rowe, R. C. Solubility studies on ethyl cellulose used in film coating. J. 
Pharm. Pharmacol. 30, 808–810 (1978). 
201. Han, K. H., Jeon, G. S., Hong, I. K. & Lee, S. B. Prediction of solubility parameter 
from intrinsic viscosity. J. Ind. Eng. Chem. 19, 1130–1136 (2013). 
202. Bustamante, P., Navarro-Lupión, J. & Escalera, B. A new method to determine the 
partial solubility parameters of polymers from intrinsic viscosity. Eur. J. Pharm. Sci. 
24, 229–237 (2005). 
203. Madsen, C. G. et al. Simple measurements for prediction of drug release from polymer 
matrices – Solubility parameters and intrinsic viscosity. Eur. J. Pharm. Biopharm. 92, 
1–7 (2015). 
204. Weerachanchai, P., Wong, Y., Lim, K. H., Tan, T. T. Y. & Lee, J.-M. Determination of 
Solubility Parameters of Ionic Liquids and Ionic Liquid/Solvent Mixtures from 
Intrinsic Viscosity. ChemPhysChem 15, 3580–3591 (2014). 
205. Mieczkowski, R. The determination of the solubility parameter components of 
polystyrene by partial specific volume measurements. Eur. Polym. J. 24, 1185–1189 
(1988). 
206. Ravindra, R., Krovvidi, K. R. & Khan, A. A. Solubility parameter of chitin and 
chitosan. Carbohydr. Polym. 36, 121–127 (1998). 
207. Mieczkowski, R. The determination of the solubility parameter components of 
polystyrene. Eur. Polym. J. 25, 1055–1057 (1989). 
208. Mieczkowski, R. Solubility parameter components of some polyols. Eur. Polym. J. 27, 
377–379 (1991). 
209. Huang, J.-C. Methods to determine solubility parameters of polymers at high 
temperature using inverse gas chromatography. J. Appl. Polym. Sci. 94, 1547–1555 
 149 
 
(2004). 
210. DiPaola-Baranyi, G. & Guillet, J. E. Estimation of Polymer Solubility Parameters by 
Gas Chromatography. Macromolecules 11, 228–235 (1978). 
211. Ito, K. & Guillet, J. E. Estimation of Solubility Parameters for Some Olefin Polymers 
and Copolymers by Inverse Gas Chromatography. Macromolecules 12, 1163–1167 
(1979). 
212. Adamska, K. & Voelkel, A. Hansen solubility parameters for polyethylene glycols by 
inverse gas chromatography. J. Chromatogr. A 1132, 260–267 (2006). 
213. Choi, P., Kavassalis, T. & Rudin, A. Measurement of Three-Dimensional Solubility 
Parameters of Nonyl Phenol Ethoxylates Using Inverse Gas Chromatography. J. 
Colloid Interface Sci. 180, 1–8 (1996). 
214. Adamska, K. & Voelkel, A. Inverse gas chromatographic determination of solubility 
parameters of excipients. Int. J. Pharm. 304, 11–17 (2005). 
215. Wang, Q., Chen, Y., Tang, J. & Zhang, Z. Determination of the Solubility Parameter of 
Epoxidized Soybean Oil by Inverse Gas Chromatography. J. Macromol. Sci. Part B 52, 
1405–1413 (2013). 
216. Adamska, K., Bellinghausen, R. & Voelkel, A. New procedure for the determination of 
Hansen solubility parameters by means of inverse gas chromatography. J. Chromatogr. 
A 1195, 146–149 (2008). 
217. Price, G. J. & Shillcock, I. M. Inverse gas chromatographic measurement of solubility 
parameters in liquid crystalline systems. J. Chromatogr. A 964, 199–204 (2002). 
218. Cakar, F., Yazici, O., Bilgin-Eran, B., Cankurtaran, O. & Karaman, F. Physicochemical 
characterization of 5-Decyloxy-2-[[[4-Hexyloxyphenyl] Imino] Methyl] Phenol liquid 
crystal by inverse gas chromatography. Optoelectron. Adv. Mater. Commun. 2, 871–
875 (2008). 
219. Liu, G. et al. Crystallization of Piroxicam Solid Forms and the Effects of Additives. 
Chem. Eng. Technol. 37, 1297–1304 (2014). 
220. Langer, S. H., Sheehan, R. J. & Huang, J. C. Gas-chromatographic study of the 
solution thermodynamics of hydroxylic derivatives and related compounds. J. Phys. 
Chem. 86, 4605–4618 (1982). 
221. Coca, J., Rodriguez, J. L., Medina, I. & Langer, S. H. Thermodynamic properties of 
some organic compounds with tetrachloroterephthaloyl oligomers by gas 
chromatography. J. Chem. Eng. Data 34, 280–284 (1989). 
222. Voelkel, A., Milczewska, K. & Jȩczalik, J. Characterization of the interactions in 
polymer/silica systems by inverse gas chromatography. Macromol. Symp. 169, 45–55 
(2001). 
223. Voelkel, A. & Fall, J. Influence of prediction method of the second virial coefficient on 
inverse gas chromatographic parameters. J. Chromatogr. A 721, 139–145 (1996). 
224. Price, G. J., Guillet, J. E. & Purnell, J. H. Measurement of solubility parameters by gas-
liquid chromatrography. J. Chromatogr. A 369, 273–280 (1986). 
225. Voelkel, A. & Grześkowiak, T. Properties of zirconate modificates of silica gel as 
examined by inverse gas chromatography. Macromol. Symp. 169, 35–44 (2001). 
226. Voelkel, A. & Janas, J. Solubility parameters of broad and narrow distributed 
oxyethylates of fatty alcohols. J. Chromatogr. A 645, 141–151 (1993). 
227. Panayiotou, C. G. Inverse gas chromatography and partial solvation parameters. J. 
Chromatogr. A 1251, 194–207 (2012). 
228. Çavus, S., Çakal, E. & Sevgili, L. M. Solvent dependent swelling behaviour of poly(N-
vinylcaprolactam) and poly(N-vinylcaprolactam-co-itaconic acid) gels and 
determination of solubility parameters. Chem. Pap. 69, 1367–1377 (2015). 
229. Bristow, G. M. & Watson, W. F. Cohesive energy densities of polymers: Part 1. - 
 150 
 
Cohesive energy densities of rubbers by swelling measurements. Trans. Faraday Soc. 
54, 1731–1741 (1958). 
230. Bristow, G. M. & Watson, W. F. Cohesive energy densities of polymers. Part 2.—
Cohesive energy densities from viscosity measurements. Trans. Faraday Soc. 54, 
1742–1747 (1958). 
231. Aharoni, S. M. The solubility parameters of aromatic polyamides. J. Appl. Polym. Sci. 
45, 813–817 (1992). 
232. Eroǧlu, M. S., Baysal, B. M. & Güven, O. Determination of solubility parameters of 
poly(epichlorohydrin) and poly(glycidyl azide) networks. Polymer (Guildf). 38, 1945–
1947 (1997). 
233. Schenderlein, S., Lück, M. & Müller, B. W. Partial solubility parameters of poly(d,l-
lactide-co-glycolide). Int. J. Pharm. 286, 19–26 (2004). 
234. Suh, K. W. & Corbett, J. M. Solubility parameters of polymers from turbidimetric 
titrations. J. Appl. Polym. Sci. 12, 2359–2370 (1968). 
235. Suh, K. W. & Clarke, D. H. Cohesive energy densities of polymers from turbidimetric 
titrations. J. Polym. Sci. Part A-1 Polym. Chem. 5, 1671–1681 (1967). 
236. Lin, X., Jiang, G. & Wang, Y. Hansen Solubility Parameters of Coal Tar-Derived 
Typical PAHs Using Turbidimetric Titration and an Extended Hansen Approach. J. 
Chem. Eng. Data 62, 954–960 (2017). 
237. Carvalho, S. P., Lucas, E. F., González, G. & Spinelli, L. S. Determining Hildebrand 
Solubility Parameter by Ultraviolet Spectroscopy and Microcalorimetry. J. Braz. Chem. 
Soc. 24, 1998–2007 (2013). 
238. Gee, G. The interaction between rubber and liquids. II. The thermodynamical basis of 
the swelling and solution of rubber. Trans. Faraday Soc. 38, 276–282 (1942). 
239. Hoy, K. L. New values of the solubility parameters from vapor pressure data. J. Paint 
Technol. 42, 76–118 (1970). 
240. Fedors, R. F. A method for estimating both the solubility parameters and molar 
volumes of liquids. Polym. Eng. Sci. 14, 147–154 (1974). 
241. Krevelen, D. W. van (Dirk W. et al. Properties of polymers: their correlation with 
chemical structure; their numerical estimation and prediction from additive group 
contributions. (Elsevier, 2009). 
242. Stefanis, E. & Panayiotou, C. A new expanded solubility parameter approach. Int. J. 
Pharm. 426, 29–43 (2012). 
243. Forster, A., Hempenstall, J., Tucker, I. & Rades, T. Selection of excipients for melt 
extrusion with two poorly water-soluble drugs by solubility parameter calculation and 
thermal analysis. Int. J. Pharm. 226, 147–161 (2001). 
244. Shah, M. & Agrawal, Y. High throughput screening: an in silico solubility parameter 
approach for lipids and solvents in SLN preparations. Pharm. Dev. Technol. 18, 582–
590 (2013). 
245. Klamt, A. COSMO-RS: from quantum chemistry to fluid phase thermodynamics and 
drug design. (Elsevier, 2005). 
246. Gupta, J., Nunes, C., Vyas, S. & Jonnalagadda, S. Prediction of Solubility Parameters 
and Miscibility of Pharmaceutical Compounds by Molecular Dynamics Simulations. J. 
Phys. Chem. B 115, 2014–2023 (2011). 
247. Ruether, F. & Sadowski, G. Modeling the solubility of pharmaceuticals in pure 
solvents and solvent mixtures for drug process design. J. Pharm. Sci. 98, 4205–4215 
(2009). 
248. Jouyban, A., Fakhree, M. A. A. & Acree, W. E. Comment on “Measurement and 
Correlation of Solubilities of ( Z )-2-(2-Aminothiazol-4-yl)-2-methoxyiminoacetic Acid 
in Different Pure Solvents and Binary Mixtures of Water + (Ethanol, Methanol, or 
 151 
 
Glycol)”. J. Chem. Eng. Data 57, 1344–1346 (2012). 
249. Rogers, M. A. & Marangoni, A. G. Kinetics of 12-Hydroxyoctadecanoic Acid SAFiN 
Crystallization Rationalized Using Hansen Solubility Parameters. Langmuir 32, 
12833–12841 (2016). 
250. Zhu, Z., Snellings, G. M. B. F., Koebel, M. M. & Malfait, W. J. Superinsulating 
Polyisocyanate Based Aerogels: A Targeted Search for the Optimum Solvent System. 
ACS Appl. Mater. Interfaces 9, 18222–18230 (2017). 
251. Masurel, E., Authier, O., Castel, C. & Roizard, C. Screening method for solvent 
selection used in tar removal by the absorption process. Environ. Technol. 36, 2556–
2567 (2015). 
252. Cascant, M. M. et al. A green analytical chemistry approach for lipid extraction: 
computation methods in the selection of green solvents as alternative to hexane. Anal. 
Bioanal. Chem. 409, 3527–3539 (2017). 
253. Laboukhi-Khorsi, S., Daoud, K. & Chemat, S. Efficient Solvent Selection Approach 
for High Solubility of Active Phytochemicals: Application for the Extraction of an 
Antimalarial Compound from Medicinal Plants. ACS Sustain. Chem. Eng. 5, 4332–
4339 (2017). 
254. Sánchez-Camargo, A. P., Montero, L., Cifuentes, A., Herrero, M. & Ibáñez, E. 
Application of Hansen solubility approach for the subcritical and supercritical selective 
extraction of phlorotannins from Cystoseira abies-marina. RSC Adv. 6, 94884–94895 
(2016). 
255. Fardi, T., Stefanis, E., Panayiotou, C., Abbott, S. & van Loon, S. Artwork conservation 
materials and Hansen solubility parameters: A novel methodology towards critical 
solvent selection. J. Cult. Herit. 15, 583–594 (2014). 
256. Pudipeddi, M. & Serajuddin, A. T. M. Trends in Solubility of Polymorphs. J. Pharm. 
Sci. 94, 929–939 (2005). 
257. Liu, R. Water-Insoluble Drug Formulation. Water-Insoluble Drug Formulation vol. 
133 (Taylor & Francis Inc., 2008). 
258. Bauer, J. et al. Ritonavir: An Extraordinary Case of Conformational Polymorphism. 
Pharm. Res. 18, 859–866 (2001). 
259. Dinnebier, R. E., Sieger, P., Nar, H., Shankland, K. & David, W. I. F. Structural 
characterization of three crystalline modifications of telmisartan by single crystal and 
high-resolution X-ray powder diffraction. J. Pharm. Sci. 89, 1465–1479 (2000). 
260. Cimarosti, Z. et al. Development of Drug Substances as Mixture of Polymorphs: 
Studies to Control Form 3 in Casopitant Mesylate. Org. Process Res. Dev. 14, 1337–
1346 (2010). 
261. Stahl, P. . & Wermuth, C. G. Handbook of pharmaceutical salts. (Wiley-VCH, 2011). 
262. S.H. Neau. Pharmaceutical salts. in Water-insoluble drug formulation (ed. R. Liu) 
(Taylor & Francis Inc., 2008). 
263. Gould, P. L. Salt selection for basic drugs. Int. J. Pharm. 33, 201–217 (1986). 
264. Paulekuhn, G. S., Dressman, J. B. & Saal, C. Trends in Active Pharmaceutical 
Ingredient Salt Selection based on Analysis of the Orange Book Database. J. Med. 
Chem. 50, 6665–6672 (2007). 
265. Saal, C. & Becker, A. Pharmaceutical salts: A summary on doses of salt formers from 
the Orange Book. Eur. J. Pharm. Sci. 49, 614–623 (2013). 
266. Berge, S. M. et al. Pharmaceutical salts. J. Pharm. Sci. 66, 1–19 (1977). 
267. Haynes, D. A., Jones, W. & Motherwell, W. D. S. Occurrence of Pharmaceutically 
Acceptable Anions and Cations in the Cambridge Structural Database. J. Pharm. Sci. 
94, 2111–2120 (2005). 
268. Paulekuhn, G. S., Dressman, J. B. & Saal, C. Salt screening and characterization for 
 152 
 
poorly soluble, weak basic compounds: Case study albendazole. Pharmazie 68, 555–
564 (2013). 
269. Nechipadappu, S. K. & R. Trivedi, D. Pharmaceutical salts of ethionamide with GRAS 
counter ion donors to enhance the solubility. Eur. J. Pharm. Sci. 96, 578–589 (2017). 
270. Fini, A., Cavallari, C., Bassini, G., Ospitali, F. & Morigi, R. Diclofenac Salts, Part 7: 
Are the Pharmaceutical Salts with Aliphatic Amines Stable? J. Pharm. Sci. 101, 3157–
3168 (2012). 
271. Surov, A. O., Manin, A. N., Churakov, A. V. & Perlovich, G. L. New Solid Forms of 
the Antiviral Drug Arbidol: Crystal Structures, Thermodynamic Stability, and 
Solubility. Mol. Pharm. 12, 4154–4165 (2015). 
272. Elder, D. P. et al. The Utility of Sulfonate Salts in Drug Development. J. Pharm. Sci. 
99, 2948–2961 (2010). 
273. Saal, C. Weber, K.-D. F. Compositions of Anions and Cations with Pharmacological 
Activity. (2016). 
274. Balk, A. et al. Ionic liquid versus prodrug strategy to address formulation challenges. 
Pharm. Res. 32, 2154–2167 (2015). 
275. Frizzo, C. P. et al. Pharmaceutical Salts: Solids to Liquids by Using Ionic Liquid 
Design. in Ionic Liquids: New Aspects for the Future (ed. Kadokawa, J. B. T.-I. L.-N. 
A. for the F.) Ch. 21 (InTech, 2013). doi:10.5772/51655. 
276. Kumar, V. & Malhotra, S. V. Ionic Liquids as Pharmaceutical Salts: A Historical 
Perspective. in Ionic Liquid Applications: Pharmaceuticals, Therapeutics, and 
Biotechnology 1–12 (2010). doi:10.1021/bk-2010-1038.ch001. 
277. Hough, W. L. et al. The third evolution of ionic liquids: active pharmaceutical 
ingredients. New J. Chem. 31, 1429–1436 (2007). 
278. FDA. List of generally regarded as safe ingredients. 
http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/. 
279. Fernández Casares, A. et al. An evaluation of salt screening methodologies. J. Pharm. 
Pharmacol. 67, 812–822 (2015). 
280. Mohammad, M. A., Alhalaweh, A. & Velaga, S. P. Hansen solubility parameter as a 
tool to predict cocrystal formation. Int. J. Pharm. 407, 63–71 (2011). 
281. Shetea, A., Murthyb, S., Korpalea, S. Cocrystals of itraconazole with amino acids: 
Screening, synthesis, solid state characterization, in vitro drug release and antifungal 
activity. J. Drug Deliv. Sci. Technol. 28, 46–55 (2015). 
282. Yuriy A. Abramov. Computational Pharmaceutical Solid State Chemistry. (Wiley 
Online Library, 2016). 
283. Rane, S. S. & Anderson, B. D. What determines drug solubility in lipid vehicles: Is it 
predictable? Adv. Drug Deliv. Rev. 60, 638–656 (2008). 
284. Persson, L. C., Porter, C. J. H., Charman, W. N. & Bergström, C. A. S. Computational 
prediction of drug solubility in lipid based formulation excipients. Pharm. Res. 30, 
3225–3237 (2013). 
285. Patel, S. V. & Patel, S. Prediction of the solubility in lipidic solvent mixture: 
Investigation of the modeling approach and thermodynamic analysis of solubility. Eur. 
J. Pharm. Sci. 77, 161–169 (2015). 
286. Alskär, L. C. C., Porter, C. J. H. J. H. & Bergström, C. a S. A. S. Tools for Early 
Prediction of Drug Loading in Lipid-Based Formulations. Mol. Pharm. 13, 251–261 
(2016). 
287. Dumanli, I. Mechanistic studies to elucidate the role of lipid vehicles on 
solubility,formulation and bioavailability of poorly soluble compounds. (University of 
Rhode Island, 2002). 
288. Shah, N. H., Phuapradit, W., Zhang, Y.-E., Ahmed, H. & Malick, A. W. Oral Lipid-
 153 
 
Based Formulations - Enhancing the Bioavailability of Poorly Water-Soluble Drugs. 
(informa healthcare, 2007). 
289. Vaughan, C. D. Solubility parameters for characterizing new raw materials. Cosmet. 
Toilet. 108, 57–64 (1993). 
290. Van Loon. Van Loon Chemical Innovations Brochure. Van Loon Chemical Innovations 
Brochure. http://www.in-
cosmetics.com/__novadocuments/326978?v=636220595266800000. 
291. Yamamoto, D. H. Hansen Solubility Parameter (HSP) and Allergens for Cosmetics. 
Hansen Solubility Parameter (HSP) and Allergens for Cosmetics 
https://www.pirika.com/NewHP/PirikaE/Allergens.html. 
292. Vaughan, C. D. Using solubility parameters in cosmetics formulation. J. Soc. Cosmet. 
Chem 36, 19–333 (1985). 
293. De La Peña-Gil, A., Toro-Vazquez, J. F. & Rogers, M. A. Simplifying Hansen 
Solubility Parameters for Complex Edible Fats and Oils. Food Biophys. 11, 283–291 
(2016). 
294. Shah, M. & Agrawal, Y. Ciprofloxacin hydrochloride-loaded glyceryl monostearate 
nanoparticle: factorial design of Lutrol F68 and Phospholipon 90G. J. Microencapsul. 
29, 331–343 (2012). 
295. Li, Y., Taulier, N., Rauth, A. M. & Wu, X. Y. Screening of Lipid Carriers and 
Characterization of Drug-Polymer-Lipid Interactions for the Rational Design of 
Polymer-Lipid Hybrid Nanoparticles (PLN). Pharm. Res. 23, 1877–1887 (2006). 
296. Breitkreutz, J. Prediction of intestinal drug absorption properties by three-dimensional 
solubility parameters. (1997). 
297. Abd, E. 2015. Targeted Skin Delivery of Topically Applied Drugs by Optimised 
Formulation Design. (The University of Queensland, 2015). 
298. Hossin, B., Rizi, K. & Murdan, S. Application of Hansen Solubility Parameters to 
predict drug–nail interactions, which can assist the design of nail medicines. Eur. J. 
Pharm. Biopharm. 102, 32–40 (2016). 
299. Kawabata, Y., Wada, K., Nakatani, M., Yamada, S. & Onoue, S. Formulation design 
for poorly water-soluble drugs based on biopharmaceutics classification system: Basic 
approaches and practical applications. Int. J. Pharm. 420, 1–10 (2011). 
300. Einfalt, T., Planinšek, O. & Hrovat, K. Methods of amorphization and investigation of 
the amorphous state. Acta Pharm. 63, 305–334 (2013). 
301. Chiou, W. L. & Riegelman, S. Pharmaceutical applications of solid dispersion systems. 
J. Pharm. Sci. 60, 1281–1302 (1971). 
302. Zhang, J. & Ma, P. X. Cyclodextrin-based supramolecular systems for drug delivery: 
Recent progress and future perspective. Adv. Drug Deliv. Rev. 65, 1215–1233 (2013). 
303. Hoppu, P., Jouppila, K., Rantanen, J., Schantz, S. & Juppo, A. M. Characterisation of 
blends of paracetamol and citric acid. J. Pharm. Pharmacol. 59, 373–381 (2007). 
304. Simovic, S., Ghouchi-Eskandar, N., Moom Sinn, A., Losic, D. & A. Prestidge, C. 
Silica Materials in Drug Delivery Applications. Curr. Drug Discov. Technol. 8, 250–
268 (2011). 
305. Xu, W., Riikonen, J. & Lehto, V.-P. Mesoporous systems for poorly soluble drugs. Int. 
J. Pharm. 453, 181–197 (2013). 
306. Huang, Y. & Dai, W.-G. Fundamental aspects of solid dispersion technology for poorly 
soluble drugs. Acta Pharm. Sin. B 4, 18–25 (2014). 
307. Karavas, E., Georgarakis, E., Sigalas, M. P., Avgoustakis, K. & Bikiaris, D. 
Investigation of the release mechanism of a sparingly water-soluble drug from solid 
dispersions in hydrophilic carriers based on physical state of drug, particle size 
distribution and drug–polymer interactions. Eur. J. Pharm. Biopharm. 66, 334–347 
 154 
 
(2007). 
308. Sekiguchi, K. & Obi, N. Studies on Absorption of Eutectic Mixture. I. A Comparison 
of the Behavior of Eutectic Mixture of Sulfathiazole and that of Ordinary Sulfathiazole 
in Man. Chem. Pharm. Bull. 9, 866–872 (1961). 
309. Thakral, S. & Thakral, N. K. Prediction of Drug–Polymer Miscibility through the use 
of Solubility Parameter based Flory–Huggins Interaction Parameter and the 
Experimental Validation: PEG as Model Polymer. J. Pharm. Sci. 102, 2254–2263 
(2013). 
310. DeBoyace, K. & Wildfong, P. L. D. The Application of Modeling and Prediction to the 
Formation and Stability of Amorphous Solid Dispersions. J. Pharm. Sci. 107, 57–74 
(2017). 
311. Djuris, J., Nikolakakis, I., Ibric, S., Djuric, Z. & Kachrimanis, K. Preparation of 
carbamazepine–Soluplus® solid dispersions by hot-melt extrusion, and prediction of 
drug–polymer miscibility by thermodynamic model fitting. Eur. J. Pharm. Biopharm. 
84, 228–237 (2013). 
312. Sarode, A. L., Sandhu, H., Shah, N., Malick, W. & Zia, H. Hot melt extrusion (HME) 
for amorphous solid dispersions: Predictive tools for processing and impact of drug–
polymer interactions on supersaturation. Eur. J. Pharm. Sci. 48, 371–384 (2013). 
313. Meng, F., Trivino, A., Prasad, D. & Chauhan, H. Investigation and correlation of drug 
polymer miscibility and molecular interactions by various approaches for the 
preparation of amorphous solid dispersions. Eur. J. Pharm. Sci. 71, 12–24 (2015). 
314. Bagley, E. B., Nelson, T. P. & Scigliano, J. M. Three-dimensional solubility 
parameters and their relationship to internal pressure measurements in polar and 
hydrogen bonding solvents. J. Paint Technol. 43, 35–42 (1971). 
315. Meaurio, E. et al. Predicting miscibility in polymer blends using the Bagley plot: 
Blends with poly(ethylene oxide). Polymer (Guildf). 113, 295–309 (2017). 
316. Arrighi, V., Cabral, J., & Cowie, J. M. Miscibility. in Encyclopedia of Polymer Science 
and Technology (John Wiley & Sons, Inc., 2002). doi:10.1002/0471440264. 
317. Paudel, A., Van Humbeeck, J. & Van den Mooter, G. Theoretical and Experimental 
Investigation on the Solid Solubility and Miscibility of Naproxen in 
Poly(vinylpyrrolidone). Mol. Pharm. 7, 1133–1148 (2010). 
318. Qian, F. et al. Solution Behavior of PVP-VA and HPMC-AS-Based Amorphous Solid 
Dispersions and Their Bioavailability Implications. Pharm. Res. 29, 2766–2776 (2012). 
319. Tian, Y. et al. Construction of Drug–Polymer Thermodynamic Phase Diagrams Using 
Flory–Huggins Interaction Theory: Identifying the Relevance of Temperature and Drug 
Weight Fraction to Phase Separation within Solid Dispersions. Mol. Pharm. 10, 236–
248 (2013). 
320. Zhao, Y., Inbar, P., Chokshi, H. P., Malick, A. W. & Choi, D. S. Prediction of the 
Thermal Phase Diagram of Amorphous Solid Dispersions by Flory–Huggins Theory. J. 
Pharm. Sci. 100, 3196–3207 (2011). 
321. Koningsveld, R., Stockmayer, W. H. & Nies, E. Polymer phase diagrams: a textbook. 
(Oxford University Press, USA, 2001). 
322. O’Shea, J. P. et al. Mesoporous silica-based dosage forms improve bioavailability of 
poorly soluble drugs in pigs: case example fenofibrate. J. Pharm. Pharmacol. 69, 
1284–1292 (2017). 
323. Lainé, A.-L. et al. Enhanced oral delivery of celecoxib via the development of a 
supersaturable amorphous formulation utilising mesoporous silica and co-loaded 
HPMCAS. Int. J. Pharm. 512, 118–125 (2016). 
324. Van Speybroeck, M. et al. Enhanced absorption of the poorly soluble drug fenofibrate 
by tuning its release rate from ordered mesoporous silica. Eur. J. Pharm. Sci. 41, 623–
 155 
 
630 (2010). 
325. Dressman, J. B. et al. Mesoporous silica-based dosage forms improve release 
characteristics of poorly soluble drugs: case example fenofibrate. J. Pharm. 
Pharmacol. 68, 634–645 (2016). 
326. McCarthy, C. A., Ahern, R. J., Dontireddy, R., Ryan, K. B. & Crean, A. M. 
Mesoporous silica formulation strategies for drug dissolution enhancement: a review. 
Expert Opin. Drug Deliv. 13, 93–108 (2016). 
327. Hideo Hata, †, Shuuya Saeki, †, Tatsuo Kimura, †, Yoshiyuki Sugahara, † and & 
Kazuyuki Kuroda*, †. Adsorption of Taxol into Ordered Mesoporous Silicas with 
Various Pore Diameters. Chem. Mater. 11, 1110–1119 (1999). 
328. ICH Expert Working Group. Impurities: Guideline for residual solvents. 
https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3
C/Q3C_R6__Step_4.pdf (2016). 
329. Piccinni, P. et al. Solubility parameter-based screening methods for early-stage 
formulation development of itraconazole amorphous solid dispersions. J. Pharm. 
Pharmacol. 68, 705–720 (2016). 
330. Sun, J. et al. Effect of particle size on solubility, dissolution rate, and oral 
bioavailability: evaluation using coenzyme Q₁₀ as naked nanocrystals. Int. J. 
Nanomedicine 7, 5733–44 (2012). 
331. Williams, H. D. et al. Strategies to Address Low Drug Solubility in Discovery and 
Development. Pharmacol. Rev. 65, 315–499 (2013). 
332. Junghanns, J.-U. A. H. & Müller, R. H. Nanocrystal technology, drug delivery and 
clinical applications. Int. J. Nanomedicine 3, 295–309 (2008). 
333. Khadka, P. et al. Pharmaceutical particle technologies: An approach to improve drug 
solubility, dissolution and bioavailability. Asian J. Pharm. Sci. 9, 304–316 (2014). 
334. Rasenack, N. & Müller, B. W. Micron‐Size Drug Particles: Common and Novel 
Micronization Techniques. Pharm. Dev. Technol. 9, 1–13 (2004). 
335. Kundu, S. Silk biomaterials for tissue engineering and regenerative medicine. 
(Woodhead Publishing, 2014). 
336. Singh, A. K. Engineered nanoparticles: structure, properties and mechanisms of 
toxicity. (Academic Press, 2015). 
337. Merisko-Liversidge, E. M. & Liversidge, G. G. Drug Nanoparticles: Formulating 
Poorly Water-Soluble Compounds. Toxicol. Pathol. 36, 43–48 (2008). 
338. Date, A. A. & Patravale, V. B. Current strategies for engineering drug nanoparticles. 
Curr. Opin. Colloid Interface Sci. 9, 222–235 (2004). 
339. Wu, L., Zhang, J. & Watanabe, W. Physical and chemical stability of drug 
nanoparticles. Adv. Drug Deliv. Rev. 63, 456–469 (2011). 
340. Latere Dwan’Isa, J. P., Rouxhet, L., Préat, V., Brewster, M. E. & Ariën, A. Prediction 
of drug solubility in amphiphilic di-block copolymer micelles: The role of polymer-
drug compatibility. Pharmazie 62, 499–504 (2007). 
341. Mahmud, A. et al. Self-Associating Poly(ethylene oxide)- b -poly(α-cholesteryl 
carboxylate-ε-caprolactone) Block Copolymer for the Solubilization of STAT-3 
Inhibitor Cucurbitacin I. Biomacromolecules 10, 471–478 (2009). 
342. Khougaz, K. & Clas, S. D. Crystallization inhibiton in solid dispersions of MK-0591 
and poly(vinylpyrrolidone) polymers. J. Pharm. Sci. 89, 1325–1334 (2000). 
343. Tantishaiyakul, V., Kaewnopparat, N. & Ingkatawornwong, S. Properties of solid 
dispersions of piroxicam in polyvinylpyrrolidone K-30. Int. J. Pharm. 143, 59–66 
(1996). 
344. Masuda, T. et al. Cocrystallization and amorphization induced by drug–excipient 
interaction improves the physical properties of acyclovir. Int. J. Pharm. 422, 160–169 
 156 
 
(2012). 
345. Matsumoto, T. & Zografi, G. Physical Properties of Solid Molecular Dispersions of 
Indomethacin with Poly(vinylpyrrolidone) and Poly(vinylpyrrolidone-co-vinyl-acetate) 
in Relation to Indomethacin Crystallization. Pharm. Res. 16, 1722–1728 (1999). 
346. Deng, Z., Xu, S. & Li, S. Understanding a relaxation behavior in a nanoparticle 
suspension for drug delivery applications. Int. J. Pharm. 351, 236–243 (2008). 
347. Marsac, P. J. et al. Effect of temperature and moisture on the miscibility of amorphous 
dispersions of felodipine and poly(vinyl pyrrolidone). J. Pharm. Sci. 99, 169–185 
(2010). 
348. Ricarte, R. G., Lodge, T. P. & Hillmyer, M. A. Detection of pharmaceutical drug 
crystallites in solid dispersions by transmission electron microscopy. Mol. Pharm. 12, 
983–990 (2015). 
349. Ricarte, R. G. et al. Direct Observation of Nanostructures during Aqueous Dissolution 
of Polymer/Drug Particles. Macromolecules 50, 3143–3152 (2017). 
350. Frank, K. J., Locher, K., Zecevic, D. E., Fleth, J. & Wagner, K. G. In vivo predictive 
mini-scale dissolution for weak bases: Advantages of pH-shift in combination with an 
absorptive compartment. Eur. J. Pharm. Sci. 61, 32–39 (2014). 
351. Ilevbare, G. A. & Taylor, L. S. Liquid-liquid phase separation in highly supersaturated 
aqueous solutions of poorly water-soluble drugs: Implications for solubility enhancing 
formulations. Cryst. Growth Des. 13, 1497–1509 (2013). 
352. Indulkar, A. S., Lou, X., Zhang, G. G. Z. Z. & Taylor, L. S. Insights into the 
Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: 
Importance of Congruent Release for Enhanced Performance. Mol. Pharm. 16, 1327–
1339 (2019). 
353. Mosquera-Giraldo, L. I. & Taylor, L. S. Glass–Liquid Phase Separation in Highly 
Supersaturated Aqueous Solutions of Telaprevir. Mol. Pharm. 12, 496–503 (2015). 
354. Raina, S. A., Alonzo, D. E., Zhang, G. G. Z. Z., Gao, Y. & Taylor, L. S. Using 
Environment-Sensitive Fluorescent Probes to Characterize Liquid-Liquid Phase 
Separation in Supersaturated Solutions of Poorly Water Soluble Compounds. Pharm. 
Res. 32, 3660–3673 (2015). 
355. Tho, I. et al. Formation of nano/micro-dispersions with improved dissolution properties 
upon dispersion of ritonavir melt extrudate in aqueous media. Eur. J. Pharm. Sci. 40, 
25–32 (2010). 
356. Uchiyama, H., Tozuka, Y., Asamoto, F. & Takeuchi, H. Fluorescence investigation of 
a specific structure formed by aggregation of transglycosylated stevias: Solubilizing 
effect of poorly water-soluble drugs. Eur. J. Pharm. Sci. 43, 71–77 (2011). 
357. Van Drooge, D. J. et al. Characterization of the mode of incorporation of lipophilic 
compounds in solid dispersions at the nanoscale using Fluorescence Resonance Energy 
Transfer (FRET). Macromol. Rapid Commun. 27, 1149–1155 (2006). 
358. Negrini, R., Aleandri, S. & Kuentz, M. Study of Rheology and Polymer Adsorption 
Onto Drug Nanoparticles in Pharmaceutical Suspensions Produced by Nanomilling. J. 
Pharm. Sci. 106, 3395–3401 (2017). 
359. Chauhan, H., Hui-Gu, C. & Atef, E. Correlating the behavior of polymers in solution as 
precipitation inhibitor to its amorphous stabilization ability in solid dispersions. J. 
Pharm. Sci. 102, 1924–1935 (2013). 
360. Usui, F., Maeda, K., Kusai, A., Nishimura, K. & Yamamoto, K. Inhibitory effects of 
water-soluble polymers on precipitation of RS-8359. Int. J. Pharm. 154, 59–66 (1997). 
361. Raghavan, S. L., Trividic, A., Davis, A. F. & Hadgraft, J. Crystallization of 
hydrocortisone acetate: Influence of polymers. Int. J. Pharm. 212, 213–221 (2001). 
362. Alonzo, D. E. et al. Dissolution and precipitation behavior of amorphous solid 
 157 
 
dispersions. J. Pharm. Sci. 100, 3316–3331 (2011). 
363. Kanaujia, P. et al. Nanoparticle formation and growth during in vitro dissolution of 
ketoconazole solid dispersion. J. Pharm. Sci. 100, 2876–2885 (2011). 
364. Guo, Y., Shalaev, E. & Smith, S. Physical stability of pharmaceutical formulations: 
Solid-state characterization of amorphous dispersions. TrAC - Trends Anal. Chem. 49, 
137–144 (2013). 
365. Bodratti, A. & Alexandridis, P. Formulation of Poloxamers for Drug Delivery. J. 
Funct. Biomater. 9, 11 (2018). 
366. Tsinman, O., Tsinman, K. & Ali, S. Excipient update - soluplus®: An understanding of 
supersaturation from amorphous solid dispersions. Drug Dev. Deliv. 15, (2015). 
367. Shamma, R. N. & Basha, M. Soluplus®: A novel polymeric solubilizer for 
optimization of Carvedilol solid dispersions: Formulation design and effect of method 
of preparation. Powder Technol. 237, 406–414 (2013). 
368. Alberty, R. A. & Hammes, G. G. Application of the theory of diffusion-controlled 
reactions to enzyme kinetics. J. Phys. Chem. 62, 154–159 (1958). 
369. Eftink, M. R. & Ghiron, C. A. Temperature and viscosity dependence of fluorescence 
quenching by oxygen in model systems. Photochem. Photobiol. 45, 745–748 (1987). 
370. Zinger, D. & Geacintoov, N. E. Acrylamide and molecular oxygen fluoirescence 
quenching as a probe of solvent-accessibility of aromatic fluorophores complexed with 
DNA in relation to their conformation: coronene-DNA and other complexes. 
Photochem. Photobiol. 47, 181–188 (1988). 
371. Ando, T. & Asai, H. Charge effects on the dynamic quenching of fluorescence of 1,N6-
ethenoadenosine oligophosphates by iodide, thallium (I) and acrylamide. J. Biochem. 
88, 255–264 (1980). 
372. Bombelli, C. et al. Efficiency of liposomes in the delivery of a photosensitizer 
controlled by the stereochemistry of a gemini surfactant component. Mol. Pharm. 7, 
130–137 (2010). 
373. Gupta, P., Thilagavathi, R., Chakraborti, A. K. & Bansal, A. K. Role of molecular 
interaction in stability of celecoxib-PVP amorphous systems. Mol. Pharm. 2, 384–391 
(2005). 
374. Sun, D. D. & Lee, P. I. Evolution of supersaturation of amorphous pharmaceuticals: 
The effect of rate of supersaturation generation. Mol. Pharm. 10, 4330–4346 (2013). 
375. Obaidat, R. M., AlTaani, B. & Ailabouni, A. Effect of different polymeric dispersions 
on In-vitro dissolution rate and stability of celecoxib class II drug. J. Polym. Res. 24, 
(2017). 
376. Juenemann, D. et al. Online monitoring of dissolution tests using dedicated 
potentiometric sensors in biorelevant media. Eur. J. Pharm. Biopharm. 78, 158–165 
(2011). 
377. Leo, E., Cameroni, R. & Forni, F. Dynamic dialysis for the drug release evaluation 
from doxorubicin–gelatin nanoparticle conjugates. Int. J. Pharm. 180, 23–30 (1999). 
378. Marasini, N. et al. Fabrication and evaluation of pH-modulated solid dispersion for 
telmisartan by spray-drying technique. Int. J. Pharm. 441, 424–432 (2013). 
379. Buckley, S. T., Frank, K. J., Fricker, G. & Brandl, M. Biopharmaceutical classification 
of poorly soluble drugs with respect to ‘enabling formulations’. Eur. J. Pharm. Sci. 50, 
8–16 (2013). 
380. Buckley, S. T. et al. In vitro models to evaluate the permeability of poorly soluble drug 
entities: Challenges and perspectives. Eur. J. Pharm. Sci. 45, 235–250 (2012). 
381. Ruff A, Fiolka T, K. E. Prediction of Ketoconazole absorption using an updated in 
vitro transfer model coupled to physiologically based pharmacokinetic modelling. Eur. 
J. Pharm. Sci. 100, 42–55 (2017). 
 158 
 
382. O’Dwyer, P. J. et al. In vitro methods to assess drug precipitation in the fasted small 
intestine - a PEARRL review. J. Pharm. Pharmacol. (2018) doi:10.1111/jphp.12951. 
383. Heigoldt, U. et al. Predicting in vivo absorption behavior of oral modified release 
dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted 
biphasic in vitro dissolution test. Eur. J. Pharm. Biopharm. 76, 105–111 (2010). 
384. Sironi, D., Rosenberg, J., Bauer-Brandl, A. & Brandl, M. PermeaLoopTM a novel in 
vitro tool for small-scale drug-dissolution/permeation studies. J. Pharm. Biomed. Anal. 
156, 247–251 (2018). 
385. Shi, Y., Gao, P., Gong, Y. & Ping, H. Application of a Biphasic Test for 
Characterization of In Vitro Drug Release of Immediate Release Formulations of 
Celecoxib and Its Relevance to In Vivo Absorption. Mol. Pharm. 7, 1458–1465 (2010). 
386. Xu, H., Vela, S., Shi, Y., Marroum, P. & Gao, P. In Vitro Characterization of Ritonavir 
Drug Products and Correlation to Human in Vivo Performance. Mol. Pharm. 14, 3801–
3814 (2017). 
387. Tsume, Y. et al. The in vivo predictive dissolution for immediate release dosage of 
donepezil and danazol, BCS class IIc drugs, with the GIS and the USP II with biphasic 
dissolution apparatus. J. Drug Deliv. Sci. Technol. 0–1 (2019) 
doi:10.1016/j.jddst.2019.01.035. 
388. Psachoulias, D. et al. Precipitation in and Supersaturation of Contents of the Upper 
Small Intestine After Administration of Two Weak Bases to Fasted Adults. Pharm. 
Res. 28, 3145–3158 (2011). 
389. Sarode A. , Obara S., T. F. Stability assessment of hypromellose acetate succinate 
(HPMCAS) NF for application in hot melt extrusion (HME). Carbohydr. Polym. 101, 
146–153 (2014). 
390. Maniruzzaman, M., Islam, M. T., Halsey, S., Amin, D. & Douroumis, D. Novel 
Controlled Release Polymer-Lipid Formulations Processed by Hot Melt Extrusion. 
AAPS PharmSciTech 17, 191–199 (2016). 
391. Alexander M, Piska I, D. D. Investigation of particle dynamics in gels involving casein 
micelles: A diffusing wave spectroscopy and rheology approach. Food Hydrocoll. 22, 
1124–1134 (2008). 
392. Vasbinder A, D. K. C. Casein–whey protein interactions in heated milk: the influence 
of pH. Int. Dairy J. 13, 669–677 (2003). 
393. Eloy, J. D. O., Saraiva, J., Albuquerque, S. De & Marchetti, J. M. Solid Dispersion of 
Ursolic Acid in Gelucire 50 / 13 : a Strategy to Enhance Drug Release and 
Trypanocidal Activity. AAPS PharmSciTech 13, 1436–1445 (2012). 
394. Barnes, H. A. Rheology: Principles, Measurements and Applications. Powder 
Technology vol. 86 (1996). 
395. Blaabjerg, L. et al. The Influence of Polymers on the Supersaturation Potential of Poor 
and Good Glass Formers. Pharmaceutics 10, 164 (2018). 
396. Aleandri, S., Jankovic, S. & Kuentz, M. Towards a better understanding of solid 
dispersions in aqueous environment by a fluorescence quenching approach. Int. J. 
Pharm. 550, 130–139 (2018). 
397. Konno H, T. L. Influence of Different Polymers on the Crystallization Tendency of 
Molecularly Dispersed Amorphous Felodipine. J. Pharm. Sci. 95, 2692–2705 (2006). 
398. Matsen, M. W. Soft Matter, Volume 1: Polymer Melts and Mixtures. (2006). 
399. Singh, Y. Martin’s physical pharmacy and pharmaceutical sciences. Rutgers, State 
Univ. New Jersey (2006). 
400. Martin, A., Swarbrick, J. & Cammarata, A. Physical pharmacy. Lea Febiger (2006). 
401. Van Duong, T. et al. Spectroscopic Investigation of the Formation and Disruption of 
Hydrogen Bonds in Pharmaceutical Semicrystalline Dispersions. Mol. Pharm. 14, 
 159 
 
1726–1741 (2017). 
402. Broman, E., Khoo, C. & Taylor, L. S. A comparison of alternative polymer excipients 
and processing methods for making solid dispersions of a poorly water soluble drug. 
Int. J. Pharm. 222, 139–151 (2001). 
403. De Kee, D. & Wissbrun, K. F. Polymer Rheology. Phys. Today 51, 24–29 (1998). 
404. Räntzsch, V. et al. Polymer Crystallization Studied by Hyphenated Rheology 
Techniques: Rheo‐NMR, Rheo‐SAXS, and Rheo‐Microscopy. Macromol. Mater. Eng. 
304, 1800586 (2019). 
405. Del Giudice, F., Tassieri, M., Oelschlaeger, C. & Shen, A. Q. When Microrheology, 
Bulk Rheology, and Microfluidics Meet: Broadband Rheology of Hydroxyethyl 
Cellulose Water Solutions. Macromolecules 50, 2951–2963 (2017). 
406. MacKintosh, F. C. & John, S. Diffusing-wave spectroscopy and multiple scattering of 
light in correlated random media. Phys. Rev. B 40, 2383–2406 (1989). 
407. Jankovic, S. et al. Biphasic drug release testing coupled with diffusing wave 
spectroscopy for mechanistic understanding of solid dispersion performance. Eur. J. 
Pharm. Sci. 137, 105001 (2019). 
408. Lacoulonche, F., Chauvet, A. & Masse, J. An investigation of flurbiprofen 
polymorphism by thermoanalytical and spectroscopic methods and a study of its 
interactions with poly-(ethylene glycol) 6000 by differential scanning calorimetry and 
modelling. Int. J. Pharm. 153, 167–179 (1997). 
409. Cheng, L. et al. Design and evaluation of bilayer pump tablet of flurbiprofen solid 
dispersion for zero-order controlled delivery. J. Pharm. Sci. 107, 1434–1442 (2018). 
410. Ditzinger, F., Scherer, U., Schönenberger, M., Holm, R. & Kuentz, M. Modified 
polymer matrix in pharmaceutical hot melt extrusion by molecular interactions with a 
carboxylic coformer. Mol. Pharm. 16, 141–150 (2018). 
411. Bellour, M., Skouri, M., Munch, J.-P. & Hébraud, P. Brownian motion of particles 
embedded in a solution of giant micelles. Eur. Phys. J. E 8, 431–436 (2002). 
412. Niederquell, A., Machado, A. H. E. E. & Kuentz, M. A diffusing wave spectroscopy 
study of pharmaceutical emulsions for physical stability assessment. Int. J. Pharm. 530, 
213–223 (2017). 
413. Niederquell, A., Dujovny, G., Probst, S. E. & Kuentz, M. A Relative Permittivity 
Approach for Fast Drug Solubility Screening of Solvents and Excipients in Lipid-
Based Delivery. J. Pharm. Sci. 108, 3457–3460 (2019). 
414. Law, S. L., Lo, W. Y., Lin, F. M. & Chaing, C. H. Dissolution and absorption of 
nifedipine in polyethylene glycol solid dispersion containing phosphatidylcholine. Int. 
J. Pharm. 84, 161–166 (1992). 
415. Lacoulonche, F., Chauvet, A., Masse, J., Egea, M. A. & Garcia, M. L. An investigation 
of FB interactions with poly(ethylene glycol) 6000, poly(ethylene glycol) 4000, and 
poly-ε-caprolactone by thermoanalytical and spectroscopic methods and modeling. J. 
Pharm. Sci. 87, 543–551 (1998). 
416. Lauritzen, J. I. & Hoffman, J. D. Formation of polymer crystals with folded chains 
from dilute solution. J. Chem. Phys. 31, 1680–1681 (1959). 
417. Tang, X., Chen, W. & Li, L. The Tough Journey of Polymer Crystallization: Battling 
with Chain Flexibility and Connectivity. Macromolecules 52, 3575–3591 (2019). 
418. He, P., Yu, W. & Zhou, C. Agglomeration of Crystals during Crystallization of 
Semicrystalline Polymers: A Suspension-Based Rheological Study. Macromolecules 
52, 1042–1054 (2019). 
419. Ballard, M. J., Buscall, R. & Waite, F. A. The theory of shear-thickening polymer 
solutions. Polymer (Guildf). 29, 1287–1293 (1988). 
420. MacMillan*, S. D. et al. In Situ Small Angle X-ray Scattering (SAXS) Studies of 
 160 
 
Polymorphism with the Associated Crystallization of Cocoa Butter Fat Using Shearing 
Conditions. (2002) doi:10.1021/CG0155649. 
421. Strobl, G. R. & IUCr. Determination of the lamellar structure of partially crystalline 
polymers by direct analysis of their small-angle X-ray scattering curves. J. Appl. 
Crystallogr. 6, 365–370 (1973). 
  
 
 
 
